<SEC-DOCUMENT>0001140361-22-037955.txt : 20221020
<SEC-HEADER>0001140361-22-037955.hdr.sgml : 20221020
<ACCEPTANCE-DATETIME>20221020160158
ACCESSION NUMBER:		0001140361-22-037955
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		17
CONFORMED PERIOD OF REPORT:	20221019
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20221020
DATE AS OF CHANGE:		20221020

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			INSMED Inc
		CENTRAL INDEX KEY:			0001104506
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				541972729
		STATE OF INCORPORATION:			VA
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30739
		FILM NUMBER:		221321268

	BUSINESS ADDRESS:	
		STREET 1:		700 US HIGHWAY 202/206
		CITY:			BRIDGEWATER
		STATE:			NJ
		ZIP:			08807
		BUSINESS PHONE:		908-977-9900

	MAIL ADDRESS:	
		STREET 1:		700 US HIGHWAY 202/206
		CITY:			BRIDGEWATER
		STATE:			NJ
		ZIP:			08807

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INSMED INC
		DATE OF NAME CHANGE:	20000128
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ny20005570x4_8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns:naics="http://xbrl.sec.gov/naics/2022" xmlns:sic="http://xbrl.sec.gov/sic/2022" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:exch="http://xbrl.sec.gov/exch/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:insm="http://insmed.com/20221019" xmlns="http://www.w3.org/1999/xhtml">
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Finanicial Soultions, Inc.
         Document created using Broadridge PROfile 22.10.1.5080
         Copyright 1995 - 2022 Broadridge -->
    <meta http-equiv="Content-Type" content="text/html" />
</head>

<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; background-color: #ffffff;">
<div id="DSPFiXBRLHidden" style="display: none;"><ix:header><ix:hidden><ix:nonNumeric name="dei:AmendmentFlag" id="Fact_12080f683548407398317973ac4115f0" contextRef="c20221019to20221019" format="ixt:fixed-false">false</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" id="Fact_0fca47dfceb24a75ba7073caea886f2d" contextRef="c20221019to20221019">0001104506</ix:nonNumeric><ix:nonNumeric name="dei:SecurityExchangeName" id="Fact_f1ba935348d944beb4334223f9085efe" contextRef="c20221019to20221019">NASDAQ</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="insm-20221019.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="c20221019to20221019"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-19</xbrli:startDate><xbrli:endDate>2022-10-19</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>

  <div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt;"> </span></div>

  <div>
    <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt;">
      <hr style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;" /></div>

    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-weight: bold;">UNITED STATES</div>

    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>

    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-weight: bold;">Washington, D.C. 20549</div>

    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>

    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 18pt; font-weight: bold;">FORM <ix:nonNumeric name="dei:DocumentType" id="Fact_6bd2a85cffd742b1b45c8f826e21de0e" contextRef="c20221019to20221019">8-K</ix:nonNumeric></div>

    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>

    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">CURRENT REPORT</div>

    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Pursuant to Section 13 or 15(d) of</div>

    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">The Securities Exchange Act of 1934</div>

    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>

    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" id="Fact_ca9cc4d419d34461ac12076991c8d9cd" contextRef="c20221019to20221019" format="ixt:date-monthname-day-year-en">October 19, 2022</ix:nonNumeric></div>

    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>

    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 24pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityRegistrantName" id="Fact_6af2df81733943f1bf092d264f0efc4e" contextRef="c20221019to20221019">INSMED INCORPORATED</ix:nonNumeric><br />
    </div>

    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">(Exact name of registrant as specified in its charter)</div>

    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>

    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 31.99%; vertical-align: top; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">
            <div style="text-align: center; font-weight: bold;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" id="Fact_c8a6a2101a494c618152a5472695866f" contextRef="c20221019to20221019" format="ixt-sec:stateprovnameen">Virginia</ix:nonNumeric><br />
            </div>
          </td>

    <td style="width: 2%; vertical-align: top; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">
            <div style="text-align: center;">&#160;</div>
          </td>

    <td style="width: 31.99%; vertical-align: top; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">
            <div style="text-align: center; font-weight: bold;"><ix:nonNumeric name="dei:EntityFileNumber" id="Fact_b365274b7891480ba1592eba534cd734" contextRef="c20221019to20221019">000-30739</ix:nonNumeric><br />
            </div>
          </td>

    <td style="width: 2%; vertical-align: top; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">
            <div style="text-align: center;">&#160;</div>
          </td>

    <td style="width: 32%; vertical-align: top; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">
            <div style="text-align: center; font-weight: bold;"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" id="Fact_ea56c1b7ac884e7085359da78bad65c8" contextRef="c20221019to20221019">54-1972729</ix:nonNumeric><br />
            </div>
          </td>

  </tr>

  <tr>

    <td style="width: 31.99%; vertical-align: top; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">
            <div style="text-align: center; font-style: italic;">(State or other jurisdiction</div>
          </td>

    <td style="width: 2%; vertical-align: top; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">
            <div style="text-align: center;">&#160;</div>
          </td>

    <td style="width: 31.99%; vertical-align: top; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">
            <div style="text-align: center; font-style: italic;">(Commission</div>
          </td>

    <td style="width: 2%; vertical-align: top; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">
            <div style="text-align: center;">&#160;</div>
          </td>

    <td style="width: 32%; vertical-align: top; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">
            <div style="text-align: center; font-style: italic;">(IRS Employer</div>
          </td>

  </tr>

  <tr>

    <td style="width: 31.99%; vertical-align: top; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">
            <div style="text-align: center; font-style: italic;">of incorporation)</div>
          </td>

    <td style="width: 2%; vertical-align: top; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">
            <div style="text-align: center;">&#160;</div>
          </td>

    <td style="width: 31.99%; vertical-align: top; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">
            <div style="text-align: center; font-style: italic;">File Number)</div>
          </td>

    <td style="width: 2%; vertical-align: top; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">
            <div style="text-align: center;">&#160;</div>
          </td>

    <td style="width: 32%; vertical-align: top; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">
            <div style="text-align: center; font-style: italic;">Identification No.)</div>
          </td>

  </tr>


</table>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>

    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 65.99%; vertical-align: top;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressAddressLine1" id="Fact_5c5bd1f8d99642df8f742745859f658e" contextRef="c20221019to20221019">700 US Highway 202/206</ix:nonNumeric><br />
            </div>
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressCityOrTown" id="Fact_9b0559d9e91d4b1397d021799293b805" contextRef="c20221019to20221019">Bridgewater</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" id="Fact_a1c4cd46ec6c43038798d7a1debc1303" contextRef="c20221019to20221019" format="ixt-sec:stateprovnameen">New Jersey</ix:nonNumeric></div>
          </td>

    <td style="width: 2%; vertical-align: top; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">
            <div style="text-align: center;">&#160;</div>
          </td>

    <td style="width: 32%; vertical-align: top;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" id="Fact_48d5900a88e849c483d178c9438d889b" contextRef="c20221019to20221019">08807</ix:nonNumeric></span><br />
              <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">(Zip Code)</span></div>
          </td>

  </tr>

  <tr>

    <td style="width: 65.99%; vertical-align: top; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">
            <div style="text-align: center; font-style: italic;">(Address of principal executive offices)</div>
          </td>

    <td style="width: 2%; vertical-align: top; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">
            <div style="text-align: center;">&#160;</div>
          </td>

    <td style="width: 32%; vertical-align: top; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">&#160;</td>

  </tr>


</table>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>

    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Registrant&#8217;s telephone number, including area code: <span style="font-weight: bold;">(<ix:nonNumeric name="dei:CityAreaCode" id="Fact_7ab65bd35a634a6d9b676a749bf361f7" contextRef="c20221019to20221019">908</ix:nonNumeric>) <ix:nonNumeric name="dei:LocalPhoneNumber" id="Fact_f0e07600430940d7baf0971ca8888a92" contextRef="c20221019to20221019">977-9900</ix:nonNumeric></span></div>

    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>

    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Not Applicable</div>

    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">(Former name or former address, if changed since last report.)</div>

    <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>

    <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
      following provisions (see General Instruction A.2. below):</div>

    <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>

    <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonNumeric name="dei:WrittenCommunications" id="Fact_7dc987ae7e6b47d2b9aa2463e2f2a73d" contextRef="c20221019to20221019" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric> Written communications pursuant to Rule
      425 under the Securities Act (17 CFR 230.425)</div>

    <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>

    <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonNumeric name="dei:SolicitingMaterial" id="Fact_4cd87d49741942c2b55b244a447b4122" contextRef="c20221019to20221019" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric> Soliciting material pursuant to Rule
      14a-12 under the Exchange Act (17 CFR 240.14a-12)</div>

    <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>

    <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonNumeric name="dei:PreCommencementTenderOffer" id="Fact_7e55e6bf99e44949a4dc9281c6ea8825" contextRef="c20221019to20221019" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric> Pre-commencement communications pursuant
      to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</div>

    <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>

    <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" id="Fact_ea4abd78b49544e29dfb4fb0c1b4155a" contextRef="c20221019to20221019" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric> Pre-commencement communications pursuant
      to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</div>

    <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt;"><br />
    </div>

    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Securities registered pursuant to Section 12(b) of the Act:</div>

    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> <br />
    </div>

    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 37.64%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt;">
            <div style="text-align: center; font-weight: bold;">Title of each class</div>
          </td>

    <td style="width: 24.83%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt;">
            <div style="text-align: center; font-weight: bold;">Trading Symbol(s)</div>
          </td>

    <td style="width: 37.54%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt;">
            <div style="text-align: center; font-weight: bold;">Name of each exchange on which registered</div>
          </td>

  </tr>

  <tr>

    <td style="width: 37.64%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt;">
            <div style="text-align: center;"><ix:nonNumeric name="dei:Security12bTitle" id="Fact_e518c26a59b2400a805d86ee7512b752" contextRef="c20221019to20221019">Common Stock, par value $0.01 per share</ix:nonNumeric><br />
            </div>
          </td>

    <td style="width: 24.83%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt;">
            <div style="text-align: center;"><ix:nonNumeric name="dei:TradingSymbol" id="Fact_a7882ed0fe0f433593bb0ef05e2cf621" contextRef="c20221019to20221019">INSM</ix:nonNumeric><br />
            </div>
          </td>

    <td style="width: 37.54%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt;">
            <div style="text-align: center;"><span style="-sec-ix-hidden:Fact_f1ba935348d944beb4334223f9085efe">Nasdaq Global Select Market</span><br />
            </div>
          </td>

  </tr>


</table>
    <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>

    <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or Rule
      12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2).</div>

    <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>

    <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Emerging growth company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" id="Fact_9ec556f9799d4b259b776721f08a6b71" contextRef="c20221019to20221019" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric></div>

    <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>

    <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
      revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</div>

    <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">
      <hr style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;" /></div>

    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

    </div>

    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Item 8.01 &#8212; Other Events.</div>

    <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt;"><br />
    </div>

    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">On</span><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt;"> October 19, 2022, Insmed Incorporated (the &#8220;Company&#8221;) entered into an Underwriting Agreement (the &#8220;Underwriting Agreement&#8221;) with J.P. Morgan Securities LLC and SVB Securities LLC, as underwriters (the &#8220;Underwriters&#8221;), pursuant to which,
        subject to satisfaction of the conditions set forth therein, the Company has agreed to sell to the Underwriters, and the Underwriters have agreed to purchase from the Company, 13,750,000 shares (the &#8220;Shares&#8221;) of the common stock, par value $0.01
        per share, of the Company. The Shares will be sold at an offering price of $20.00 per share. Gross proceeds to the Company, before deducting underwriting discounts and commissions and other offering expenses payable by the Company, will be $275
        million.</span></div>

    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt;"> <br />
      </span></div>

    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">The offering of the Shares (the &#8220;Offering&#8221;) is being made pursuant to the
        Company&#8217;s shelf registration statement on Form S-3 (Registration Statement No. 333-238560) that became automatically effective upon filing with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on May 21, 2020, which includes a base prospectus
        dated May 21, 2020 (the &#8220;Registration Statement&#8221;), as supplemented by a prospectus supplement dated October </span><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt;">19, 2022.</span></div>

    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt;"> <br />
      </span></div>

    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">The Company made certain customary representations, warranties and covenants in
        the Underwriting Agreement concerning the Company, the Registration Statement and the offering of the Shares. The Company has agreed to indemnify the Underwriters against certain liabilities, including liabilities under the Securities Act of 1933,
        as amended (the &#8220;Securities Act&#8221;). The Company and the Underwriters expect to consummate the sale and purchase of the Shares pursuant to the Underwriting Agreement on October </span><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt;">21, 2022, subject to the satisfaction of customary closing conditions.</span></div>

    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt;"> <br />
      </span></div>

    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">A copy of the Underwriting Agreement is filed as Exhibit 1.1 to this Current Report on Form 8-K and is incorporated by reference herein. The foregoing
      description of the terms of the Underwriting Agreement does not purport to be complete and is qualified in its entirety by reference to the Underwriting Agreement.</div>

    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> <br />
    </div>

    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The legal opinion of Hunton Andrews Kurth LLP relating to the Shares is filed herewith as Exhibit 5.1.</div>

    <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt;"><br />
    </div>

    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Item 7.01 &#8212; Regulation FD Disclosure.</div>

    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"> <br />
    </div>

    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">On October 19, 2022, the Company issued a press release announcing the Offering as well as its $350 million senior secured term loan and $150 million revenue
      interest purchase agreement, which were previously reported on a Current Report on Form 8-K filed by the Company on October 19, 2022. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.</div>

    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> <br />
    </div>

    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The information contained in this Item 7.01 shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the
      &#8220;Exchange Act&#8221;), or incorporated by reference in any filing under the Securities Act, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.</div>

    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>

    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Item 9.01 &#8212; Financial Statements and Exhibits.</div>

    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>

    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(d) Exhibits.</div>

    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>

    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 7%; vertical-align: bottom; border-bottom: #000000 2px solid;">
            <div style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-weight: bold;">Exhibit</div>
          </td>

    <td style="width: 2%; vertical-align: bottom;">
            <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-weight: bold;">&#160;</div>
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
          </td>

    <td style="width: 90.99%; vertical-align: bottom; border-bottom: #000000 2px solid;">
            <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-weight: bold;">Description</div>
          </td>

  </tr>

  <tr>

    <td style="width: 7%; vertical-align: top; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">&#160;</td>

    <td style="width: 2%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">&#160;</td>

    <td style="width: 90.99%; vertical-align: top; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 7%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="ny20005570x4_ex1-1.htm">1.1</a></div>
          </td>

    <td style="width: 2%; vertical-align: bottom;">
            <div style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">&#160;</div>
          </td>

    <td style="width: 90.99%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Underwriting Agreement, dated October 19, 2022, by and among Insmed Incorporated, J.P. Morgan Securities LLC and SVB Securities LLC.</div>
          </td>

  </tr>

  <tr>

    <td style="width: 7%; vertical-align: top;" rowspan="1">&#160;</td>

    <td style="width: 2%; vertical-align: bottom;" rowspan="1">&#160;</td>

    <td style="width: 90.99%; vertical-align: top;" rowspan="1">&#160;</td>

  </tr>

  <tr>

    <td style="width: 7%; vertical-align: top; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">
            <div style="text-align: left;"><a href="ny20005570x4_ex5-1.htm">5.1</a></div>
          </td>

    <td style="width: 2%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">&#160;</td>

    <td style="width: 90.99%; vertical-align: top; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">
            <div style="text-align: left;">Opinion of Hunton Andrews Kurth LLP related to the Shares.</div>
          </td>

  </tr>

  <tr>

    <td style="width: 7%; vertical-align: top; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">&#160;</td>

    <td style="width: 2%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">&#160;</td>

    <td style="width: 90.99%; vertical-align: top; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 7%; vertical-align: top; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">
            <div style="text-align: left;"><a href="ny20005570x4_ex5-1.htm">23.1</a></div>
          </td>

    <td style="width: 2%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">&#160;</td>

    <td style="width: 90.99%; vertical-align: top; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">
            <div style="text-align: left;">Consent of Hunton Andrews Kurth LLP (included in Exhibit 5.1).</div>
          </td>

  </tr>

  <tr>

    <td style="width: 7%; vertical-align: top; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">&#160;</td>

    <td style="width: 2%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">&#160;</td>

    <td style="width: 90.99%; vertical-align: top; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 7%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="ny20005570x4_ex99-1.htm">99.1</a></div>
          </td>

    <td style="width: 2%; vertical-align: bottom;">
            <div style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">&#160;</div>
          </td>

    <td style="width: 90.99%; vertical-align: top; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">
            <div style="text-align: left;">Press Release issued by Insmed Incorporated on October 19, 2022.</div>
          </td>

  </tr>

  <tr>

    <td rowspan="1" style="width: 7%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 2%; vertical-align: bottom;">&#160;</td>

    <td rowspan="1" style="width: 90.99%; vertical-align: top; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 7%; vertical-align: top; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">
            <div style="text-align: left;">104</div>
          </td>

    <td style="width: 2%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">&#160;</td>

    <td style="width: 90.99%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Cover Page Interactive Date File (embedded within the Inline XBRL document).</div>
          </td>

  </tr>


</table>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

    </div>

    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"><span style="text-decoration: underline;">SIGNATURES</span></div>

    <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt;"><br />
    </div>

    <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
      by the undersigned hereunto duly authorized.</div>

    <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt;"><br />
    </div>

    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);">


  <tr>

    <td style="width: 50%; vertical-align: top; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">
            <div style="text-align: left;">Dated: October 20, 2022</div>
          </td>

    <td style="vertical-align: top; font-family: 'Times New Roman',Times,serif; font-size: 10pt;" colspan="2">
            <div style="text-align: left;">INSMED INCORPORATED</div>
          </td>

  </tr>

  <tr>

    <td style="width: 50%; vertical-align: top; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">&#160;</td>

    <td style="vertical-align: top; font-family: 'Times New Roman',Times,serif; font-size: 10pt;" colspan="2">&#160;</td>

  </tr>

  <tr>

    <td style="width: 50%; vertical-align: top; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">&#160;</td>

    <td style="width: 5%; vertical-align: top; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">&#160;</td>

    <td style="width: 45%; vertical-align: top; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 50%; vertical-align: top; font-family: 'Times New Roman',Times,serif; font-size: 10pt; padding-bottom: 2px;">&#160;</td>

    <td style="width: 5%; vertical-align: top; font-family: 'Times New Roman',Times,serif; font-size: 10pt; padding-bottom: 2px;">
            <div style="text-align: justify;">By:</div>
          </td>

    <td style="width: 45%; vertical-align: top; font-family: 'Times New Roman',Times,serif; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: justify;">/s/ Michael Smith</div>
          </td>

  </tr>

  <tr>

    <td style="width: 50%; vertical-align: top; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">&#160;</td>

    <td style="width: 5%; vertical-align: top; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">
            <div style="text-align: left;">Name:</div>
          </td>

    <td style="width: 45%; vertical-align: top; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">
            <div style="text-align: left;">Michael Smith</div>
          </td>

  </tr>

  <tr>

    <td style="width: 50%; vertical-align: top; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">&#160;</td>

    <td style="width: 5%; vertical-align: top; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">
            <div style="text-align: left;">Title:</div>
          </td>

    <td style="width: 45%; vertical-align: top; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">
            <div style="text-align: left;">General Counsel and Corporate Secretary</div>
          </td>

  </tr>


</table>
    <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt;"><br />
    </div>

    <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt;">
      <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;" /></div>

    <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt;"><br />
    </div>

  </div>

  <div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt;"> </span></div>

</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>ny20005570x4_ex1-1.htm
<DESCRIPTION>EXHIBIT 1.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Finanicial Soultions, Inc.
         Document created using Broadridge PROfile 22.10.1.5080
         Copyright 1995 - 2022 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;" bgcolor="#ffffff">
  <div>
    <hr style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade">
    <div>
      <div style="text-align: right; font-weight: bold;">Exhibit 1.1</div>
      <div><br>
      </div>
      <div style="text-align: center; font-weight: bold;">13,750,000 Shares</div>
      <div><br>
      </div>
      <div style="text-align: center; font-weight: bold;">INSMED INCORPORATED</div>
      <div><br>
      </div>
      <div style="text-align: center; font-weight: bold;">Common Stock, Par Value $0.01 Per Share</div>
      <div><br>
      </div>
      <div style="text-align: center; font-weight: bold;">UNDERWRITING AGREEMENT</div>
      <div><br>
      </div>
      <div style="text-align: right;">October 19, 2022</div>
      <div><br>
      </div>
      <div>J.P. Morgan Securities LLC</div>
      <div>SVB Securities LLC</div>
      <div style="margin-left: 18pt;">as Representatives of the several Underwriters</div>
      <div><br>
      </div>
      <div>c/o J.P. Morgan Securities LLC</div>
      <div>383 Madison Avenue</div>
      <div>New York, NY 10179</div>
      <div><br>
      </div>
      <div>c/o SVB Securities LLC</div>
      <div>53 State Street, 40<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup> Floor</div>
      <div>Boston, MA 02109</div>
      <div><br>
      </div>
      <div>Ladies and Gentlemen:</div>
      <div><br>
      </div>
      <div style="text-indent: 36pt;">Insmed Incorporated, a Virginia corporation (the &#8220;<font style="font-weight: bold;">Company</font>&#8221;), proposes to issue and sell to the several Underwriters named in Schedule I hereto (the &#8220;<font style="font-weight: bold;">Underwriters</font>&#8221;)
        for whom you are acting as representatives (the &#8220;<font style="font-weight: bold;">Representatives</font>&#8221;) 13,750,000 shares of its common stock, par value $0.01 per share (the &#8220;<font style="font-weight: bold;">Common Stock</font>&#8221;) (such shares to be issued and sold by the Company being hereinafter called the &#8220;<font style="font-weight: bold;">Shares</font>&#8221;), in accordance with this Underwriting Agreement (the &#8220;<font style="font-weight: bold;">Agreement</font>&#8221;).</div>
      <div><br>
      </div>
      <div style="text-indent: 36pt;">The Company has filed with the Securities and Exchange Commission (the &#8220;<font style="font-weight: bold;">Commission</font>&#8221;) an automatic shelf registration statement, including a prospectus, on Form S-3 (File No. 333-238560) relating to securities (the &#8220;<font style="font-weight: bold;">Shelf Securities</font>&#8221;), including the Shares, to be issued from time to time by the Company, which automatic shelf registration statement became effective under Rule 462(e) under the Securities Act of 1933, as
        amended (the &#8220;<font style="font-weight: bold;">Securities Act</font>&#8221;). Such registration statement including the information (if any) deemed to be part of the registration statement at
        the time of effectiveness pursuant to Rule 430A or Rule 430B under the Securities Act is hereinafter referred to as the &#8220;<font style="font-weight: bold;">Registration Statement</font>&#8221;,
        and the related prospectus covering the Shelf Securities dated May 21, 2020 in the form first used to confirm sales of the Shares (or in the form first made available to the Underwriters by the Company to meet requests of purchasers pursuant to
        Rule 173 under the Securities Act) is hereinafter referred to as the &#8220;<font style="font-weight: bold;">Basic Prospectus</font>.&#8221; The Basic Prospectus, as supplemented by the prospectus
        supplement specifically relating to the Shares in the form first used to confirm sales of the Shares (or in the form first made available to the Underwriters by the Company to meet requests of purchasers pursuant to Rule 173 of the Securities Act)
        is hereinafter referred to as the &#8220;<font style="font-weight: bold;">Prospectus</font>.&#8221;.</div>
      <div><br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <!--PROfilePageNumberReset%Num%2%%%-->
      <div><br>
      </div>
      <div style="text-indent: 36pt;">For purposes of this Agreement, &#8220;<font style="font-weight: bold;">free
          writing prospectus</font>&#8221; has the meaning set forth in Rule 405 under the Securities Act, &#8220;<font style="font-weight: bold;">Time of Sale Prospectus</font>&#8221; means the documents and
        pricing information set forth in Schedule II hereto, and &#8220;<font style="font-weight: bold;">broadly available road show</font>&#8221; means a &#8220;bona fide electronic road show&#8221; as defined in
        Rule 433(h)(5) under the Securities Act that has been made available without restriction to any person. As used herein, the terms &#8220;Registration Statement,&#8221; &#8220;Basic Prospectus,&#8221; &#8220;Time of Sale Prospectus&#8221; and &#8220;Prospectus&#8221; shall include the documents,
        if any, incorporated by reference therein. The terms &#8220;<font style="font-weight: bold;">supplement</font>,&#8221; &#8220;<font style="font-weight: bold;">amendment</font>,&#8221; and &#8220;<font style="font-weight: bold;">amend</font>&#8221; as used herein with respect to the Registration Statement, the Basic Prospectus, the Time of
        Sale Prospectus or any free writing prospectus shall include all documents subsequently filed by the Company with the Commission pursuant to the Securities Exchange Act of 1934, as amended (the &#8220;<font style="font-weight: bold;">Exchange Act</font>&#8221;), that are deemed to be incorporated by reference therein.</div>
      <div><br>
      </div>
      <div style="text-indent: 32.4pt; margin-left: 3.6pt;">1.<font style="font-style: italic;">&#160;
          Representations and Warranties</font>. The Company represents and warrants to and agrees with each of the Underwriters that:</div>
      <div><br>
      </div>
      <div style="text-indent: 36pt; margin-left: 13.5pt;">(a)&#160; The Registration Statement became effective upon filing; the filing date of the Registration Statement was not
        earlier than the date three years before the execution date of this Agreement; and no stop order suspending the effectiveness of the Registration Statement is in effect, and no proceedings for such purpose are pending before or, to the knowledge of
        the Company, threatened by, the Commission.&#160; (i) At the time of filing the Registration Statement, (ii) at the time of the most recent amendment thereto for the purposes of complying with Section 10(a)(3) of the Securities Act (whether such
        amendment was by post-effective amendment, incorporated report filed pursuant to Sections 13 or 15(d) of the Exchange Act or form of prospectus), (iii) at the time the Company or any person acting on its behalf (within the meaning, for this clause
        only, of Rule 163(c)) made any offer relating to the Shares in reliance on the exemption in Rule 163, and (iv) as of the date hereof, the Company was or is, as applicable, a &#8220;well-known seasoned issuer&#8221; (as defined in Rule 405 under the Securities
        Act) eligible to use the Registration Statement as an automatic shelf registration statement and the Company has not received notice that the Commission objects to the use of the Registration Statement as an automatic shelf registration statement.</div>
      <div><br>
      </div>
      <div style="text-indent: 36pt; margin-left: 13.5pt;">(b)&#160; (i) Each document, if any, filed or to be filed pursuant to the Exchange Act and incorporated by reference in
        the Time of Sale Prospectus or the Prospectus complied or will comply when so filed in all material respects with the Exchange Act and the applicable rules and regulations of the Commission thereunder, (ii) each part of the Registration Statement,
        when such part became effective, did not contain, and each such part, as amended or supplemented, if applicable, as of the Closing Date (as defined in Section 4) will not contain any untrue statement of a material fact or omit to state a material
        fact required to be stated therein or necessary to make the statements therein not misleading, (iii) the Registration Statement, as of the date hereof, does not and, as of the Closing Date, will not contain any untrue statement of a material fact
        or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading, (iv) the Registration Statement and the Prospectus comply, and as amended or supplemented, if applicable, will comply in all
        material respects with the Securities Act and the applicable rules and regulations of the Commission thereunder, (v) the Time of Sale Prospectus does not, and at the time of each sale of the Shares in connection with the offering when the
        Prospectus is not yet available to prospective purchasers and at the Closing Date, the Time of Sale Prospectus, as then amended or supplemented by the Company, if applicable, will not, contain any untrue statement of a material fact or omit to
        state a material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading, (vi) each broadly available road show, if any, when considered together with the Time of Sale Prospectus,
        does not and will not as of the Closing Date contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading and
        (vii) the Prospectus as of the date hereof does not contain and, as amended or supplemented, if applicable, as of the Closing Date will not contain any untrue statement of a material fact or omit to state a material fact necessary to make the
        statements therein, in the light of the circumstances under which they were made, not misleading, except that the representations and warranties set forth in this paragraph do not apply to statements or omissions in the Registration Statement, the
        Time of Sale Prospectus or the Prospectus based upon information relating to any Underwriter furnished to the Company in writing by such Underwriter through you expressly for use therein.</div>
      <div><br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">2</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div><br>
      </div>
      <div style="text-indent: 36pt; margin-left: 13.5pt;">(c)&#160; (i) At the earliest time after the filing of the Registration Statement that the Company or another offering
        participant made a <font style="font-style: italic;">bona fide</font> offer (within the meaning of Rule 164(h)(2)) of the Shares and (ii) as of the date hereof, the Company is not an
        &#8220;ineligible issuer&#8221; in connection with the offering pursuant to Rules 164, 405 and 433 under the Securities Act. Any free writing prospectus that the Company is required to file pursuant to Rule 433(d) under the Securities Act has been, or will be,
        filed with the Commission in accordance with the requirements of the Securities Act and the applicable rules and regulations of the Commission thereunder. Each free writing prospectus that the Company has filed, or is required to file, pursuant to
        Rule 433(d) under the Securities Act or that was prepared by or on behalf of or used or referred to by the Company (x) complies or will comply in all material respects with the requirements of the Securities Act and the applicable rules and
        regulations of the Commission thereunder and (y) does not include any information that conflicts with the information contained in the Registration Statement, including any document incorporated therein by reference and any prospectus supplement
        deemed to be a part thereof that has not been superseded or modified. Except for the free writing prospectuses, if any, identified in Schedule II hereto forming part of the Time of Sale Prospectus, and electronic road shows, if any, each furnished
        to you before first use, the Company has not prepared, used or referred to, and will not, without your prior consent, prepare, use or refer to, any free writing prospectus.</div>
      <div><br>
      </div>
      <div style="text-indent: 36pt; margin-left: 13.5pt;">(d)&#160; There has not occurred any material adverse change, or any development involving a prospective material adverse
        change, in the condition, financial or otherwise, or in the earnings, business or operations of the Company and its subsidiaries, taken as a whole, from that set forth in the Time of Sale Prospectus.</div>
      <div><br>
      </div>
      <div style="text-indent: 36pt; margin-left: 13.5pt;">(e)&#160; The Company has been duly incorporated, is validly existing as a corporation in good standing under the laws of
        the jurisdiction of its incorporation, has the corporate power and authority to own its property and to conduct its business as described in the Time of Sale Prospectus and is duly qualified to transact business and is in good standing in each
        jurisdiction in which the conduct of its business or its ownership or leasing of property requires such qualification, except to the extent that the failure to be so qualified or be in good standing would not have a material adverse effect on the
        Company and its subsidiaries, taken as a whole.</div>
      <div><br>
      </div>
      <div style="text-indent: 36pt; margin-left: 13.5pt;">(f)&#160; The Company&#8217;s only subsidiaries are as listed in Schedule III hereto.</div>
      <div><br>
      </div>
      <div style="text-indent: 36pt; margin-left: 13.5pt;">(g)&#160; This Agreement has been duly authorized, executed and delivered by the Company.</div>
      <div><br>
      </div>
      <div style="text-indent: 36pt; margin-left: 13.5pt;">(h)&#160; The authorized capital stock of the Company conforms as to legal matters to the description thereof contained
        in each of the Time of Sale Prospectus and the Prospectus.</div>
      <div><br>
      </div>
      <div style="text-indent: 36pt; margin-left: 13.5pt;">(i)&#160; The shares of Common Stock outstanding prior to the issuance of the Shares have been duly authorized and are
        validly issued, fully paid and non-assessable.</div>
      <div><br>
      </div>
      <div style="text-indent: 36pt; margin-left: 13.5pt;">(j)&#160; The Shares have been duly authorized and, when issued and delivered in accordance with the terms of this
        Agreement, will be validly issued, fully paid and non-assessable, and the issuance of such Shares will not be subject to any preemptive or similar rights, which have not otherwise been waived.</div>
      <div><br>
      </div>
      <div style="text-indent: 36pt; margin-left: 13.5pt;">(k)&#160; The execution and delivery by the Company of, and the performance by the Company of its obligations under, this
        Agreement will not contravene any provision of (i) applicable law, (ii) the articles of incorporation or bylaws of the Company, (iii) any agreement or other instrument binding upon the Company or any of its subsidiaries or (iv) any judgment, order
        or decree of any governmental body, agency or court having jurisdiction over the Company or any subsidiary, except in the cases of clauses (i), (iii) and (iv) for any such contravention that would not, singly or in the aggregate, have a material
        adverse effect on the Company and its subsidiaries taken as a whole, and no consent, approval, authorization or order of, or qualification with, any governmental body or agency is required for the performance by the Company of its obligations under
        this Agreement, except such as may be required under the Securities Act or the rules and regulations thereunder or by the securities or Blue Sky laws of the various states or the rules and regulations of the Financial Industry Regulatory Authority
        (&#8220;<font style="font-weight: bold;">FINRA</font>&#8221;) in connection with the offer and sale of the Shares.</div>
      <div><br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">3</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div><br>
      </div>
      <div style="text-indent: 36pt; margin-left: 13.5pt;">(l)&#160; There are no legal or governmental proceedings pending or, to the knowledge of the Company, threatened to which
        the Company or any of its subsidiaries is a party or to which any of the properties of the Company or any of its subsidiaries is subject other than (i) proceedings accurately described in all material respects in the Time of Sale Prospectus or (ii)
        proceedings that would not reasonably be expected to have a material adverse effect on the Company and its subsidiaries, taken as a whole, or on the power or ability of the Company to perform its obligations under this Agreement or to consummate
        the transactions contemplated by the Time of Sale Prospectus; and there are no statutes, regulations, contracts or other documents that are required to be described in the Registration Statement or the Prospectus or to be filed as exhibits to the
        Registration Statement that are not described or filed as required.</div>
      <div><br>
      </div>
      <div style="text-indent: 36pt; margin-left: 13.5pt;">(m)&#160; The interactive data in eXtensible Business Reporting Language included or incorporated by reference in the
        Registration Statement fairly presents the information called for in all material respects and has been prepared in accordance with the Commission&#8217;s rules and guidelines applicable thereto.</div>
      <div><br>
      </div>
      <div style="text-indent: 36pt; margin-left: 13.5pt;">(n)The Company is not, and after giving effect to the offering and sale of the Shares to be sold by the Company and
        the application of the proceeds thereof as described in the Prospectus will not be, required to be registered as an &#8220;investment company&#8221; as such term is defined in the Investment Company Act of 1940, as amended.</div>
      <div><br>
      </div>
      <div style="text-indent: 36pt; margin-left: 13.5pt;">(o)&#160; The Company and its subsidiaries (i) are in compliance with any and all applicable foreign, federal, state and
        local laws and regulations relating to the protection of human health and safety, the environment or hazardous or toxic substances or wastes, pollutants or contaminants (&#8220;<font style="font-weight: bold;">Environmental Laws</font>&#8221;), (ii) have received all permits, licenses or other approvals required of them under applicable Environmental Laws to conduct their respective businesses and (iii) are in compliance with all terms
        and conditions of any such permit, license or approval, except where such noncompliance with Environmental Laws, failure to receive required permits, licenses or other approvals or failure to comply with the terms and conditions of such permits,
        licenses or approvals would not, singly or in the aggregate, have a material adverse effect on the Company and its subsidiaries, taken as a whole.</div>
      <div><br>
      </div>
      <div style="text-indent: 36pt; margin-left: 13.5pt;">(p)&#160; To the Company&#8217;s knowledge, there are no facts currently existing that will require the Company or any of its
        subsidiaries to incur costs or liabilities associated with Environmental Laws (including, without limitation, any capital or operating expenditures required for clean-up, closure of properties or compliance with Environmental Laws or any permit,
        license or approval, any related constraints on operating activities and any potential liabilities to third parties) which would, singly or in the aggregate, have a material adverse effect on the Company and its subsidiaries, taken as a whole.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; margin-left: 13.5pt;">(q)&#160; Except as disclosed in the Time of Sale Prospectus and the Prospectus, none of the Company nor any of its
        subsidiaries is or, since January 1, 2020 has been, in violation of any Health Care Laws, except where the failure to be in compliance would not, individually or in the aggregate, reasonably be expected to result in a material adverse effect on the
        Company and its subsidiaries taken as a whole. For purposes of this Agreement, &#8220;<font style="font-weight: bold;">Health Care Laws</font>&#8221; means, to the extent applicable to the Company,
        (i) the Federal Food, Drug, and Cosmetic Act, and the regulations promulgated thereunder, (ii) all federal and state fraud and abuse laws, including, without limitation, the federal Anti-Kickback Statute (42 U.S.C. &#167;1320a-7b(b)), the Stark Law (42
        U.S.C. &#167;1395nn), the civil False Claims Act (31 U.S.C. &#167;3729 et seq.), Sections 1320a-7 and 1320a-7a of Title 42 of the United States Code and the regulations promulgated pursuant to such statutes, (iii) the administrative simplification provisions
        of the Health Insurance Portability and Accountability Act of 1996 (18 U.S.C. &#167;&#167;669, 1035, 1347 and 1518; 42 U.S.C. &#167;1320d et seq.) and the regulations promulgated thereunder, (iv) Titles XVIII (42 U.S.C. &#167;1395 et seq.) and XIX (42 U.S.C. &#167;1396 et
        seq.) of the Social Security Act and the regulations promulgated thereunder, (v) the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (42 U.S.C. &#167;1395w-101 et seq.) and the regulations promulgated thereunder, (vi) the
        so-called federal &#8220;Sunshine Law&#8221; or Open Payments (42 U.S.C. &#167;1320a-7h) and state or local laws regulating or requiring reporting of interactions between pharmaceutical manufacturers and members of the healthcare industry and regulations
        promulgated thereunder, (vii) laws governing government pricing or price reporting programs and regulations promulgated thereunder, including without limitation the Medicaid Drug Rebate Program (42 U.S.C. &#167; 1396r-8) and any state supplemental
        rebate program, the Public Health Service Act (42 U.S.C. &#167; 256b), the VA Federal Supply Schedule (38 U.S.C. &#167; 8126) or any state pharmaceutical assistance program or U.S. Department of Veterans Affairs agreement, and any successor government
        programs, (viii) all statutes, rules or regulations of applicable governmental authorities applicable to the ownership, testing, research, development, manufacture, quality, safety, accreditation, packaging, storage, use, distribution, labeling,
        promotion, sale, offer for sale, import, export or disposal of any product manufactured or distributed by the Company or its subsidiaries, including current good manufacturing practices requirements; and (ix) any and all other health care laws and
        regulations applicable to&#160; the Company or its subsidiaries or their respective businesses, each as currently conducted, as described in the Time of Sale Prospectus, each of (i) through (ix) as may be amended from time to time.</div>
      <div><br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">4</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; margin-left: 13.5pt;">(r)&#160; Neither the Company nor any of its subsidiaries has received written notice of any pending or threatened
        claim, suit, proceeding, hearing, enforcement, audit, investigation, arbitration or other legal action that has not been resolved from any applicable governmental authority or any third party, including employees, former employees or competitors,
        alleging that any operation or activity of the Company or any of its subsidiaries is in violation of any applicable Health Care Laws, except as would not, singly or in the aggregate, reasonably be expected to result in a material adverse effect on
        the Company and its subsidiaries taken as a whole.&#160; Except as would not, singly or in the aggregate, reasonably be expected to result in a material adverse effect on the Company and its subsidiaries taken as a whole, (i) the Company and its
        subsidiaries have timely submitted all registrations or other filings required under any applicable Health Care Laws with governmental authorities, (ii) and those filings have, to the knowledge of the Company, been complete and accurate when filed
        or corrected as appropriate by the Company if subsequently determined not to be complete or to be inaccurate.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; margin-left: 13.5pt;">(s)&#160; Except as would not, singly or in the aggregate, reasonably be expected to result in a material adverse
        effect on the Company and its subsidiaries taken as a whole, the Company: (i) has in place current agreements for its marketed product to participate in Federal Health Care Programs; and (ii) is in compliance with all such agreements including,
        without limitation, provisions in such agreements pertaining to the timely and current submission of accurate prices to federal and state agencies.&#160; For purposes of this Agreement, &#8220;<font style="font-weight: bold;">Federal Health Care Program</font>&#8221; has the meaning set forth in 42 U.S.C. 1320a-7b(f).</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; margin-left: 13.5pt;">(t)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The
          Company and its subsidiaries have an operational healthcare compliance program that: (i) governs all employees and contractors, including sales representatives; (ii) is materially consistent with the current U.S. Federal Sentencing Guidelines
          standards for effective compliance programs and U.S. Department of Health and Human Services Office of Inspector General Voluntary Compliance Guidance for Pharmaceutical Manufacturers; (iii) complies with the Pharmaceutical Research and
          Manufacturers of America Code on Interactions with Healthcare Professionals; and (iv) addresses compliance with Health Care Laws.&#160; The Company and each of its subsidiaries operates in material compliance with such healthcare compliance program.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; margin-left: 13.5pt;">(u) Neither the Company nor any of its subsidiaries is a party to any corporate integrity agreements, monitoring
        agreements, consent decrees, settlement orders or similar agreements with or imposed by any governmental authority.</div>
      <div><br>
      </div>
      <div style="text-indent: 36pt; margin-left: 13.5pt;">(v) None of the Company, its subsidiaries, or any of their respective officers, directors, or employees, or to the
        knowledge of the Company, any independent contractor, is excluded, suspended or debarred from participation in any Federal Health Care Program or human research study or clinical trial or, to the knowledge of the Company, is or has been the subject
        of a governmental inquiry, investigation, proceeding or other action, including a criminal conviction or imposition of a civil monetary penalty, that would reasonably be expected to result in debarment, suspension, or exclusion. The Company
        periodically conducts screening of officers, directors, employees and independent contractors to confirm such persons are not excluded, suspended or debarred from participation in any Federal Health Care Program or human research study or clinical
        trial.</div>
      <div><br>
      </div>
      <div style="text-indent: 36pt; margin-left: 13.5pt;">(w)&#160; Except as described in the Time of Sale Prospectus and the Prospectus, there are no contracts, agreements or
        understandings between the Company and any person granting such person the right to require the Company to file a registration statement under the Securities Act with respect to any securities of the Company or to require the Company to include
        such securities with the Shares registered pursuant to the Registration Statement.</div>
      <div><br>
      </div>
      <div style="text-indent: 36pt; margin-left: 13.5pt;">(x)&#160; Neither the Company nor any of its subsidiaries or affiliates, nor any director or officer, nor to the
        knowledge of the Company, any employee, agent or representative of the Company or of any of its subsidiaries or affiliates, has taken any action (i) in violation of the Foreign Corrupt Practices Act of 1977, as amended, or any applicable law or
        regulation implementing the OECD Convention on Combating Bribery of Foreign Public Officials in International Business Transactions, and the Bribery Act 2010 of the United Kingdom or any other applicable anti-bribery or anti-corruption law
        (collectively &#8220;<font style="font-weight: bold;">Anti-Corruption Laws</font>&#8221;), or (ii) in furtherance of an offer, payment, promise to pay, or authorization or approval of the payment
        or giving or receiving of money, property, gifts or anything else of value (including nonmonetary benefits such as employment opportunities, gifts, travel, or entertainment), directly or indirectly, to any &#8220;government official&#8221; (including any
        officer or employee of a government or government-owned or controlled entity or of a public international organization, or any person acting in an official capacity for or on behalf of any of the foregoing, or any political party or party official
        or candidate for political office) or any other person to improperly influence official action, to improperly gain or retain business, or secure an improper advantage for the benefit of the Company. The Company and its subsidiaries have conducted
        their businesses in compliance in all material respects with the Anti-Corruption Laws, and the Company and its subsidiaries will not knowingly, directly or indirectly, use the proceeds of the offering and sale of the Shares, or lend, contribute or
        otherwise make available such proceeds to any subsidiary, affiliate, agent, partner or other person or entity, for the purpose of financing or facilitating any activity that would violate any of the Anti-Corruption Laws.</div>
      <div><br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">5</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div><br>
      </div>
      <div style="text-indent: 36pt; margin-left: 13.5pt;">(y)&#160; The operations of the Company and its subsidiaries are and have been conducted at all times in compliance with
        applicable financial recordkeeping and reporting requirements, including, without limitation, those of the Bank Secrecy Act, as amended by Title III of the Uniting and Strengthening America by Providing Appropriate Tools Required to Intercept and
        Obstruct Terrorism Act of 2001, and the applicable anti-money laundering statutes of jurisdictions where the Company and its subsidiaries conduct business, the rules and regulations thereunder and any related or similar rules, regulations or
        guidelines, issued, administered or enforced by any governmental agency where the Company and its subsidiaries conduct business (collectively, the &#8220;<font style="font-weight: bold;">Anti-Money
          Laundering Laws</font>&#8221;), and no action, suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company or any of its subsidiaries with respect to the Anti-Money Laundering Laws is
        pending or, to the best knowledge of the Company, threatened.</div>
      <div><br>
      </div>
      <div style="text-indent: 36pt; margin-left: 13.5pt;">(z)&#160; Neither the Company nor any of its subsidiaries or, any director, officer, or to the knowledge of the Company,
        any employee, agent, affiliate or representative of the Company or any of its subsidiaries, is an individual or entity (&#8220;<font style="font-weight: bold;">Person</font>&#8221;) that is, or is
        owned or controlled by a Person that is: (i) the subject of any sanctions administered or enforced by the U.S. Department of Treasury&#8217;s Office of Foreign Assets Control (and including, without limitation, the designation as a &#8220;specially designated
        national&#8221; or &#8220;blocked person&#8221;), the United Nations Security Council, the European Union, Her Majesty&#8217;s Treasury or other relevant sanctions authority (collectively, &#8220;<font style="font-weight: bold;">Sanctions</font>&#8221;), nor (ii) located, organized or resident in a country or territory that is the subject of Sanctions (including, without limitation, the Crimea Region of Ukraine, the so-called Donetsk People&#8217;s Republic, the
        so-called Luhansk People&#8217;s Republic, Cuba, Iran, North Korea and Syria).&#160; For the past five years, the Company has not knowingly engaged in and is not now knowingly engaged in any dealings or transactions with any Person, or in any country or
        territory, that at the time of the dealing or transaction is or was the subject of Sanctions.</div>
      <div><br>
      </div>
      <div style="text-indent: 36pt; margin-left: 13.5pt;">(aa)&#160; Subsequent to the respective dates as of which information is given in each of the Registration Statement, the
        Time of Sale Prospectus and the Prospectus, (i) the Company and its subsidiaries have not incurred any material liability or obligation, direct or contingent, nor entered into any material transaction; (ii) the Company has not purchased any of its
        outstanding capital stock, nor declared, paid or otherwise made any dividend or distribution of any kind on its capital stock other than ordinary and customary dividends and net settlements in connection with the Company&#8217;s existing employee
        compensation plans; and (iii) there has not been any material change in the capital stock, short-term debt or long-term debt of the Company and its subsidiaries, except in each case as described in each of the Registration Statement, the Time of
        Sale Prospectus and the Prospectus, respectively, or except for a change in the number of outstanding shares of common stock of the Company due to the issuance of shares upon the exercise of currently outstanding options or other stock-based awards
        or the vesting of restricted stock units under (i) the Company&#8217;s Amended and Restated 2000 Stock Incentive Plan (the &#8220;<font style="font-weight: bold;">2000 Plan</font>&#8221;), 2013 Incentive
        Plan (the &#8220;<font style="font-weight: bold;">2013 Plan</font>&#8221;), 2015 Incentive Plan (the &#8220;<font style="font-weight: bold;">2015
          Plan</font>&#8221;), 2017 Incentive Plan (the &#8220;<font style="font-weight: bold;">2017 Plan</font>&#8221;) and the 2019 Incentive Plan, as amended (the &#8220;<font style="font-weight: bold;">2019 Plan</font>&#8221;) or (ii) inducement grants previously made to new employees.</div>
      <div><br>
      </div>
      <div style="text-indent: 36pt; margin-left: 13.5pt;">(bb)&#160; The Company and its subsidiaries do not own any real property. The Company and its subsidiaries have good
        title to all personal property owned by them which is material to the business of the Company and its subsidiaries, in each case free and clear of all liens, encumbrances and defects except such as are described in the Time of Sale Prospectus or
        such as do not materially affect the value of such property and do not interfere with the use made and proposed to be made of such property by the Company and its subsidiaries; and any material real property and buildings held under lease by the
        Company and its subsidiaries are held by them under valid, subsisting and enforceable leases with such exceptions as are not material and do not interfere with the use made and proposed to be made of such property and buildings by the Company and
        its subsidiaries, in each case except as described in the Time of Sale Prospectus.</div>
      <div><br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">6</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div><br>
      </div>
      <div style="text-indent: 36pt; margin-left: 13.5pt;">(cc)&#160; Except as described in the Time of Sale Prospectus, (A) the Company and its subsidiaries own or possess, or
        can acquire on reasonable terms, all material patents, patent rights, licenses, inventions, copyrights, know-how (including trade secrets and other unpatented and/or unpatentable proprietary or confidential information, systems or procedures),
        trademarks, service marks, trade names and other intellectual property (collectively, &#8220;<font style="font-weight: bold;">Intellectual Property</font>&#8221;) currently used and proposed to be
        used by them in connection with the Company&#8217;s business as now conducted and as described in the Time of Sale Prospectus, and (B) neither the Company nor any of its subsidiaries has breached any material provision of any Intellectual Property
        license or received any notice of infringement of or conflict with asserted rights of others with respect to any of the foregoing, in the case of each of (A) and (B), which, singly or in the aggregate, if the subject of an unfavorable decision,
        ruling or finding, would reasonably be expected to have a material adverse effect on the Company and its subsidiaries, taken as a whole. There are no valid and enforceable rights of third parties to any Intellectual Property that are or would be
        infringed by the business currently conducted or planned to be conducted by the Company and its subsidiaries or in the manufacture, use, sale or offer for sale of its presently proposed products, as such planned business and proposed products are
        described in the Time of Sale Prospectus which infringement, singly or in the aggregate, would reasonably be expected to have a material adverse effect on the Company and its subsidiaries, taken as a whole. There are no pending patent applications
        of which the Company is aware, which, if granted in current form, would be infringed by the business currently conducted by it or proposed to be conducted by it as described in the Time of Sale Prospectus, which infringement, singly or in the
        aggregate, would reasonably be expected to have a material adverse effect on the Company and its subsidiaries, taken as a whole. Neither the Company, nor any of its subsidiaries, is subject to any judgment, order, writ, injunction or decree of any
        court or any federal, state, local, foreign or other governmental department, commission, board, bureau, agency or instrumentality, domestic or foreign, or any arbitrator, nor has it entered into or is it a party to any contract, in the case of
        each of the foregoing, which materially restricts or impairs its use of any Intellectual Property and which restriction or impairment, singly or in the aggregate, would reasonably be expected to have a material adverse effect on the Company and its
        subsidiaries, taken as a whole.&#160; To the knowledge of the Company, there are no ongoing infringements by others of any Intellectual Property owned by the Company or its subsidiaries in connection with the business currently conducted by the Company
        and its subsidiaries or its presently proposed products, as described in the Time of Sale Prospectus, which infringement, singly or in the aggregate, would reasonably be expected to have a material adverse effect on the Company and its
        subsidiaries, taken as a whole. The Company is not aware of any reason why any Intellectual Property owned or controlled by it is or should be held to be invalid or unenforceable, which holding, singly or in the aggregate, would reasonably be
        expected to have a material adverse effect on the Company and its subsidiaries, taken as a whole.</div>
      <div><br>
      </div>
      <div style="text-indent: 36pt; margin-left: 13.5pt;">(dd)&#160; Except as described in the Time of Sale Prospectus, no material labor dispute with the employees of the
        Company or any of its subsidiaries exists or, to the knowledge of the Company, is imminent; and the Company is not aware of any existing, threatened or imminent labor disturbance by the employees of any of its principal suppliers, manufacturers or
        contractors that could have a material adverse effect on the Company and its subsidiaries, taken as a whole.</div>
      <div><br>
      </div>
      <div style="text-indent: 36pt; margin-left: 13.5pt;">(ee)&#160; The Company and each of its subsidiaries are insured by insurers of recognized financial responsibility
        against such losses and risks and in such amounts as are prudent in the reasonable opinion of the Company&#8217;s management and customary in the businesses in which they are engaged; neither the Company nor any of its subsidiaries has been refused any
        insurance coverage sought or applied for; and neither the Company nor any of its subsidiaries has any reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain comparable
        coverage from similar insurers as may be necessary to continue its business at a cost that would not reasonably be expected to have a material adverse effect on the Company and its subsidiaries, taken as a whole, except as described in the Time of
        Sale Prospectus.</div>
      <div><br>
      </div>
      <div style="text-indent: 36pt; margin-left: 13.5pt;">(ff)&#160; The Company and its subsidiaries possess all material certificates, authorizations and permits issued by the
        appropriate federal, state or foreign regulatory authorities necessary to conduct their respective businesses in the manner described in the Time of Sale Prospectus, including, without limitation, (i) all U.S. Food and Drug Administration (the &#8220;<font style="font-weight: bold;">FDA</font>&#8221;) clearances or approvals necessary to conduct the Company&#8217;s business as now conducted and (ii) applicable foreign regulatory agency clearances,
        permits or approvals necessary to conduct the Company&#8217;s business as now conducted. Neither the Company nor any of its subsidiaries has received any notice of proceedings relating to the revocation or modification of any such certificate,
        authorization or permit, including, without limitation, any FDA Form 483, notice of adverse finding, warning letter, untitled letter or other correspondence or notice from the FDA, any other governmental or regulatory authority or any third party
        which, singly or in the aggregate, if the subject of an unfavorable decision, ruling or finding, would reasonably be expected to have a material adverse effect on the Company and its subsidiaries, taken as a whole, except as described in the Time
        of Sale Prospectus.</div>
      <div><br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">7</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div><br>
      </div>
      <div style="text-indent: 36pt; margin-left: 13.5pt;">(gg)&#160; The Company and each of its subsidiaries have operated their businesses and currently are in compliance in all
        material respects with all applicable rules, regulations and policies of the FDA and any applicable comparable foreign regulatory organization, including, without limitation, all applicable directives and regulations of the European Medicines
        Agency. The Company has not received notice of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from the FDA, any other federal, state, local or foreign governmental or regulatory authority or
        third party alleging that any product operation or activity is in material violation of any applicable laws or material certificates, authorizations or permits and has no knowledge that the FDA or any other federal, state, local or foreign
        governmental or regulatory authority or third party is considering any such claim, litigation, arbitration, action, suit, investigation or proceeding.</div>
      <div><br>
      </div>
      <div style="text-indent: 36pt; margin-left: 13.5pt;">(hh)&#160; The description of the results of the studies, tests and trials conducted by or on behalf of the Company
        contained in the Time of Sale Prospectus and the Prospectus are accurate in all material respects and the Company has no knowledge of any other studies, tests or trials, the results of which are materially inconsistent with the results described in
        the Time of Sale Prospectus and the Prospectus.</div>
      <div><br>
      </div>
      <div style="text-indent: 36pt; margin-left: 13.5pt;">(ii)&#160; Any clinical trials or human and animal studies conducted by or on behalf of the Company and described in the
        Time of Sale Prospectus were and, if still pending, are being conducted (to the Company&#8217;s knowledge, after due inquiry, with respect to such studies conducted by third parties) in accordance, in all material respects, with standard medical and
        scientific research procedures, the Federal Food, Drug and Cosmetic Act and the rules and regulations promulgated thereunder, and all applicable rules, regulations and policies of the FDA, including, where applicable, current good clinical
        practices and Good Laboratory Practices, as such terms are understood in the Company&#8217;s industry, and all applicable foreign regulatory requirements and standards. Except as described in the Time of Sale Prospectus or the Registration Statement, the
        Company has not received any notices or correspondence from the FDA or any other governmental authority contemplating or requiring the termination, suspension or modification of any studies, tests or preclinical or clinical trials conducted by or
        on behalf of the Company, other than ordinary course communications with respect to modifications in connection with the design and implementation of such studies, trials and tests, none of which modifications would have a material impact on such
        study, trial or test.</div>
      <div><br>
      </div>
      <div style="text-indent: 36pt; margin-left: 13.5pt;">(jj)&#160; Except as described in the Time of Sale Prospectus or the Registration Statement, the Company and each of its
        subsidiaries maintain a system of internal accounting controls sufficient to provide reasonable assurance that (i) transactions are executed in accordance with management&#8217;s general or specific authorizations; (ii) transactions are recorded as
        necessary to permit preparation of financial statements in conformity with generally accepted accounting principles as applied in the United States (&#8220;<font style="font-weight: bold;">U.S.
          GAAP</font>&#8221;) and to maintain asset accountability; (iii) access to assets is permitted only in accordance with management&#8217;s general or specific authorization; and (iv) the recorded accountability for assets is compared with the existing assets
        at reasonable intervals and appropriate action is taken with respect to any differences. Except as described in the Time of Sale Prospectus, since the end of the Company&#8217;s most recent audited fiscal year, there has been (A) no material weakness in
        the Company&#8217;s internal control over financial reporting (whether or not remediated) and (B) no change in the Company&#8217;s internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, the
        Company&#8217;s internal control over financial reporting.</div>
      <div><br>
      </div>
      <div style="text-indent: 36pt; margin-left: 13.5pt;">(kk)&#160; Except as described in the Time of Sale Prospectus or the Registration Statement, the Company has not sold,
        issued or distributed any shares of Common Stock during the six-month period preceding the date hereof, including any sales pursuant to Rule 144A under, or Regulation D or S of, the Securities Act, other than shares issued pursuant to employee
        benefit plans, qualified stock option plans or other compensation or incentive plans or pursuant to the exercise or vesting of, as applicable, outstanding options, restricted stock units, other stock-based awards or inducement grants made to new
        employee hires.</div>
      <div><br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">8</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div><br>
      </div>
      <div style="text-indent: 36pt; margin-left: 13.5pt;">(ll)&#160; The Company and its subsidiaries&#8217; information technology assets and equipment, computers, systems, networks,
        hardware, software, websites, applications, and databases (collectively, &#8220;<font style="font-weight: bold;">IT Systems</font>&#8221;) are adequate for, and operate and perform in all material
        respects as required in connection with the operation of the business of the Company and its subsidiaries as currently conducted.&#160; The Company and its subsidiaries have implemented and maintained commercially reasonable controls, policies,
        procedures, and safeguards designed to maintain and protect their material confidential information and the integrity, continuous operation, redundancy and security of all IT Systems and data (including all personal, personally identifiable,
        sensitive, confidential or regulated data (&#8220;<font style="font-weight: bold;">Personal Data</font>&#8221;)) used in connection with their businesses, and there have been no breaches,
        violations, outages or unauthorized uses of or accesses to same, nor any incidents under internal review or investigations relating to the same, except as would not, individually or in the aggregate, reasonably be expected to result in a material
        adverse effect on the Company and its subsidiaries taken as a whole. The Company and its subsidiaries are presently in compliance with all applicable laws or statutes and all judgments, orders, rules and regulations of any court or arbitrator or
        governmental or regulatory authority, internal policies and contractual obligations relating to the privacy and security of IT Systems and Personal Data and to the protection of such IT Systems and Personal Data from unauthorized use, access,
        misappropriation or modification, except for such noncompliance as would not, individually or in the aggregate, reasonably be expected to result in a material adverse effect on the Company and its subsidiaries taken as a whole.</div>
      <div><br>
      </div>
      <div style="text-indent: 36pt; margin-left: 13.5pt;">(mm)&#160; The Company has filed all federal, state, local and foreign tax returns required to be filed through the date
        of this Agreement or has requested extensions thereof (except, in each case, where the failure to file would not, individually or in the aggregate, reasonably be expected to have a material adverse effect on the Company and its subsidiaries, taken
        as a whole) and has paid all taxes required to be paid thereon (except for cases in which the failure to file or pay would not reasonably be expected to have a material adverse effect on the Company and its subsidiaries, taken as a whole, or,
        except as currently being contested in good faith and for which reserves required by U.S. GAAP have been recorded in the financial statements of the Company), and there is no tax deficiency which if determined adversely to the Company would
        reasonably be expected to have (nor does the Company have any notice or knowledge of any tax deficiency which would reasonably be expected to be determined adversely to the Company and which would reasonably be expected to have) a material adverse
        effect on the Company and its subsidiaries, taken as a whole.</div>
      <div><br>
      </div>
      <div style="text-indent: 36pt; margin-left: 13.5pt;">(nn) Except as disclosed in the Time of Sale Prospectus or the Registration Statement, the Company and each of its
        subsidiaries are presently in compliance in all material respects with all applicable privacy and data protection laws, judgments, orders, and other contractual or legal obligations binding on the Company or its subsidiaries; statutes, rules and
        regulations of any court or arbitrator or other governmental or regulatory authority, in each case, relating to the privacy and security of the information technology systems and personal data used in connection with the operation of the Company&#8217;s
        and its subsidiaries&#8217; businesses as currently conducted. The Company and each of its subsidiaries have, in accordance with industry standard practices for companies comparable in size to the Company, taken steps designed to protect the information
        technology systems and personal data of the Company used in connection with the operation of the Company&#8217;s and its subsidiaries&#8217; businesses. Except as disclosed in the Time of Sale Prospectus or the Registration Statement and to the knowledge of
        the Company, there has been no material security breach, compromise, misuse, misappropriation, or unauthorized use, access, disablement, or modification of or relating to any such information technology system or personal data, and the Company and
        its subsidiaries have not been notified of, and have no knowledge of any event or condition that would reasonably be expected to result in, any material security breach, compromise, misuse, misappropriation, or unauthorized use, access,
        disablement, or modification of or relating to any such information technology system or personal data.</div>
      <div><br>
      </div>
      <div style="text-indent: 32.4pt;">2.<font style="font-style: italic;"> Agreements to Sell and Purchase</font>.
        The Company hereby agrees to sell to the several Underwriters, and each Underwriter, upon the basis of the representations and warranties herein contained, but subject to the conditions hereinafter stated, agrees, severally and not jointly, to
        purchase from the Company the respective number of Shares set forth in Schedule I hereto opposite its name at $18.85 per share (the &#8220;<font style="font-weight: bold;">Purchase Price</font>&#8221;).</div>
      <div><br>
      </div>
      <div style="text-indent: 32.4pt; margin-left: 3.6pt;">3.<font style="font-style: italic;">&#160; Terms of
          Public Offering</font>.&#160; The Company is advised by you that the Underwriters propose to make a public offering of their respective portions of the Shares as soon after the Registration Statement and this Agreement have become effective as in your
        judgment is advisable.&#160; The Company is further advised by you that the Shares are to be offered to the public initially at $20.00 per share (the &#8220;<font style="font-weight: bold;">Public
          Offering Price</font>&#8221;).</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">9</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div><br>
      </div>
      <div style="text-indent: 32.4pt; margin-left: 3.6pt;">4.<font style="font-style: italic;">&#160; Payment and
          Delivery</font>. Payment for the Shares shall be made to the Company in Federal or other funds immediately available in New York City against delivery of such Shares for the respective accounts of the several Underwriters at 10:00 a.m., New York
        City time, on October 21, 2022 or at such other time on the same or such other date, not later than the fifth business day thereafter, as shall be designated in writing by you. The time and date of such payment are hereinafter referred to as the &#8220;<font style="font-weight: bold;">Closing Date</font>.&#8221;</div>
      <div><br>
      </div>
      <div style="text-indent: 36pt;">The Shares shall be registered in such names and in such denominations as you shall request in writing not later than one full business
        day prior to the Closing Date. The Shares shall be delivered to you on the Closing Date for the respective accounts of the several Underwriters, with any transfer taxes payable in connection with the transfer of the Shares to the Underwriters duly
        paid, against payment of the Purchase Price therefor.</div>
      <div><br>
      </div>
      <div style="text-indent: 32.4pt; margin-left: 3.6pt;">5.&#160; <font style="font-style: italic;">Conditions to
          the Underwriters&#8217; Obligations</font>. The several obligations of the Underwriters are subject to the following conditions:</div>
      <div><br>
      </div>
      <div style="text-indent: 36pt; margin-left: 13.5pt;">(a)&#160; Subsequent to the execution and delivery of this Agreement and prior to the Closing Date:</div>
      <div><br>
      </div>
      <div style="text-indent: 36pt; margin-left: 36pt;">(i)&#160; there shall not have occurred any downgrading, nor shall any notice have been given to the Company of any
        intended or potential downgrading or of any review for a possible change that does not indicate the direction of the possible change, in the rating accorded any of the securities of the Company or any of its subsidiaries by any &#8220;nationally
        recognized statistical rating organization,&#8221; as such term is defined for purposes of Section 3(A)(62) of the Exchange Act; and</div>
      <div><br>
      </div>
      <div style="text-indent: 36pt; margin-left: 36pt;">(ii)&#160; there shall not have occurred any change, or any development involving a prospective change, in the condition,
        financial or otherwise, or in the earnings, business, prospects or operations of the Company and its subsidiaries, taken as a whole, from that set forth in the Time of Sale Prospectus as of the date of this Agreement that, in your judgment, is
        material and adverse or is reasonably likely to be material and adverse, and that makes it, in your judgment, impracticable to market the Shares on the terms and in the manner contemplated in the Time of Sale Prospectus.</div>
      <div><br>
      </div>
      <div style="text-indent: 36pt; margin-left: 13.5pt;">(b)&#160; The Underwriters shall have received on the Closing Date a certificate, dated the Closing Date and signed by an
        executive officer of the Company, to the effect set forth in Section 5(a)(i) above and to the effect that (i) the representations and warranties of the Company contained in this Agreement are true and correct as of the Closing Date and (ii) that
        the Company has complied with all of the agreements and satisfied all of the conditions on its part to be performed or satisfied hereunder on or before the Closing Date. The officer signing and delivering such certificate may rely upon the best of
        his or her knowledge as to proceedings threatened.</div>
      <div><br>
      </div>
      <div style="text-indent: 36pt; margin-left: 13.5pt;">(c)&#160; The Underwriters shall have received on the Closing Date an opinion and negative assurance letter of Covington
        &amp; Burling LLP, special counsel for the Company, dated the Closing Date, in the form previously agreed, which shall be rendered to the Underwriters at the request of the Company and shall so state therein.</div>
      <div><br>
      </div>
      <div style="text-indent: 36pt; margin-left: 13.5pt;">(d) The Underwriters shall have received on the Closing Date an opinion of Hunton Andrews Kurth LLP, Virginia
        counsel for the Company, dated the Closing Date, in the form previously agreed, which shall be rendered to the Underwriters at the request of the Company and shall so state therein.</div>
      <div><br>
      </div>
      <div style="text-indent: 36pt; margin-left: 13.5pt;">(e)&#160; The Underwriters shall have received on the Closing Date an opinion of Cooley LLP, intellectual property
        counsel to the Company, dated the Closing Date, in the form previously agreed.</div>
      <div><br>
      </div>
      <div style="text-indent: 36pt; margin-left: 13.5pt;">(f)&#160; The Underwriters shall have received on the Closing Date an opinion or opinions of Ropes &amp; Gray LLP,
        counsel for the Underwriters, dated the Closing Date, in form and substance reasonably satisfactory to the Representatives, and such counsel shall have received such papers and information as they may reasonably request to enable them to pass upon
        such matters.</div>
      <div><br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">10</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div><br>
      </div>
      <div style="text-indent: 36pt; margin-left: 13.5pt;">(g)&#160; The Underwriters shall have received, on each of the date hereof and the Closing Date, a letter, dated the date
        hereof or the Closing Date, as the case may be, in form and substance satisfactory to the Underwriters, from Ernst &amp; Young LLP, independent public accountants, containing statements and information of the type ordinarily included in
        accountants&#8217; &#8220;comfort letters&#8221; to underwriters with respect to the financial statements and certain financial information contained in the Registration Statement, the Time of Sale Prospectus and the Prospectus; provided that the letter delivered on
        the Closing Date shall use a &#8220;cut-off date&#8221; not earlier than the date hereof.</div>
      <div><br>
      </div>
      <div style="text-indent: 36pt; margin-left: 13.5pt;">(h)&#160; The Underwriters shall have received, on each of the date hereof and the Closing Date, dated the date hereof or
        the Closing Date, as the case may be, in form and substance satisfactory to the Underwriters, a certificate executed by the Chief Financial Officer of the Company with respect to certain previously agreed financial information contained in the
        Registration Statement, the Time of Sale Prospectus and the Prospectus.</div>
      <div><br>
      </div>
      <div style="text-indent: 36pt; margin-left: 13.5pt;">(i)The &#8220;lock-up&#8221; agreements, each substantially in the form of Exhibit A hereto, between you and each executive
        officer and director of the Company relating to sales and certain other dispositions of shares of Common Stock or certain other securities, delivered to you on or before the date hereof, shall be in full force and effect on the Closing Date.</div>
      <div><br>
      </div>
      <div style="text-indent: 32.4pt; margin-left: 3.6pt;">6.&#160; <font style="font-style: italic;">Covenants of
          the Company</font>. The Company covenants with each Underwriter as follows:</div>
      <div><br>
      </div>
      <div style="text-indent: 36pt; margin-left: 13.5pt;">(a)&#160; To furnish to you, without charge, a signed copy of the Registration Statement (including exhibits thereto) and
        for delivery to each other Underwriter a conformed copy of the Registration Statement (without exhibits thereto) and to furnish to you in New York City, without charge, as promptly as practicable and in any event no later than 10:00 a.m. New York
        City time on the second business day succeeding the date of this Agreement and during the period mentioned in Section 6(e) or 6(f) below, as many copies of the Time of Sale Prospectus, the Prospectus and any supplements and amendments thereto or to
        the Registration Statement as you may reasonably request.</div>
      <div><br>
      </div>
      <div style="text-indent: 36pt; margin-left: 13.5pt;">(b)&#160; Before amending or supplementing the Registration Statement, the Time of Sale Prospectus or the Prospectus, to
        furnish to you a copy of each such proposed amendment or supplement and to provide you a reasonable opportunity to comment on any such proposed amendment or supplement prior to filing it, and to file with the Commission within the applicable period
        specified in Rule 424(b) under the Securities Act any prospectus required to be filed pursuant to such Rule.</div>
      <div><br>
      </div>
      <div style="text-indent: 36pt; margin-left: 13.5pt;">(c)&#160; To furnish to you a copy of each proposed free writing prospectus to be prepared by or on behalf of, used by,
        or referred to by the Company with respect to the Shares and not to use or refer to any such proposed free writing prospectus to which you reasonably and promptly object.</div>
      <div><br>
      </div>
      <div style="text-indent: 36pt; margin-left: 13.5pt;">(d)&#160; Not to take any action that would result in an Underwriter or the Company being required to file with the
        Commission pursuant to Rule 433(d) under the Securities Act a free writing prospectus prepared by or on behalf of the Underwriter that the Underwriter otherwise would not have been required to file thereunder.</div>
      <div><br>
      </div>
      <div style="text-indent: 36pt; margin-left: 13.5pt;">(e)&#160; If the Time of Sale Prospectus is being used to solicit offers to buy the Shares at a time when the Prospectus
        is not yet available to prospective purchasers and any event shall occur or condition exist as a result of which it is necessary to amend or supplement the Time of Sale Prospectus in order to make the statements therein, in the light of the
        circumstances, not misleading, or if, in the opinion of counsel for the Company or the Underwriters, it is necessary to amend or supplement the Time of Sale Prospectus to comply with applicable law, promptly to prepare, file with the Commission and
        furnish, at its own expense, to the Underwriters and to any dealer upon request, either amendments or supplements to the Time of Sale Prospectus so that the statements in the Time of Sale Prospectus as so amended or supplemented will not, in the
        light of the circumstances under which they were made, when the Time of Sale Prospectus is delivered to a prospective purchaser, be misleading, or so that the Time of Sale Prospectus, as amended or supplemented, will comply with applicable law.</div>
      <div><br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">11</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div><br>
      </div>
      <div style="text-indent: 36pt; margin-left: 13.5pt;">(f)&#160; If, during such period after the first date of the public offering of the Shares as in the opinion of counsel
        for the Company or the Underwriters the Prospectus (or in lieu thereof the notice referred to in Rule 173(a) under the Securities Act) is required by law to be delivered in connection with sales by an Underwriter or dealer, any event shall occur or
        condition exist as a result of which it is necessary to amend or supplement the Prospectus in order to make the statements therein, in the light of the circumstances under which they were made, when the Prospectus (or in lieu thereof the notice
        referred to in Rule 173(a) under the Securities Act) is delivered to a purchaser, not misleading, or if, in the opinion of counsel for the Company or the Underwriters, it is necessary to amend or supplement the Prospectus to comply with applicable
        law, promptly to prepare, file with the Commission and furnish, at its own expense, to the Underwriters and to the dealers (whose names and addresses you will furnish to the Company) to which Shares may have been sold by you on behalf of the
        Underwriters and to any other dealers upon request, either amendments or supplements to the Prospectus so that the statements in the Prospectus as so amended or supplemented will not, in the light of the circumstances under which they were made,
        when the Prospectus (or in lieu thereof the notice referred to in Rule 173(a) under the Securities Act) is delivered to a purchaser, be misleading or so that the Prospectus, as amended or supplemented, will comply with applicable law.</div>
      <div><br>
      </div>
      <div style="text-indent: 36pt; margin-left: 13.5pt;">(g)&#160; To endeavor to qualify the Shares for offer and sale under the securities or Blue Sky laws of such
        jurisdictions as you shall reasonably request; provided that in no event shall the Company or any of its subsidiaries be obligated to qualify to do business as a foreign corporation in any jurisdiction in which it is not now so qualified or to file
        any general consent to service of process.</div>
      <div><br>
      </div>
      <div style="text-indent: 36pt; margin-left: 13.5pt;">(h)&#160; To make generally available to the Company&#8217;s security holders and to you as soon as practicable an earning
        statement covering a period of at least 12 months beginning with the first fiscal quarter of the Company occurring after the date of this Agreement which shall satisfy the provisions of Section 11(a) of the Securities Act and the rules and
        regulations of the Commission thereunder.</div>
      <div><br>
      </div>
      <div style="text-indent: 36pt; margin-left: 13.5pt;">(i)&#160; The Company will not, directly or indirectly, knowingly use the proceeds of the offering, or lend, contribute
        or otherwise make available such proceeds to any subsidiary, joint venture partner or other Person: (x) to fund or facilitate any activities or business of or with any Person or in any country or territory that, at the time of such funding or
        facilitation, is the subject of Sanctions; or (y) in any other manner that will result in a violation of Sanctions by any Person (including any Person participating in the offering, whether as underwriter, advisor, investor or otherwise).</div>
      <div><br>
      </div>
      <div style="text-indent: 36pt; margin-left: 13.5pt;">(j)&#160; Whether or not the transactions contemplated in this Agreement are consummated or this Agreement is terminated,
        to pay or cause to be paid all expenses incident to the performance of the Company&#8217;s obligations under this Agreement, including: (i) the fees, disbursements and expenses of the Company&#8217;s counsel and the Company&#8217;s accountants in connection with the
        registration and delivery of the Shares under the Securities Act and all other fees or expenses in connection with the preparation and filing of the Registration Statement, the Time of Sale Prospectus, the Prospectus, any free writing prospectus
        prepared by or on behalf of, used by, or referred to by the Company and amendments and supplements to any of the foregoing, including all printing costs associated therewith, and the mailing and delivering of copies thereof to the Underwriters and
        dealers, in the quantities hereinabove specified, (ii) all costs and expenses related to the transfer and delivery of the Shares to the Underwriters, including any transfer or other taxes payable thereon, (iii) the cost of printing or producing any
        Blue Sky or Legal Investment memorandum in connection with the offer and sale of the Shares under state securities laws and all expenses in connection with the qualification of the Shares for offer and sale under state securities laws as provided
        in Section 6(g) hereof, including filing fees and the reasonable fees and disbursements of counsel for the Underwriters in connection with such qualification and in connection with the Blue Sky or Legal Investment memorandum, (iv) all filing fees
        and the reasonable fees and disbursements of counsel to the Underwriters incurred in connection with the review and qualification of the offering of the Shares by FINRA, (v) all costs and expenses incident to listing the Shares on the Nasdaq Global
        Select Market, (vi) the cost of printing certificates representing the Shares, (vii) the costs and charges of any transfer agent, registrar or depositary for the Shares, (viii) the costs and expenses of the Company relating to investor
        presentations on any &#8220;road show&#8221; undertaken in connection with the marketing of the offering of the Shares, including, without limitation, expenses associated with the preparation or dissemination of any electronic road show, expenses associated
        with the production of road show slides and graphics, fees and expenses of any consultants engaged in connection with the road show presentations with the prior written approval of the Company, travel and lodging expenses of the representatives and
        officers of the Company and any such consultants, and the cost of any aircraft chartered in connection with any road show (provided that the prior written approval of the Company is obtained prior to the chartering of any such aircraft), (ix) the
        document production charges and expenses associated with printing this Agreement, and (x) all other costs and expenses incident to the performance of the obligations of the Company hereunder for which provision is not otherwise made in this Section
        6. It is understood, however, that except as provided in this Section 6, Section 8 below, the last sentence of Section 9 below and the last paragraph of Section 10 below, the Underwriters will pay all of their costs and expenses, including fees and
        disbursements of their counsel, stock transfer taxes payable on resale of any of the Shares by them, travel and lodging expenses of their representatives in connection with any road show, and any advertising expenses connected with any offers they
        may make, it being further understood, however, that the fees and disbursements of counsel for the Underwriters to be paid by the Company pursuant to clauses (iii) and (iv) above shall not exceed $10,000, in the aggregate.</div>
      <div><br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">12</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div><br>
      </div>
      <div style="text-indent: 36pt;">The Company also covenants with each Underwriter that, without the prior written consent of the Representatives on behalf of the
        Underwriters, it will not, during the period through the 60<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup> day after the date of the Prospectus, (A) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any
        option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities convertible into or exercisable or exchangeable for Common Stock or (B) enter into any swap or
        other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of the Common Stock, whether any such transaction described in clause (A) or (B) above is to be settled by delivery of Common Stock or
        such other securities, in cash or otherwise or (C) file any registration statement (other than on Form S-8) with the Commission relating to the offering of any shares of Common Stock or any securities convertible into or exercisable or exchangeable
        for Common Stock.</div>
      <div><br>
      </div>
      <div style="text-indent: 36pt;">The restrictions contained in the preceding paragraph shall not apply to (1) the Shares to be sold hereunder, (2) the issuance and sale
        of Common Stock pursuant to that certain Sales Agreement, dated as of February 25, 2021, between the Company and SVB Leerink LLC (now known as SVB Securities LLC), provided that no sales shall be made under the Sales Agreement until 30 days after
        the date hereof, (3) (i) the issuance by the Company of Common Stock upon the exercise of outstanding stock options or other stock-based awards or vesting of outstanding restricted stock units or other stock-based awards or issuances of shares of
        Common Stock under the 2000 Plan, the 2013 Plan, the 2015 Plan, the 2017 Plan or the 2019 Plan or pursuant to inducement grants to new employees or upon the exercise of currently outstanding options granted outside of such plans, (ii) the grant by
        the Company of stock options, restricted stock units or other stock-based awards under the 2019 Plan or pursuant to inducement grants to new employees or (iii) the conversion of a security outstanding on the date hereof described in the
        Registration Statement or of which the Underwriters have been advised in writing or (4) issuances of Common Stock or other securities in connection with a transaction that includes a commercial relationship (including joint ventures, marketing or
        distribution arrangements, collaboration agreements or intellectual property license agreements) or any acquisition of assets or at least a controlling portion of the equity of another entity provided that (x) the aggregate number of shares of
        securities issued pursuant to this clause (4) shall not exceed 10% of the total number of outstanding shares of Common Stock immediately following the issuance and sale of the Shares pursuant hereto and (y) the holder of such shares or securities
        shall sign a lock-up agreement in the form attached hereto as Exhibit A if the issuance of Common Stock or other securities occurs during the 60-day restricted period.</div>
      <div><br>
      </div>
      <div style="text-indent: 32.4pt; margin-left: 3.6pt;">7.<font style="font-style: italic;">&#160; Covenants of
          the Underwriters</font>. Each Underwriter severally covenants with the Company not to take any action that would result in the Company being required to file with the Commission under Rule 433(d) a free writing prospectus prepared by or on behalf
        of such Underwriter that otherwise would not be required to be filed by the Company thereunder, but for the action of the Underwriter.</div>
      <div><br>
      </div>
      <div style="text-indent: 32.4pt; margin-left: 3.6pt;">8.&#160; <font style="font-style: italic;">Indemnity and
          Contribution</font>.</div>
      <div><br>
      </div>
      <div style="text-indent: 36pt; margin-left: 13.5pt;">(a)&#160; The Company agrees to indemnify and hold harmless each Underwriter, the directors, officers, employees,
        affiliates and agents of each Underwriter and each person, if any, who controls any Underwriter within the meaning of either Section 15 of the Securities Act or Section 20 of the Exchange Act and each affiliate of any Underwriter within the meaning
        of Rule 405 under the Securities Act from and against any and all losses, claims, damages and liabilities (including, without limitation, any legal or other expenses reasonably incurred in connection with defending or investigating any such action
        or claim) caused by any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement or any amendment thereof, the Time of Sale Prospectus or any amendment or supplement thereto, any issuer free writing
        prospectus as defined in Rule 433(h) under the Securities Act, any Company information that the Company has filed, or is required to file, pursuant to Rule 433(d) under the Securities Act, any road show as defined in Rule 433(h) under the
        Securities Act (a &#8220;<font style="font-weight: bold;">road show</font>&#8221;) or the Prospectus or any amendment or supplement thereto, or caused by any omission or alleged omission to state
        therein a material fact required to be stated therein or necessary to make the statements therein not misleading, except insofar as such losses, claims, damages or liabilities are caused by any such untrue statement or omission or alleged untrue
        statement or omission based upon information relating to any Underwriter furnished to the Company in writing by such Underwriter through you expressly for use therein. For purposes of this Agreement, the only information furnished shall be (a) the
        table following the first paragraph under the caption &#8220;Underwriting&#8221; in the Prospectus, setting forth the names of the Underwriters and number of Shares to be purchased by each Underwriter; (b) the third paragraph under the under the caption
        &#8220;Underwriting&#8221; in the Prospectus, concerning the terms of the offering by the Underwriters; and (c) paragraphs fifteen and sixteen under the caption &#8220;Underwriting&#8221; in the Prospectus, relating to stabilizing transactions, short sales, purchases to
        cover positions created by short sales and the imposition of penalty bids by the Underwriters (the &#8220;<font style="font-weight: bold;">Underwriter Information</font>&#8221;).</div>
      <div><br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">13</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div><br>
      </div>
      <div style="text-indent: 36pt; margin-left: 13.5pt;">(b)&#160; Each Underwriter agrees, severally and not jointly, to indemnify and hold harmless the Company, its directors,
        its officers who sign the Registration Statement and each person, if any, who controls the Company within the meaning of either Section 15 of the Securities Act or Section 20 of the Exchange Act to the same extent as the foregoing indemnity from
        the Company to the Underwriters, but only with reference to the Underwriter Information.</div>
      <div><br>
      </div>
      <div style="text-indent: 36pt; margin-left: 13.5pt;">(c)&#160; In case any proceeding (including any governmental investigation) shall be instituted involving any person in
        respect of which indemnity may be sought pursuant to Section 8(a) or 8(b), such person (the &#8220;<font style="font-weight: bold;">indemnified party</font>&#8221;) shall promptly notify the person
        against whom such indemnity may be sought (the &#8220;<font style="font-weight: bold;">indemnifying party</font>&#8221;) in writing and the indemnifying party, upon request of the indemnified
        party, shall retain counsel reasonably satisfactory to the indemnified party to represent the indemnified party and any others the indemnifying party may designate in such proceeding and shall pay the reasonably incurred fees and disbursements of
        such counsel related to such proceeding. In any such proceeding, any indemnified party shall have the right to retain its own counsel, but the fees and expenses of such counsel shall be at the expense of such indemnified party unless (i) the
        indemnifying party and the indemnified party shall have mutually agreed to the retention of such counsel, (ii) the named parties to any such proceeding (including any impleaded parties) include both the indemnifying party and the indemnified party
        and representation of both parties by the same counsel would be inappropriate due to actual or potential differing interests between them or (iii) the use of counsel chosen by the indemnifying party to represent the indemnified party would present
        such counsel with a conflict of interest. It is understood that the indemnifying party shall not, in respect of the legal expenses of any indemnified party in connection with any proceeding or related proceedings in the same jurisdiction, be liable
        for the fees and expenses of more than one separate firm (in addition to any local counsel) for all such indemnified parties, and that all such fees and expenses shall be reimbursed as they are incurred. Such firm shall be designated in writing by
        the Representatives, in the case of parties indemnified pursuant to Section 8(a), and by the Company, in the case of parties indemnified pursuant to Section 8(b). The indemnifying party shall not be liable for any settlement of any proceeding
        effected without its written consent, but if settled with such consent or if there be a final judgment for the plaintiff, the indemnifying party agrees to indemnify the indemnified party from and against any loss or liability by reason of such
        settlement or judgment. No indemnifying party shall, without the prior written consent of the indemnified party, effect any settlement of any pending or threatened proceeding in respect of which any indemnified party is or could have been a party
        and indemnity could have been sought hereunder by such indemnified party, unless such settlement includes an unconditional release of such indemnified party from all liability on claims that are the subject matter of such proceeding and does not
        include a statement as to or an admission of fault, culpability or a failure to act by or on behalf of any indemnified party.</div>
      <div><br>
      </div>
      <div style="text-indent: 36pt; margin-left: 13.5pt;">(d)&#160; To the extent the indemnification provided for in Section 8(a) or 8(b) is unavailable to an indemnified party
        or insufficient in respect of any losses, claims, damages or liabilities referred to therein, then each indemnifying party under such paragraph, in lieu of indemnifying such indemnified party thereunder, shall contribute to the amount paid or
        payable by such indemnified party as a result of such losses, claims, damages or liabilities (i) in such proportion as is appropriate to reflect the relative benefits received by the indemnifying party or parties on the one hand and the indemnified
        party or parties on the other hand from the offering of the Shares or (ii) if the allocation provided by Section 8(d)(i) above is not permitted by applicable law, in such proportion as is appropriate to reflect not only the relative benefits
        referred to in Section 8(d)(i) above but also the relative fault of the indemnifying party or parties on the one hand and of the indemnified party or parties on the other hand in connection with the statements or omissions that resulted in such
        losses, claims, damages or liabilities, as well as any other relevant equitable considerations. The relative benefits received by the indemnifying party or parties on the one hand and the indemnified party or parties on the other hand in connection
        with the offering of the Shares shall be deemed to be in the same respective proportions as the net proceeds from the offering of the Shares (before deducting expenses) received by the Company and the total underwriting discounts and commissions
        received by the Underwriters, as such net proceeds received by the Company and total underwriting discounts and commissions received by the Underwriters are set forth in the section of the Prospectus entitled &#8220;Underwriting&#8221;, bear to the aggregate
        Public Offering Price of the Shares. The relative fault of the indemnifying party or parties on the one hand and the indemnified party or parties on the other hand shall be determined by reference to, among other things, whether the untrue or
        alleged untrue statement fact or the omission or alleged omission to state a material fact relates to information supplied by the indemnifying party or parties on the one hand or by the indemnified party or parties on the other hand, and the
        parties&#8217; relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission. The Underwriters&#8217; respective obligations to contribute pursuant to this Section 8 are several in proportion to the
        respective number of Shares they have purchased hereunder, and not joint.</div>
      <div><br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">14</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div><br>
      </div>
      <div style="text-indent: 36pt; margin-left: 13.5pt;">(e)&#160; The Company and the Underwriters agree that it would not be just or equitable if contribution pursuant to this
        Section 8 were determined by pro rata allocation (even if the Underwriters were treated as one entity for such purpose) or by any other method of allocation that does not take account of the equitable considerations referred to in Section 8(d). The
        amount paid or payable by an indemnified party as a result of the losses, claims, damages and liabilities referred to in Section 8(d) shall be deemed to include, subject to the limitations set forth above, any legal or other expenses reasonably
        incurred by such indemnified party in connection with investigating or defending any such action or claim. Notwithstanding the provisions of this Section 8, no Underwriter shall be required to contribute any amount in excess of the amount by which
        the total underwriting discounts and commissions received by such Underwriter with respect to the offering of the Shares exceeds the amount of any damages that such Underwriter has otherwise been required to pay by reason of such untrue or alleged
        untrue statement or omission or alleged omission. Notwithstanding anything herein to the contrary, no person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution from
        any person who was not guilty of such fraudulent misrepresentation. The remedies provided for in this Section 8 are not exclusive and shall not limit any rights or remedies which may otherwise be available to any indemnified party at law or in
        equity.</div>
      <div><br>
      </div>
      <div style="text-indent: 36pt; margin-left: 13.5pt;">(f)&#160; The indemnity and contribution provisions contained in this Section 8 and the representations and warranties of
        the Company contained in this Agreement shall remain operative and in full force and effect regardless of (i) any termination of this Agreement, (ii) any investigation made by or on behalf of any Underwriter, any person controlling any Underwriter
        or any affiliate of any Underwriter, or by or on behalf of the Company, its officers or directors or any person controlling the Company and (iii) acceptance of and payment for any of the Shares.</div>
      <div><br>
      </div>
      <div style="text-indent: 32.4pt; margin-left: 3.6pt;">9.&#160; <font style="font-style: italic;">Termination</font>.
        The Underwriters may terminate this Agreement by notice given by you to the Company if, after the execution and delivery of this Agreement and prior to the Closing Date, (a) trading generally shall have been suspended or materially limited on, or
        by, as the case may be, any of the Commission, the New York Stock Exchange, NYSE American (formerly known as the American Stock Exchange), the Nasdaq Global Select Market or the Nasdaq Global Market, (b) trading of any securities of the Company
        shall have been suspended on any exchange or in any over-the-counter market, (c) a material disruption in securities settlement, payment or clearance services in the United States shall have occurred, (d) any moratorium on commercial banking
        activities shall have been declared by Federal or New York state authorities, or (e) there shall have occurred any outbreak or escalation of hostilities, or any change in financial markets or any calamity or crisis that, in your judgment, is
        material and adverse and which, singly or together with any other event specified in this clause (e), makes it, in your judgment, impracticable or inadvisable to proceed with the offer, sale or delivery of the Shares on the terms and in the manner
        contemplated in the Time of Sale Prospectus or the Prospectus. If this Agreement shall be terminated by the Underwriters pursuant to this Section 9, the Company will reimburse the Underwriters for all out-of-pocket accountable expenses (including
        the fees and disbursements of their counsel) reasonably incurred by such Underwriters in connection with this Agreement or the offering contemplated hereunder.</div>
      <div><br>
      </div>
      <div style="text-indent: 32.4pt; margin-left: 3.6pt;">10.&#160; <font style="font-style: italic;">Effectiveness;
          Defaulting Underwriters</font>. This Agreement shall become effective upon the execution and delivery hereof by the parties hereto.</div>
      <div><br>
      </div>
      <div style="text-indent: 36pt;">If, on the Closing Date, any one or more of the Underwriters shall fail or refuse to purchase Shares that it has or they have agreed to
        purchase hereunder on such date, and the aggregate number of Shares which such defaulting Underwriter or Underwriters agreed but failed or refused to purchase is not more than one-tenth of the aggregate number of the Shares to be purchased on such
        date, the non-defaulting Underwriters shall be obligated severally in the proportions that the number of Shares set forth opposite their respective names in Schedule I bears to the aggregate number of Shares set forth opposite the names of all such
        non-defaulting Underwriters, or in such other proportions as you may specify, to purchase the Shares which such defaulting Underwriter or Underwriters agreed but failed or refused to purchase on such date; provided that in no event shall the number
        of Shares that any Underwriter has agreed to purchase pursuant to this Agreement be increased pursuant to this Section 10 by an amount in excess of one-ninth of such number of Shares without the written consent of such Underwriter. If, on the
        Closing Date, any Underwriter or Underwriters shall fail or refuse to purchase Shares and the aggregate number of Shares with respect to which such default occurs is more than one-tenth of the aggregate number of Shares to be purchased on such
        date, and arrangements satisfactory to you and the Company for the purchase of such Shares are not made within 48 hours after such default, this Agreement shall terminate. In the event of such termination, the Company shall not have any liability
        to any Underwriter (except to the extent provided in Sections 6(j) and 8 hereof) nor shall any Underwriter (other than an Underwriter who shall have failed otherwise than for some reason permitted under this Agreement to purchase the amount of
        Shares agreed by such Underwriter to be purchased hereunder) be under any liability to the Company (except to the extent provided under Sections 6(j) and 8 hereof). In any such case either you or the Company shall have the right to postpone the
        Closing Date, but in no event for longer than seven days, in order that the required changes, if any, in the Registration Statement, in the Time of Sale Prospectus, in the Prospectus or in any other documents or arrangements may be effected. Any
        action taken under this paragraph shall not relieve any defaulting Underwriter from liability in respect of any default of such Underwriter under this Agreement.</div>
      <div><br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">15</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div><br>
      </div>
      <div style="text-indent: 36pt;">If this Agreement shall be terminated by the Underwriters because of any failure or refusal on the part of the Company to comply with the
        terms or to fulfill any of the conditions of this Agreement, or if for any reason the Company shall be unable to perform its obligations under this Agreement (unless such failure to comply or inability to perform is due primarily to any default of
        any Underwriter), the Company will reimburse the Underwriters or such Underwriters as have so terminated this Agreement with respect to themselves, severally, for all out-of-pocket accountable expenses (including the fees and disbursements of their
        counsel) reasonably incurred by such Underwriters in connection with this Agreement or the offering contemplated hereunder.</div>
      <div><br>
      </div>
      <div style="text-indent: 32.4pt; margin-left: 3.6pt;">11.&#160; <font style="font-style: italic;">Entire
          Agreement</font>.</div>
      <div><br>
      </div>
      <div style="text-indent: 36pt; margin-left: 13.5pt;">(a)&#160; This Agreement, together with any contemporaneous written agreements that relate to the offering of the Shares,
        represents the entire agreement between the Company on one hand and the Underwriters on the other hand, with respect to the preparation of the Time of Sale Prospectus, the Prospectus, the conduct of the offering, and the purchase and sale of the
        Shares.</div>
      <div><br>
      </div>
      <div style="text-indent: 36pt; margin-left: 13.5pt;">(b)&#160; The Company acknowledges that in connection with the offering of the Shares: (i) the Underwriters have acted at
        arms&#8217; length, are not agents of, and owe no fiduciary duties to, the Company or any other person, (ii) the Underwriters owe the Company only those duties and obligations set forth in this Agreement and prior written agreements (to the extent not
        superseded by this Agreement), if any, and (iii) the Underwriters may have interests that differ from those of the Company. The Company waives to the full extent permitted by applicable law any claims it may have against the Underwriters arising
        from an alleged breach of fiduciary duty in connection with the offering of the Shares.</div>
      <div><br>
      </div>
      <div style="text-indent: 32.4pt; margin-left: 3.6pt;">12.&#160; <font style="font-style: italic;">Waiver of
          Jury Trial</font>.&#160; The Company hereby irrevocably waives, to the fullest extent permitted by applicable law, any and all right to trial by jury in any legal proceeding arising out of or relating to this Agreement or the transactions contemplated
        hereby.</div>
      <div><br>
      </div>
      <div style="text-indent: 32.4pt; margin-left: 3.6pt;">13.<font style="font-style: italic;">&#160; Recognition
          of the U.S. Special Resolution Regimes</font>. In the event that any Underwriter that is a Covered Entity becomes subject to a proceeding under a U.S. Special Resolution Regime, the transfer from such Underwriter of this Agreement, and any
        interest and obligation in or under this Agreement, will be effective to the same extent as the transfer would be effective under the U.S. Special Resolution Regime if this Agreement, and any such interest and obligation, were governed by the laws
        of the United States or a state of the United States.</div>
      <div><br>
      </div>
      <div style="text-indent: 36pt; margin-left: 13.5pt;">(a) In the event that any Underwriter that is a Covered Entity or a BHC Act Affiliate of such Underwriter becomes
        subject to a proceeding under a U.S. Special Resolution Regime, Default Rights under this Agreement that may be exercised against such Underwriter are permitted to be exercised to no greater extent than such Default Rights could be exercised under
        the U.S. Special Resolution Regime if this Agreement were governed by the laws of the United States or a state of the United States.</div>
      <div><br>
      </div>
      <div style="text-indent: 36pt; margin-left: 13.5pt;">(b) For purposes of this Section 13, a &#8220;<font style="font-weight: bold;">BHC Act Affiliate</font>&#8221; has the meaning assigned to the term &#8220;affiliate&#8221; in, and shall be interpreted in accordance with, 12 U.S.C. &#167; 1841(k). &#8220;<font style="font-weight: bold;">Covered Entity</font>&#8221; means any of the following: (i) a &#8220;covered entity&#8221; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 252.82(b); (ii) a &#8220;covered bank&#8221; as that term is defined in, and interpreted
        in accordance with, 12 C.F.R. &#167; 47.3(b); or (iii) a &#8220;covered FSI&#8221; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 382.2(b). &#8220;<font style="font-weight: bold;">Default
          Right</font>&#8221; has the meaning assigned to that term in, and shall be interpreted in accordance with, 12 C.F.R. &#167;&#167; 252.81, 47.2 or 382.1, as applicable. &#8220;<font style="font-weight: bold;">U.S. Special Resolution Regime</font>&#8221; means each of (i) the Federal Deposit Insurance Act and the regulations promulgated thereunder and (ii) Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act and the regulations
        promulgated thereunder.</div>
      <div><br>
      </div>
      <div style="text-indent: 32.4pt; margin-left: 3.6pt;">14.<font style="font-style: italic;">&#160; Counterparts</font>.
        This Agreement may be signed in two or more counterparts (which may include counterparts delivered by any standard form of electronic communication), each of which shall be an original, with the same effect as if the signatures thereto and hereto
        were upon the same instrument.</div>
      <div><br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">16</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div><br>
      </div>
      <div style="text-indent: 32.4pt; margin-left: 3.6pt;">15.&#160; <font style="font-style: italic;">Applicable
          Law</font>. This Agreement shall be governed by and construed in accordance with the laws of the state of New York without regard to principles of conflict of laws that would result in the application of any law other than the laws of the state
        of New York. The Company agrees that any suit or proceeding arising in respect of this Agreement will be tried exclusively in the U.S. District Court for the Southern District of New York or, if that court does not have subject matter jurisdiction,
        in any state court located in The City and County of New York, and the Company agrees to submit to the jurisdiction of, and to venue in, such courts.</div>
      <div><br>
      </div>
      <div style="text-indent: 32.4pt; margin-left: 3.6pt;">16.&#160; <font style="font-style: italic;">Headings</font>.
        The headings of the sections of this Agreement have been inserted for convenience of reference only and shall not be deemed a part of this Agreement.</div>
      <div><br>
      </div>
      <div style="text-indent: 32.4pt; margin-left: 3.6pt;">17.&#160; <font style="font-style: italic;">Notices</font>.
        All communications hereunder shall be in writing and effective only upon receipt and</div>
      <div><br>
      </div>
      <div style="text-indent: 36pt; margin-left: 13.5pt;">(a) if to the Underwriters shall be delivered, mailed or sent to J.P. Morgan Securities LLC, 383 Madison Avenue, New
        York, New York 10179, Attention: Eileen Shin, Esq. and SVB Securities LLC, 1301 Avenue of the Americans, 12<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup> Floor, New York, New York 10019 Attention: Stuart Nayman, Esq.; and</div>
      <div><br>
      </div>
      <div style="text-indent: 36pt; margin-left: 13.5pt;">(b) if to the Company shall be delivered, mailed or sent to 700 US Highway 202/206, Bridgewater, New Jersey 08807,
        Attention: General Counsel, with a copy (which shall not constitute notice) to Covington &amp; Burling LLP, One CityCenter, 850 Tenth Street, NW, Washington, DC 20001-4956, Attention: Michael J. Riella, email: [***]@[***].</div>
      <div><br>
      </div>
      <div style="text-align: center; margin-left: 3.6pt; font-style: italic;">(Remainder of page intentionally left blank.)</div>
      <div><br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">17</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div><br>
      </div>
      <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z9922df64daf2400ba9ae0393c132a99a" border="0" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td colspan="2" style="vertical-align: top;">
              <div>Very truly yours,</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 5%; vertical-align: top;">&#160;</td>
            <td style="width: 45%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td colspan="2" style="vertical-align: top;">
              <div>INSMED INCORPORATED</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 5%; vertical-align: top;">&#160;</td>
            <td style="width: 45%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
            <td style="width: 5%; vertical-align: top; padding-bottom: 2px;">
              <div>By:</div>
            </td>
            <td style="width: 45%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div>/s/ Sara M. Bonstein</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 5%; vertical-align: top;">&#160;</td>
            <td style="width: 45%; vertical-align: top;">
              <div>Name: Sara M. Bonstein</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 5%; vertical-align: top;">&#160;</td>
            <td style="width: 45%; vertical-align: top;">
              <div>Title: Chief Financial Officer</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div><br>
      </div>
      <div><br>
      </div>
      <div><br>
      </div>
      <div style="text-align: center; font-style: italic;">[Underwriting Agreement]</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div><br>
      </div>
      <div><br>
      </div>
      <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="zb2a96dc860684d1d953f81d93ebe62e7" border="0" cellpadding="0" cellspacing="0">

          <tr>
            <td colspan="3" style="vertical-align: top;">
              <div>Accepted as of the date hereof</div>
            </td>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 5%; vertical-align: top;">&#160;</td>
            <td style="width: 6%; vertical-align: top;">&#160;</td>
            <td style="width: 44%; vertical-align: top;">&#160;</td>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="vertical-align: top;">
              <div>J.P. MORGAN SECURITIES LLC</div>
            </td>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="vertical-align: top;">
              <div>SVB SECURITIES LLC</div>
            </td>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 5%; vertical-align: top;">&#160;</td>
            <td style="width: 6%; vertical-align: top;">&#160;</td>
            <td style="width: 44%; vertical-align: top;">&#160;</td>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="vertical-align: top;">
              <div>Acting severally on behalf of themselves and the</div>
            </td>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="vertical-align: top;">
              <div style="font-family: 'Times New Roman',Times,serif; margin-left: 18pt;">several Underwriters named in Schedule I</div>
            </td>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td colspan="3" style="vertical-align: top;">
              <div style="font-family: 'Times New Roman',Times,serif; margin-left: 18pt;">hereto.</div>
            </td>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 5%; vertical-align: top;">&#160;</td>
            <td style="width: 6%; vertical-align: top;">&#160;</td>
            <td style="width: 44%; vertical-align: top;">&#160;</td>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 5%; vertical-align: top;">
              <div>By:</div>
            </td>
            <td colspan="2" style="vertical-align: top;">
              <div>J.P. Morgan Securities LLC</div>
            </td>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 5%; vertical-align: top;">&#160;</td>
            <td style="width: 6%; vertical-align: top;">&#160;</td>
            <td style="width: 44%; vertical-align: top;">&#160;</td>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 5%; vertical-align: top; padding-bottom: 2px;">
              <div>By:</div>
            </td>
            <td colspan="2" style="vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div>/s/ David Ke</div>
            </td>
            <td style="width: 50%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 5%; vertical-align: top;">&#160;</td>
            <td style="width: 6%; vertical-align: top;">
              <div>Name:</div>
            </td>
            <td style="width: 44%; vertical-align: top;">
              <div>David Ke</div>
            </td>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 5%; vertical-align: top;">&#160;</td>
            <td style="width: 6%; vertical-align: top;">
              <div>Title:</div>
            </td>
            <td style="width: 44%; vertical-align: top;">
              <div>Managing Director</div>
            </td>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 5%; vertical-align: top;">&#160;</td>
            <td style="width: 6%; vertical-align: top;">&#160;</td>
            <td style="width: 44%; vertical-align: top;">&#160;</td>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 5%; vertical-align: top;">
              <div>By:</div>
            </td>
            <td colspan="2" style="vertical-align: top;">
              <div>SVB Securities LLC</div>
            </td>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 5%; vertical-align: top;">&#160;</td>
            <td style="width: 6%; vertical-align: top;">&#160;</td>
            <td style="width: 44%; vertical-align: top;">&#160;</td>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 5%; vertical-align: top; padding-bottom: 2px;">
              <div>By:</div>
            </td>
            <td colspan="2" style="vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div>/s/ Dan Dubin</div>
            </td>
            <td style="width: 50%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 5%; vertical-align: top;">&#160;</td>
            <td style="width: 6%; vertical-align: top;">
              <div>Name:</div>
            </td>
            <td style="width: 44%; vertical-align: top;">
              <div>Dan Dubin</div>
            </td>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 5%; vertical-align: top;">&#160;</td>
            <td style="width: 6%; vertical-align: top;">
              <div>Title:</div>
            </td>
            <td style="width: 44%; vertical-align: top;">
              <div>Vice Chairman and Co-Head of Healthcare Investment Banking</div>
            </td>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
          </tr>

      </table>
      <div><br>
      </div>
      <div><br>
      </div>
      <div><br>
      </div>
      <div style="text-align: center; font-style: italic;">[Underwriting Agreement]</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <!--PROfilePageNumberReset%Num%1%I-%%-->
      <div><br>
      </div>
      <div style="text-align: right; font-weight: bold;">SCHEDULE I</div>
      <div><br>
      </div>
      <table class="cfttable" id="z8d52be572a5b4e91a283a8da0c20addf" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

          <tr>
            <td style="vertical-align: bottom; width: 10%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">
              <div style="font-weight: bold;">Underwriter</div>
            </td>
            <td style="vertical-align: bottom; padding-bottom: 2px; width: 78%;" valign="bottom">&#160;</td>
            <td class="cftguttercell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;" valign="bottom">&#160;</td>
            <td colspan="2" style="vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">
              <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Number of</div>
              <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Shares To Be</div>
              <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Purchased</div>
            </td>
            <td class="cftfncell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;" nowrap="nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td colspan="2" style="vertical-align: top; background-color: rgb(204, 238, 255);" valign="bottom">
              <div>J.P. Morgan Securities LLC</div>
            </td>
            <td class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
            <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
            <td class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
              <div>8,250,000</div>
            </td>
            <td class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" nowrap="nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td colspan="2" style="vertical-align: top;" valign="bottom">
              <div>SVB Securities LLC</div>
            </td>
            <td class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>
            <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>
            <td class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
              <div>5,500,000</div>
            </td>
            <td class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;" nowrap="nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td colspan="2" style="vertical-align: top; background-color: rgb(204, 238, 255);" valign="bottom">
              <div style="font-family: 'Times New Roman',Times,serif; font-weight: bold; margin-left: 18pt;">Total:</div>
            </td>
            <td class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
            <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
            <td class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
              <div>13,750,000</div>
            </td>
            <td class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" nowrap="nowrap" valign="bottom">&#160;</td>
          </tr>

      </table>
      <div><br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">I-1</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <!--PROfilePageNumberReset%Num%1%II-%%-->
      <div><br>
      </div>
      <div style="text-align: right; font-weight: bold;">SCHEDULE II</div>
      <div><br>
      </div>
      <div style="text-align: center; font-weight: bold;">Time of Sale Prospectus</div>
      <div><br>
      </div>
      <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zce3d47500f8348c3af3efe60644152a1" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top;">1.</td>
            <td style="width: auto; vertical-align: top;">
              <div>Basic Prospectus, dated May 21, 2020 and included in the Registration Statement</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zce4a9bb46b8345a5aea6a261b406783a" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top;">2.</td>
            <td style="width: auto; vertical-align: top;">
              <div>Orally communicated pricing information:</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div style="margin-left: 63pt;">Number of shares to be offered by the Company: 13,750,000</div>
      <div><br>
      </div>
      <div style="margin-left: 63pt;">Public offering price: $20.00</div>
      <div><br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">II-1</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <!--PROfilePageNumberReset%Num%1%III-%%-->
      <div><br>
      </div>
      <div style="text-align: right; font-weight: bold;">SCHEDULE III</div>
      <div><br>
      </div>
      <div style="text-align: center; font-weight: bold;">Subsidiaries</div>
      <div><br>
      </div>
      <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z47887a186089473eac8649f3c7617b24" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 49%; vertical-align: top; border-bottom: 2px solid black;">
              <div>Name</div>
            </td>
            <td colspan="1" style="width: 2%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
            <td style="width: 49%; vertical-align: top; border-bottom: 2px solid black;">
              <div>Jurisdiction of Incorporation</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 49%; vertical-align: top;">&#160;</td>
            <td rowspan="1" colspan="1" style="width: 2%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 49%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 49%; vertical-align: top;">
              <div>Insmed Gene Therapy LLC</div>
            </td>
            <td colspan="1" style="width: 2%; vertical-align: top;">&#160;</td>
            <td style="width: 49%; vertical-align: top;">
              <div>Delaware</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 49%; vertical-align: top;">&#160;</td>
            <td rowspan="1" colspan="1" style="width: 2%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 49%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 49%; vertical-align: top;">
              <div>Celtrix Pharmaceuticals, Inc.</div>
            </td>
            <td colspan="1" style="width: 2%; vertical-align: top;">&#160;</td>
            <td style="width: 49%; vertical-align: top;">
              <div>Delaware</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 49%; vertical-align: top;">&#160;</td>
            <td rowspan="1" colspan="1" style="width: 2%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 49%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 49%; vertical-align: top;">
              <div>Insmed Limited</div>
            </td>
            <td colspan="1" style="width: 2%; vertical-align: top;">&#160;</td>
            <td style="width: 49%; vertical-align: top;">
              <div>England and Wales</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 49%; vertical-align: top;">&#160;</td>
            <td rowspan="1" colspan="1" style="width: 2%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 49%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 49%; vertical-align: top;">
              <div>Insmed Holdings Limited</div>
            </td>
            <td colspan="1" style="width: 2%; vertical-align: top;">&#160;</td>
            <td style="width: 49%; vertical-align: top;">
              <div>Ireland</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 49%; vertical-align: top;">&#160;</td>
            <td rowspan="1" colspan="1" style="width: 2%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 49%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 49%; vertical-align: top;">
              <div>Insmed Ireland Limited</div>
            </td>
            <td colspan="1" style="width: 2%; vertical-align: top;">&#160;</td>
            <td style="width: 49%; vertical-align: top;">
              <div>Ireland</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 49%; vertical-align: top;">&#160;</td>
            <td rowspan="1" colspan="1" style="width: 2%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 49%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 49%; vertical-align: top;">
              <div>Insmed Netherlands B.V.</div>
            </td>
            <td colspan="1" style="width: 2%; vertical-align: top;">&#160;</td>
            <td style="width: 49%; vertical-align: top;">
              <div>The Netherlands</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 49%; vertical-align: top;">&#160;</td>
            <td rowspan="1" colspan="1" style="width: 2%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 49%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 49%; vertical-align: top;">
              <div>Insmed Netherlands Holdings B.V.</div>
            </td>
            <td colspan="1" style="width: 2%; vertical-align: top;">&#160;</td>
            <td style="width: 49%; vertical-align: top;">
              <div>The Netherlands</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 49%; vertical-align: top;">&#160;</td>
            <td rowspan="1" colspan="1" style="width: 2%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 49%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 49%; vertical-align: top;">
              <div>Insmed Germany GmbH</div>
            </td>
            <td colspan="1" style="width: 2%; vertical-align: top;">&#160;</td>
            <td style="width: 49%; vertical-align: top;">
              <div>Germany</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 49%; vertical-align: top;">&#160;</td>
            <td rowspan="1" colspan="1" style="width: 2%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 49%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 49%; vertical-align: top;">
              <div>Insmed France SAS</div>
            </td>
            <td colspan="1" style="width: 2%; vertical-align: top;">&#160;</td>
            <td style="width: 49%; vertical-align: top;">
              <div>France</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 49%; vertical-align: top;">&#160;</td>
            <td rowspan="1" colspan="1" style="width: 2%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 49%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 49%; vertical-align: top;">
              <div>Insmed Godo Kaisha</div>
            </td>
            <td colspan="1" style="width: 2%; vertical-align: top;">&#160;</td>
            <td style="width: 49%; vertical-align: top;">
              <div>Japan</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 49%; vertical-align: top;">&#160;</td>
            <td rowspan="1" colspan="1" style="width: 2%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 49%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 49%; vertical-align: top;">
              <div>Insmed Switzerland GmbH</div>
            </td>
            <td colspan="1" style="width: 2%; vertical-align: top;">&#160;</td>
            <td style="width: 49%; vertical-align: top;">
              <div>Switzerland</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 49%; vertical-align: top;">&#160;</td>
            <td rowspan="1" colspan="1" style="width: 2%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 49%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 49%; vertical-align: top;">
              <div>Insmed Italy S.R.L.</div>
            </td>
            <td colspan="1" style="width: 2%; vertical-align: top;">&#160;</td>
            <td style="width: 49%; vertical-align: top;">
              <div>Italy</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div><br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">III-1</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <!--PROfilePageNumberReset%Num%1%A-%%-->
      <div><br>
      </div>
      <div style="text-align: right; text-indent: 36pt;">&#160;<font style="font-weight: bold;">EXHIBIT A</font></div>
      <div><br>
      </div>
      <div style="text-align: center;">FORM OF LOCK-UP LETTER</div>
      <div><br>
      </div>
      <div style="text-align: right;"><u>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</u>, 2022</div>
      <div><br>
      </div>
      <div>J.P. Morgan Securities LLC</div>
      <div>SVB Securities LLC</div>
      <div style="margin-left: 18pt;">as Representatives of the several Underwriters</div>
      <div><br>
      </div>
      <div>c/o J.P. Morgan Securities LLC</div>
      <div>383 Madison Avenue</div>
      <div>New York, NY 10179</div>
      <div><br>
      </div>
      <div>c/o SVB Securities LLC</div>
      <div>53 State Street, 40<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup> Floor</div>
      <div>Boston, MA 02109</div>
      <div><br>
      </div>
      <div>Ladies and Gentlemen:</div>
      <div><br>
      </div>
      <div style="text-indent: 36pt;">The undersigned understands that J.P. Morgan Securities LLC and SVB Securities LLC, as representatives of the Underwriters (as defined
        below) (the &#8220;<font style="font-weight: bold;">Representatives</font>&#8221;), propose to enter into an Underwriting Agreement (the &#8220;<font style="font-weight: bold;">Underwriting Agreement</font>&#8221;) with Insmed Incorporated, a Virginia corporation (the &#8220;<font style="font-weight: bold;">Company</font>&#8221;),
        providing for the public offering (the &#8220;<font style="font-weight: bold;">Offering</font>&#8221;) by the several Underwriters listed on Schedule I to the Underwriting Agreement (the &#8220;<font style="font-weight: bold;">Underwriters</font>&#8221;), of shares of common stock, $0.01 par value per share, of the Company (the &#8220;<font style="font-weight: bold;">Common Stock</font>&#8221;).</div>
      <div><br>
      </div>
      <div style="text-indent: 36pt;">To induce the Underwriters that may participate in the Offering to continue their efforts in connection with the Offering, the
        undersigned hereby agrees that, without the prior written consent of the Representatives, on behalf of the Underwriters, it will not, during the period commencing on the date hereof through the 60<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup> day after the date of the final
        prospectus relating to the Offering (the &#8220;<font style="font-weight: bold;">Restricted Period</font>&#8221;), (1) offer, pledge, sell, contract to sell, sell any option or contract to
        purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock beneficially owned (as such term is used in Rule 13d-3
        of the Securities Exchange Act of 1934, as amended (the &#8220;<font style="font-weight: bold;">Exchange Act</font>&#8221;)), by the undersigned or any securities so owned convertible into or
        exercisable or exchangeable for Common Stock or (2) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of the Common Stock, whether any such transaction described
        in clause (1) or (2) above is to be settled by delivery of Common Stock or such other securities, in cash or otherwise.</div>
      <div><br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">A-1</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div><br>
      </div>
      <div style="text-indent: 36pt;">The foregoing sentence shall not apply to (a) transfers of shares of Common Stock or any security convertible into Common Stock as a bona
        fide gift or by will, other testamentary document or intestate succession, (b) distributions of shares of Common Stock or any security convertible into Common Stock to limited partners, members, stockholders, or wholly-owned subsidiaries of the
        undersigned, (c) transfers of shares of Common Stock or any security convertible into Common Stock pursuant to any order or settlement agreement not involving any public sale of shares of Common Stock or other securities and approved by any court
        of competent jurisdiction, (d) transfers of shares of Common Stock or any security convertible into Common Stock to any trust for the direct or indirect benefit of the undersigned or the immediate family of the undersigned, (e) transfers of shares
        of Common Stock or any security convertible into Common Stock to any corporation, partnership, limited liability company or similar entity of which all of the beneficial ownership interests are held by the undersigned or the immediate family of the
        undersigned; provided that in the case of any transfer or distribution pursuant to clauses (a)-(e), (i) each donee, distributee or transferee shall sign and deliver to the Representatives a lock-up letter substantially in the form of this letter,
        (ii) no public announcement or filing by any party (the undersigned, donor, donee, distributor, distributee, transferor or transferee) under the Exchange Act,
        including, without limitation, any Section 16(a) filing, shall be required or voluntarily
        made in connection with such transfer or distribution and (iii) any such transfer or distribution shall not involve a disposition for value, (f) the establishment
        of a new trading plan pursuant to Rule 10b5-1 under the Exchange Act (a &#8220;<font style="font-weight: bold;">10b5-1 trading plan</font>&#8221;) providing for dispositions or sales of Common
        Stock; provided that such plan does not permit dispositions or sales of shares of Common Stock or any security convertible into Common Stock during the Restricted Period and no public announcement or filing under the Exchange Act regarding the
        establishment of such plan shall be voluntarily made during the Restricted Period, (g) transfers of shares of Common Stock pursuant to a 10b5-1 trading plan entered into prior to the date of this agreement; provided that to the extent a public
        announcement or filing under the Exchange Act is required for such transfer, such announcement or filing shall include a statement to the effect that the transfer was made pursuant to a 10b5-1 trading plan, (h) the exercise of options or other
        stock-based awards to purchase Common Stock or vesting of restricted stock units or other stock-based awards outstanding as of the date hereof or granted under equity incentive plans or pursuant to inducement awards in effect as of the date hereof
        or described in the registration statement with respect to the Offering; provided that the underlying Common Stock continues to be subject to the terms of this agreement, (i) transfers of shares of Common Stock or any security convertible into
        Common Stock pursuant to a bona fide third party tender offer, merger, consolidation or other similar transaction made to holders of the Common Stock involving a change of control of the Company; provided that in the event that the tender offer,
        merger, consolidation or other such transaction is not completed during the Restricted Period, the undersigned shall remain subject to the restrictions contained herein during such period, (j) the repurchase by the Company or forfeiture of
        securities to the Company in connection with termination of the undersigned&#8217;s employment with the Company, and (k) the settlement of restricted stock, restricted stock units, options or other stock-based awards on a &#8220;net&#8221; basis or any other
        withholding of shares of Common Stock by the Company upon vesting and/or settlement of restricted stock, restricted stock units, options or other stock-based awards, or any sale of shares of Common Stock under a &#8220;sell to cover&#8221; arrangement for the
        payment of taxes, including estimated taxes, and remittance payments due as a result of such vesting, settlement or exercise; provided that (x) the underlying shares of Common Stock received by the undersigned shall continue to be subject to the
        restrictions on transfer set forth in this agreement and (y) any such settled or withheld shares are surrendered to the Company in the net exercise; provided further, in each case (a) through (f) and (h) through (k), that the undersigned shall
        provide you two days&#8217; advance notice of such transfers, distributions, plan establishments, exercises, repurchases, forfeitures, settlements or withholdings, as applicable.</div>
      <div><br>
      </div>
      <div style="text-indent: 36pt;">In addition, the undersigned agrees that, without the prior written consent of the Representatives on behalf of the Underwriters, it will
        not, during the Restricted Period, make any demand for or exercise any right with respect to, the registration of any shares of Common Stock or any security convertible into or exercisable or exchangeable for Common Stock. The undersigned also
        agrees and consents to the entry of stop transfer instructions with the Company&#8217;s transfer agent and registrar against the transfer of the undersigned&#8217;s shares of Common Stock except in compliance with the foregoing restrictions.</div>
      <div><br>
      </div>
      <div style="text-indent: 36pt;">The undersigned understands that the Company and the Underwriters are relying upon this agreement in proceeding toward consummation of
        the Offering. The undersigned further understands that this agreement is irrevocable and shall be binding upon the undersigned&#8217;s heirs, legal representatives, successors and assigns.</div>
      <div><br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">A-2</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div><br>
      </div>
      <div style="text-indent: 36pt;">Whether or not either the Offering actually occurs depends on a number of factors, including market conditions. The Offering will only be
        made pursuant to the Underwriting Agreement, the terms of which are subject to negotiation between the Company and the Representatives. If (i) the closing of the Offering has not occurred prior to November 30, 2022, (ii) the Company notifies you in
        writing prior to the date of the execution of the Underwriting Agreement that it does not intend to proceed with the Offering, (iii) prior to the date of the execution of the Underwriting Agreement, the registration statement filed with respect to
        the Offering is withdrawn or (iv) for any reason the Underwriting Agreement shall be terminated prior to the Closing Date (as defined in the Underwriting Agreement), this agreement shall be of no further force or effect.</div>
      <div><br>
      </div>
      <div style="text-indent: 36pt;">This agreement shall be governed by and construed in accordance with the laws of the State of New York, without regard to the conflict of
        laws principles thereof.</div>
      <div><br>
      </div>
      <div style="text-align: center; font-style: italic;">[Signature page follows]</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">A-3</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div><br>
      </div>
      <div><br>
      </div>
      <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z4a180debc0da489f8646a25f8f8f8ab0" border="0" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 55%; vertical-align: top;">&#160;</td>
            <td style="width: 45%; vertical-align: top;">
              <div>Very truly yours,</div>
            </td>
          </tr>
          <tr>
            <td style="width: 55%; vertical-align: top;">&#160;</td>
            <td style="width: 45%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 55%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
            <td style="width: 45%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          </tr>
          <tr>
            <td style="width: 55%; vertical-align: top;">&#160;</td>
            <td style="width: 45%; vertical-align: top;">
              <div>(Name of Party&#8212;Please Print)</div>
            </td>
          </tr>
          <tr>
            <td style="width: 55%; vertical-align: top;">&#160;</td>
            <td style="width: 45%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 55%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
            <td style="width: 45%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          </tr>
          <tr>
            <td style="width: 55%; vertical-align: top;">&#160;</td>
            <td style="width: 45%; vertical-align: top;">
              <div>(Signature)</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
    </div>
  </div>
  <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">A-4</font></div>
  <div class="BRPFPageNumberArea" style="text-align: center;">
    <hr style="height: 2px; color: #000000; background-color: #000000; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;"> </font></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>3
<FILENAME>ny20005570x4_ex5-1.htm
<DESCRIPTION>EXHIBIT 5.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Finanicial Soultions, Inc.
         Document created using Broadridge PROfile 22.10.1.5080
         Copyright 1995 - 2022 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <font style="font-size: 10pt;"> </font>
  <div>
    <div style="text-align: right;">
      <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"><font style="font-weight: bold;"> Exhibit 5.1</font><br>
    </div>
    <div> <br>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="zafc0158cfaac470d848b5abf1d1da3be">

        <tr>
          <td style="width: 69.21%; vertical-align: top;">
            <div style="text-align: left; font-size: 10pt;"><img width="178" height="48" src="ny20005570x4_ex5-1img01.jpg"></div>
            <div style="font-size: 10pt;">&#160;</div>
          </td>
          <td style="width: 30.79%; vertical-align: top;"><br>
            <div style="font-size: 10pt;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 69.21%; vertical-align: top; font-size: 10pt;">&#160;</td>
          <td rowspan="2" style="width: 30.79%; vertical-align: top; font-size: 10pt;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 69.21%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: left; font-family: 'Times New Roman',Times,serif;">October 20, 2022</div>
          </td>
        </tr>

    </table>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">Insmed Incorporated</div>
    <div style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">700 US Highway 202/206</div>
    <div style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">Bridgewater, New Jersey 08807</div>
    <div style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt;"> <br>
    </div>
    <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: center;">Insmed Incorporated</div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-weight: bold;">Public Offering of 13,750,000 Shares of Common Stock</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">Ladies and Gentlemen:</div>
    <div style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt;"> <br>
    </div>
    <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">We have acted as Virginia counsel to Insmed Incorporated, a Virginia corporation (the &#8220;Company&#8221;), in connection with the Company&#8217;s issuance
      and sale of 13,750,000 shares of the Company&#8217;s common stock, par value $0.01 per share (the &#8220;Shares&#8221;), pursuant to (i) the Registration Statement on Form S-3 (File No. 333-238560) filed by the Company with the Securities and Exchange Commission (the
      &#8220;Commission&#8221;) on May 21, 2020 (the &#8220;Registration Statement&#8221;) pursuant to the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), and (ii) the prospectus, dated May 21, 2020, contained in the Registration Statement and the prospectus supplement
      thereto, dated October 19, 2022 (collectively, the &#8220;Prospectus&#8221;).</div>
    <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt;"> <br>
    </div>
    <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">This opinion letter is being furnished in accordance with the requirements of Item 16 of Form S-3 and Item 601(b)(5)(i) of Regulation S-K.</div>
    <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt;"> <br>
    </div>
    <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">In connection with this opinion letter, we have examined originals or copies, certified or otherwise identified to our satisfaction, of such
      documents and records of the Company, certificates of public officials and officers of the Company and such other documents, certificates and records as we have deemed necessary to render the opinions set forth herein, including, among other things,
      (i) the Company&#8217;s Articles of Incorporation, as amended through the date hereof, (ii) the Company&#8217;s Amended and Restated Bylaws, as amended through the date hereof, (iii) the Registration Statement, (iv) the Prospectus, (v) the Underwriting
      Agreement, dated as of October 19, 2022 (the &#8220;Underwriting Agreement&#8221;), among the Company, J.P. Morgan Securities LLC, SVB Securities LLC and the several underwriters (the &#8220;Underwriters&#8221;) named in <font style="font-family: 'Times New Roman',Times,serif;"><u>Schedule I</u></font> to the Underwriting Agreement, for whom J.P. Morgan Securities LLC and SVB Securities LLC are acting as representatives, (vi) resolutions of the Company&#8217;s Board of Directors and pricing committee
      thereof and (vii) a certificate issued by the Clerk of the State Corporation Commission of the Commonwealth of Virginia on October 20, 2022 to the effect that the Company is existing under the laws of the Commonwealth of Virginia and in good standing
      (the &#8220;Good Standing Certificate&#8221;).</div>
    <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt;"> <br>
    </div>
    <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">
      <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 6pt;">ATLANTA&#160;&#160; AUSTIN&#160;&#160; BANGKOK&#160;&#160; BEIJING&#160;&#160; BOSTON&#160;&#160; BRUSSELS&#160;&#160; CHARLOTTE&#160;&#160; DALLAS&#160;&#160; DUBAI&#160;&#160; HOUSTON&#160;&#160; LONDON</div>
      <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 6pt;">LOS ANGELES&#160;&#160; MIAMI&#160;&#160; NEW YORK&#160;&#160; NORFOLK&#160;&#160; RICHMOND&#160;&#160; SAN FRANCISCO&#160;&#160; THE WOODLANDS&#160;&#160; TOKYO&#160;&#160; TYSONS&#160;&#160; WASHINGTON, DC</div>
      <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 6pt;">www.HuntonAK.com</div>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">
      <div style="text-align: left; font-size: 10pt;"><img width="178" height="48" src="ny20005570x4_ex5-1img01.jpg">
        <div><br>
        </div>
        <div>
          <div style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">Insmed Incorporated</div>
          <div style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">October 20, 2022</div>
          <div style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">Page 2</div>
        </div>
      </div>
    </div>
    <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt;"> <br>
    </div>
    <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">For purposes of the opinions expressed below, we have assumed (i) the legal capacity of all natural persons, (ii) the genuineness of all
      signatures, (iii) the authenticity of all documents submitted to us as originals, (iv) the conformity to authentic original documents of all documents submitted to us as certified, electronic or photostatic copies and (v) the due authorization,
      execution and delivery of all documents by all parties and the validity, binding effect and enforceability thereof (other than the authorization, execution and delivery of certain documents by the Company).</div>
    <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt;"> <br>
    </div>
    <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">As to factual matters, we have relied upon, and assumed the accuracy of, representations included in the documents submitted to us, upon
      certificates of officers of the Company and upon certificates of public officials.&#160; Except as otherwise expressly indicated, we have not undertaken any independent investigation of factual matters.</div>
    <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt;"> <br>
    </div>
    <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">We do not purport to express an opinion on any laws other than those of the Commonwealth of Virginia.</div>
    <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt;"> <br>
    </div>
    <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">Based upon the foregoing and such other information and documents as we have considered necessary for the purposes hereof, and subject to the
      assumptions, qualifications and limitations stated herein, we are of the opinion that:</div>
    <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt;"> <br>
    </div>
    <div>
      <div>
        <div style="margin: 0px 0px 0px 36pt; font-family: 'Times New Roman', Times, serif; text-align: left; text-indent: 36pt;"><font style="font-family: 'Times New Roman', Times, serif; text-align: left;">1. &#160; &#160; &#160; </font>The Company is a corporation
          validly existing and in good standing under the laws of the Commonwealth of Virginia.</div>
      </div>
      <div> <br>
      </div>
    </div>
    <div>
      <div>
        <div style="margin: 0px 0px 0px 36pt; font-family: 'Times New Roman', Times, serif; text-align: left; text-indent: 36pt;"><font style="font-family: 'Times New Roman', Times, serif; text-align: left;">2. &#160; &#160; &#160; </font>The Shares have been duly
          authorized by the Company and, when issued and delivered to and paid for by the Underwriters in accordance with the terms of the Underwriting Agreement, will be validly issued, fully paid and nonassessable.</div>
      </div>
    </div>
    <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt;"> <br>
    </div>
    <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">The opinion set forth in paragraph 1 above as to the valid existence and good standing of the Company is based solely upon our review of the
      Good Standing Certificate.</div>
    <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt;"> <br>
    </div>
    <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">We hereby consent to (i) the filing of this opinion letter with the Commission as an exhibit to the Company&#8217;s Current Report on Form 8-K
      filed on the date hereof, (ii) the incorporation by reference of this opinion letter into the Registration Statement and (iii) the reference to our firm under the heading &#8220;Legal Matters&#8221; in the Registration Statement and the Prospectus.&#160; In giving
      this consent, we do not admit that we are within the category of persons whose consent is required by Section 7 of the Securities Act and the rules and regulations of the Commission promulgated thereunder.</div>
    <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt;"> <br>
    </div>
    <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">This opinion letter is rendered as of the date hereof, and we disclaim any obligation to advise you of facts, circumstances, events or
      developments that hereafter may be brought to our attention and that may alter, affect or modify the opinion expressed herein.&#160; This opinion letter is expressly limited to the matters set forth above and we render no opinion, whether by implication
      or otherwise, as to any matters beyond the matters expressly set forth herein.</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="font-size: 10pt;">
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;" id="ze3c7431742124e1386485de7dacf9588">

          <tr>
            <td style="width: 50.00%;">
              <div>&#160;</div>
            </td>
            <td style="width: 50.00%;">
              <div>Very truly yours,</div>
              <div> <br>
              </div>
              <div> /s/ Hunton Andrews Kurth LLP<br>
              </div>
            </td>
          </tr>

      </table>
    </div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">
      <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="font-size: 10pt;"><br>
    </div>
    <br>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="font-size: 10pt;"><br>
    </div>
  </div>
  <font style="font-size: 10pt;"> </font>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>4
<FILENAME>ny20005570x4_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Finanicial Soultions, Inc.
         Document created using Broadridge PROfile 22.10.1.5080
         Copyright 1995 - 2022 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <font style="font-size: 10pt;">
  </font>
  <div>
    <div style="text-align: center; font-size: 10pt;">
      <div style="text-align: right;">
        <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"><font style="font-weight: bold;">Exhibit 99.1</font><br>
      </div>
      <div><br>
      </div>
      <img width="176" height="81" src="ny20005570x4_ex99-1img01.jpg"></div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-weight: bold;">Insmed Announces Strategic Financings Totaling $775 Million</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-style: italic;">&#8212;$500 million secured in non-dilutive structured financings consisting of a term loan and capped royalty financing&#8212;</div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-style: italic;"> <br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-style: italic;">&#8212;$275 million underwritten offering of common stock&#8212;</div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-style: italic;"> <br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-style: italic;">&#8212;Financings increase cash and cash equivalents and marketable securities to approximately $1.3 billion&#8212;</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div>
      <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">BRIDGEWATER</font><font style="font-size: 10pt;">,
          NJ,&#160;October 19, 2022&#160;--&#160;Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced three strategic financings resulting in aggregate gross
          proceeds of $775 million. Proceeds from the transactions will strengthen Insmed&#8217;s financial position, which will place the Company in a position to deliver clinical data from each of its four pillars.</font></div>
      <div style="font-size: 10pt;"><br>
      </div>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">&#8220;Insmed is at a pivotal moment in its history, as we prepare to serve significantly more patients with serious and rare diseases. We believe these
      financings provide the company with ample resources to advance our four pillars through key clinical trials and prepare for the potential commercial availability of ARIKAYCE for frontline NTM lung disease and brensocatib for bronchiectasis,&#8221;
      commented&#160;Will Lewis, Chair and Chief Executive Officer of Insmed. &#8220;We appreciate the extensive due diligence completed by the investors involved and share their enthusiasm for the Insmed pipeline and our vision for the future.&#8221;</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">&#8220;We are excited to partner with Insmed as it advances its mission,&#8221; said Pedro Gonzalez de Cosio, CEO of Pharmakon Advisors, LP.&#160; &#8220;Led by a highly
      experienced management team, Insmed strives to improve the lives of patients suffering from debilitating diseases and is investing meaningfully in additional therapies which address significant unmet needs.&#8221;</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">&#8220;This partnership exemplifies our collective confidence in the strength of Insmed&#8217;s global ARIKAYCE franchise and the potential of brensocatib to
      address neutrophil-driven diseases,&#8221; said Matthew Rizzo, General Partner of OrbiMed. &#8220;We are pleased to support Insmed as the Company advances its rare disease pipeline.&#8221;</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div>
      <div style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-weight: bold;">$350 Million Senior Secured Loan</div>
      <div style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">Insmed has entered into a $350 million senior secured term loan agreement with funds managed by Pharmakon Advisors, LP, a leading investor in
        non-dilutive debt for the life sciences industry and the investment manager of the BioPharma Credit funds (the &#8220;Term Loan&#8221;). The five-year Term Loan matures in October 2027. The Term Loan bears interest at a rate based upon the secured overnight
        financing rate (SOFR), subject to a SOFR floor of 2.5%, in addition to a margin of 7.75% per annum.</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-weight: bold;">$150 Million Synthetic Royalty Financing Agreement</div>
      <div style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">The Company has also entered into a $150 million secured royalty financing agreement with OrbiMed, a leading investor in the healthcare industry.
        Under the agreement, <font style="font-family: 'Times New Roman',Times,serif;">OrbiMed will be entitled to receive royalties of 4% on global net sales of ARIKAYCE&#174; (amikacin liposome inhalation suspension) until September 1, 2025, and
          royalties of 4.5% on ARIKAYCE global net sales from September 1, 2025, as well as royalties of 0.75% on brensocatib global net sales (the &#8220;Royalty Financing&#8221;). The total royalty payable by Insmed to OrbiMed is capped at 1.8x of the purchase price
          up to a maximum of 1.9x of the purchase price under certain conditions.</font></div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">The Term Loan and the Royalty Financing will be secured by an all-assets collateral package that is governed by the terms of an intercreditor
        agreement entered into among BioPharma Credit PLC, as collateral agent, OrbiMed Royalty &amp; Credit Opportunities IV, LP and Insmed.</div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">Transactions for both the Term Loan and Royalty Financing closed on October 19, 2022.</div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-weight: bold;">Advisors</div>
      <div style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">SVB Securities LLC acted as an exclusive financial advisor to Insmed on the Term Loan and Royalty Financing.&#160; Covington &amp; Burling LLP acted as
        counsel to Insmed on the Term Loan and Royalty Financing.&#160; Akin Gump Strauss Hauer &amp; Feld LLP acted as counsel to Pharmakon Advisors, LP on the Term Loan. Morrison &amp; Foerster LLP acted as counsel to OrbiMed on the Royalty Financing.</div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-weight: bold;">$275 Million Underwritten Offering of Common Stock</div>
    </div>
    <div>
      <div style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">Additionally, Insmed announced today that it has agreed to sell 13,750,000&#160; shares of its common stock at a price per share of $20.00 in an
        underwritten offering (the &#8220;Offering&#8221;). Insmed anticipates gross proceeds from the Offering to be approximately $275 million, before deducting underwriting discounts and commissions and other offering expenses. The Offering is expected to close on
        October 21, 2022, subject to customary closing conditions.</div>
      <div style="font-size: 10pt;"><br>
      </div>
    </div>
    <div>
      <div style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">J.P. Morgan Securities LLC and SVB Securities LLC are acting as joint book-running managers for the Offering.</div>
      <div style="font-size: 10pt;"><br>
      </div>
    </div>
    <div>
      <div style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-weight: normal;">Insmed intends to use net proceeds from the Term Loan, the Royalty Financing and the Offering to fund activities related to the
        commercialization of ARIKAYCE, potential commercial launch of brensocatib, if approved, and further research and development of ARIKAYCE, brensocatib, TPIP, its translational medicine efforts or any of its product candidates, and for other general
        corporate purposes, including business expansion activities.</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">The Offering is being made pursuant to Insmed&#8217;s shelf registration statement on Form S-3 (File No. 333-238560) that was previously filed with the
        Securities and Exchange Commission (&#8220;SEC&#8221;) and became automatically effective on May 21, 2020. A final prospectus supplement and accompanying prospectus relating to the Offering will be filed with the SEC and will be available on the SEC&#8217;s website
        located at http://www.sec.gov. Copies of the final prospectus supplement and accompanying prospectus may be obtained, when available, from: J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY
        11717, by telephone at (866) 803-9204 or by email at prospectus-eq_fi@jpmorgan.com; or SVB Securities LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, Massachusetts 02109, by telephone at (800) 808-7525, ext. 6105, or by
        email at syndicate@svbsecurities.com.</div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in
        any jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.</div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-weight: bold;">About Insmed</div>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed&#8217;s
      first commercial product is a first-in-disease therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. The Company is also progressing a robust pipeline of investigational therapies targeting areas of
      serious unmet need, including neutrophil-mediated inflammatory diseases and rare pulmonary disorders. Insmed is headquartered in Bridgewater, New Jersey, with a footprint across Europe and in Japan. For more information, visit www.insmed.com.</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">About Pharmakon Advisors</font><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><br>
      </font><font style="font-size: 10pt;">Pharmakon Advisors, LP is a leading investor in non-dilutive debt for the life sciences industry and is the investment manager of the BioPharma Credit funds.&#160; Established in 2009, funds managed by Pharmakon
        Advisors have committed $6.5 billion across 46 investments.</font></div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">About OrbiMed</font><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><br>
      OrbiMed is a leading healthcare investment firm, with approximately $18 billion in assets under management. OrbiMed invests globally across the healthcare
        industry, from start-ups to large multinational corporations, through a range of private equity funds, public equity funds, and royalty/credit funds. OrbiMed seeks to be a capital provider of choice, providing tailored financing solutions and
        extensive global team resources to help build world-class healthcare companies. OrbiMed&#8217;s team of over 130 professionals is based in New York City, San Francisco, Shanghai, Hong Kong, Mumbai, Herzliya, and other key global markets.&#160;<u>www.orbimed.com</u>.<u><br>
        </u></font></div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-weight: bold;">Forward-looking Statements</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">This press release contains forward-looking statements that involve substantial risks and uncertainties. &#8220;Forward-looking statements,&#8221; as that term is
      defined in the Private Securities Litigation Reform Act of 1995, are statements that are not historical facts and involve a number of risks and uncertainties. Words herein such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;expects,&#8221; &#8220;plans,&#8221;
      &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;projects,&#8221; &#8220;predicts,&#8221; &#8220;intends,&#8221; &#8220;potential,&#8221; &#8220;continues,&#8221; and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) may identify forward-looking
      statements.</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">The forward-looking statements in this press release are based upon the Company&#8217;s current expectations and beliefs, and involve known and unknown
      risks, uncertainties and other factors, which may cause the Company&#8217;s actual results, performance and achievements and the timing of certain events to differ materially from the results, performance, achievements or timings discussed, projected,
      anticipated or indicated in any forward-looking statements. Such risks, uncertainties and other factors include, among others, the following: the risks and uncertainties associated with, and the perceived benefits of, the Term Loan and the Royalty
      Financing, including the Company&#8217;s ability to maintain compliance with the covenants in the agreements for the Term Loan and Royalty Financing and the impact of the restrictions on the Company&#8217;s operations under these agreements; the risks and
      uncertainties associated with market conditions and the satisfaction of customary closing conditions related to the Offering; uncertainties regarding the Company&#8217;s cash runway; failure to obtain, or delays in obtaining, regulatory approvals for
      ARIKAYCE outside the U.S., Europe or Japan, or for the Company&#8217;s product candidates in the U.S.,&#160;Europe,&#160;Japan&#160;or other markets, including separate regulatory approval for the Lamira<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>&#160;Nebulizer System and other product candidate devices in
      each market and for each usage; failure to successfully commercialize ARIKAYCE, the Company&#8217;s only approved product, in the U.S., Europe or Japan (amikacin liposome inhalation suspension, Liposomal 590 mg Nebuliser Dispersion, and amikacin sulfate
      inhalation drug product, respectively), or to maintain U.S., European or Japanese approval for ARIKAYCE; business or economic disruptions due to catastrophes or other events, including natural disasters or public health crises; impact of the COVID-19
      pandemic and efforts to reduce its spread on the Company&#8217;s business, employees, including key personnel, patients, partners and suppliers;<font style="font-family: 'Times New Roman',Times,serif; font-weight: bold;">&#160;</font>risk that
      brensocatib does not prove effective or safe for patients in ongoing and future clinical studies, including the ASPEN study;<font style="font-family: 'Times New Roman',Times,serif; font-weight: bold;">&#160;</font>risk that TPIP does not prove
      to be effective or safe for patients in ongoing and future clinical studies;<font style="font-family: 'Times New Roman',Times,serif; font-weight: bold;">&#160;</font>uncertainties in the degree of market acceptance of ARIKAYCE by physicians,
      patients, third-party payors and others in the healthcare community; the Company&#8217;s inability to obtain full approval of ARIKAYCE from the U.S. Food and Drug Administration, including the risk that the Company will not successfully or in a timely
      manner complete the study to validate a patient reported outcome tool and the confirmatory post-marketing clinical trial required for full approval of ARIKAYCE; inability of the Company, PARI or the Company&#8217;s other third-party manufacturers to comply
      with regulatory requirements related to ARIKAYCE or the Lamira<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>&#160;Nebulizer System; the Company&#8217;s inability to obtain adequate reimbursement from government or third-party payors for ARIKAYCE or acceptable prices for ARIKAYCE; development of
      unexpected safety or efficacy concerns related to ARIKAYCE or the Company&#8217;s product candidates; inaccuracies in the Company&#8217;s estimates of the size of the potential markets for ARIKAYCE, brensocatib, TPIP or the Company&#8217;s other product candidates or
      in data the Company has used to identify physicians, expected rates of patient uptake, duration of expected treatment, or expected patient adherence or discontinuation rates; the Company&#8217;s inability to create an effective direct sales and marketing
      infrastructure or to partner with third parties that offer such an infrastructure for distribution of ARIKAYCE or any of the Company&#8217;s product candidates that are approved in the future;<font style="font-family: 'Times New Roman',Times,serif; font-weight: bold;">&#160;</font>failure to obtain regulatory approval to expand ARIKAYCE&#8217;s indication to a broader patient population;<font style="font-family: 'Times New Roman',Times,serif; font-weight: bold;">&#160;</font>risk
      that the Company&#8217;s competitors may obtain orphan drug exclusivity for a product that is essentially the same as a product the Company is developing for a particular indication;<font style="font-family: 'Times New Roman',Times,serif; font-weight: bold;">&#160;</font>failure to successfully predict the time and cost of development, regulatory approval and commercialization for novel gene therapy products;<font style="font-family: 'Times New Roman',Times,serif; font-weight: bold;">&#160;</font>failure to successfully conduct future clinical trials for ARIKAYCE, brensocatib, TPIP and the Company&#8217;s other product candidates due to the Company&#8217;s limited experience in conducting preclinical development activities and clinical
      trials necessary for regulatory approval and its potential inability to enroll or retain sufficient patients to conduct and complete the trials or generate data necessary for regulatory approval, among other things;<font style="font-family: 'Times New Roman',Times,serif; font-weight: bold;">&#160;</font>risks that the Company&#8217;s clinical studies will be delayed or that serious side effects will be identified during drug development; failure of third parties on which the Company is
      dependent to manufacture sufficient quantities of ARIKAYCE or the Company&#8217;s product candidates for commercial or clinical needs, to conduct the Company&#8217;s clinical trials, or to comply with the Company&#8217;s agreements or laws and regulations that impact
      the Company&#8217;s business or agreements with the Company;<font style="font-family: 'Times New Roman',Times,serif; font-weight: bold;">&#160;</font>the Company&#8217;s inability to attract and retain key personnel or to effectively manage the Company&#8217;s
      growth; the Company&#8217;s inability to successfully integrate its recent acquisitions and appropriately manage the amount of management&#8217;s time and attention devoted to integration activities; risks that the Company&#8217;s acquired technologies, products and
      product candidates are not commercially successful; the Company&#8217;s inability to adapt to its highly competitive and changing environment;<font style="font-family: 'Times New Roman',Times,serif; font-weight: bold;">&#160;</font>risk that the
      Company is unable to maintain its significant customers; risk that government healthcare reform materially increases the Company&#8217;s costs and damages its financial condition; the Company&#8217;s inability to adequately protect its intellectual property
      rights or prevent disclosure of its trade secrets and other proprietary information and costs associated with litigation or other proceedings related to such matters; restrictions or other obligations imposed on the Company by agreements related to
      ARIKAYCE or the Company&#8217;s product candidates, including its license agreements with PARI and AstraZeneca AB, and failure of the Company to comply with its obligations under such agreements; the cost and potential reputational damage resulting from
      litigation to which the Company is or may become a party, including product liability claims; risk that the Company&#8217;s operations are subject to a material disruption in the event of a cybersecurity attack or issue; business disruptions or expenses
      related to the upgrade to the Company&#8217;s enterprise resource planning system; the Company&#8217;s limited experience operating internationally; changes in laws and regulations applicable to the Company&#8217;s business, including any pricing reform, and failure
      to comply with such laws and regulations; the Company&#8217;s history of operating losses, and the possibility that the Company may never achieve or maintain profitability; goodwill impairment charges affecting the Company&#8217;s results of operations and
      financial condition; inability to repay the Company&#8217;s existing indebtedness and uncertainties with respect to the Company&#8217;s ability to access future capital; and delays in the execution of plans to build out an additional third-party manufacturing
      facility approved by the appropriate regulatory authorities and unexpected expenses associated with those plans.</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">The Company may not actually achieve the results, plans, intentions or expectations indicated by the Company&#8217;s forward-looking statements because, by
      their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. For additional information about the risks and uncertainties that may affect
      the Company&#8217;s business, please see the factors discussed in Item 1A, &#8220;Risk Factors,&#8221; in the Company&#8217;s Annual Report on Form 10-K for the year ended&#160;December 31, 2021 and any subsequent Company filings with the Securities and Exchange Commission
      (SEC).</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">The Company cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date of this press
      release. The Company disclaims any obligation, except as specifically required by law and the rules of the SEC, to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which
      any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-weight: bold;">Contact:</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">Investors:</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">Eleanor Barisser</div>
    <div style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">Associate Director, Investor Relations</div>
    <div style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">Insmed</div>
    <div style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">(718) 594-5332</div>
    <div style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">eleanor.barisser@insmed.com</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">Media:</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">Mandy Fahey</div>
    <div style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">Executive Director, Corporate Communications</div>
    <div style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">Insmed</div>
    <div style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">(732) 718-3621</div>
    <div style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">amanda.fahey@insmed.com</div>
    <div style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt;"> <br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">
      <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"> </div>
  </div>
  <font style="font-size: 10pt;">
  </font>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>insm-20221019.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 22.10.1.5080 Broadridge-->
<xs:schema targetNamespace="http://insmed.com/20221019" elementFormDefault="qualified" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:insm="http://insmed.com/20221019" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="insm-20221019_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="insm-20221019_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://insmed.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000100 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/currency/2022" schemaLocation="https://xbrl.sec.gov/currency/2022/currency-2022.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/exch/2022" schemaLocation="https://xbrl.sec.gov/exch/2022/exch-2022.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/naics/2022" schemaLocation="https://xbrl.sec.gov/naics/2022/naics-2022.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/sic/2022" schemaLocation="https://xbrl.sec.gov/sic/2022/sic-2022.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/stpr/2022" schemaLocation="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" />
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/2004/ref" schemaLocation="http://www.xbrl.org/2004/ref-2004-08-10.xsd" />
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xs:import namespace="http://fasb.org/us-types/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" />
  <xs:import namespace="http://fasb.org/srt-types/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd" />
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>insm-20221019_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 22.10.1.5080 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:label xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CoverAbstract_lbl" xml:lang="en-US" id="dei_CoverAbstract_lbl">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:title="label: CoverAbstract to dei_CoverAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentType_lbl" xml:lang="en-US" id="dei_DocumentType_lbl">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentType" xlink:to="dei_DocumentType_lbl" xlink:title="label: DocumentType to dei_DocumentType_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="WrittenCommunications" xlink:title="WrittenCommunications" />
    <link:label xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_WrittenCommunications_lbl" xml:lang="en-US" id="dei_WrittenCommunications_lbl">Written Communications</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:title="label: WrittenCommunications to dei_WrittenCommunications_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="SolicitingMaterial" xlink:title="SolicitingMaterial" />
    <link:label xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_SolicitingMaterial_lbl" xml:lang="en-US" id="dei_SolicitingMaterial_lbl">Soliciting Material</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:title="label: SolicitingMaterial to dei_SolicitingMaterial_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="PreCommencementTenderOffer" xlink:title="PreCommencementTenderOffer" />
    <link:label xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US" id="dei_PreCommencementTenderOffer_lbl">Pre-commencement Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:title="label: PreCommencementTenderOffer to dei_PreCommencementTenderOffer_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="PreCommencementIssuerTenderOffer" xlink:title="PreCommencementIssuerTenderOffer" />
    <link:label xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US" id="dei_PreCommencementIssuerTenderOffer_lbl">Pre-commencement Issuer Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:title="label: PreCommencementIssuerTenderOffer to dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:label xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_AmendmentFlag_lbl" xml:lang="en-US" id="dei_AmendmentFlag_lbl">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:title="label: AmendmentFlag to dei_AmendmentFlag_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" id="dei_DocumentFiscalYearFocus_lbl">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:title="label: DocumentFiscalYearFocus to dei_DocumentFiscalYearFocus_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" id="dei_DocumentFiscalPeriodFocus_lbl">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:title="label: DocumentFiscalPeriodFocus to dei_DocumentFiscalPeriodFocus_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" id="dei_DocumentPeriodEndDate_lbl">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:title="label: DocumentPeriodEndDate to dei_DocumentPeriodEndDate_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:label xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityRegistrantName_lbl" xml:lang="en-US" id="dei_EntityRegistrantName_lbl">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:title="label: EntityRegistrantName to dei_EntityRegistrantName_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:label xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" id="dei_EntityCentralIndexKey_lbl">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:title="label: EntityCentralIndexKey to dei_EntityCentralIndexKey_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityFileNumber_lbl" xml:lang="en-US" id="dei_EntityFileNumber_lbl">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:title="label: EntityFileNumber to dei_EntityFileNumber_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" id="dei_EntityTaxIdentificationNumber_lbl">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:title="label: EntityTaxIdentificationNumber to dei_EntityTaxIdentificationNumber_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" id="dei_EntityIncorporationStateCountryCode_lbl">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:title="label: EntityIncorporationStateCountryCode to dei_EntityIncorporationStateCountryCode_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:label xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" id="dei_EntityEmergingGrowthCompany_lbl">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:title="label: EntityEmergingGrowthCompany to dei_EntityEmergingGrowthCompany_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" id="dei_EntityAddressAddressLine1_lbl">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:title="label: EntityAddressAddressLine1 to dei_EntityAddressAddressLine1_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="EntityAddressAddressLine2" xlink:title="EntityAddressAddressLine2" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US" id="dei_EntityAddressAddressLine2_lbl">Entity Address, Address Line Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:title="label: EntityAddressAddressLine2 to dei_EntityAddressAddressLine2_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="EntityAddressAddressLine3" xlink:title="EntityAddressAddressLine3" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine3_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US" id="dei_EntityAddressAddressLine3_lbl">Entity Address, Address Line Three</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:title="label: EntityAddressAddressLine3 to dei_EntityAddressAddressLine3_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" id="dei_EntityAddressCityOrTown_lbl">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:title="label: EntityAddressCityOrTown to dei_EntityAddressCityOrTown_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" id="dei_EntityAddressStateOrProvince_lbl">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:title="label: EntityAddressStateOrProvince to dei_EntityAddressStateOrProvince_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="EntityAddressCountry" xlink:title="EntityAddressCountry" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressCountry_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressCountry_lbl" xml:lang="en-US" id="dei_EntityAddressCountry_lbl">Entity Address, Country</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:title="label: EntityAddressCountry to dei_EntityAddressCountry_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" id="dei_EntityAddressPostalZipCode_lbl">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:title="label: EntityAddressPostalZipCode to dei_EntityAddressPostalZipCode_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:label xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CityAreaCode_lbl" xml:lang="en-US" id="dei_CityAreaCode_lbl">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:title="label: CityAreaCode to dei_CityAreaCode_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:label xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_LocalPhoneNumber_lbl" xml:lang="en-US" id="dei_LocalPhoneNumber_lbl">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:title="label: LocalPhoneNumber to dei_LocalPhoneNumber_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:label xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_Security12bTitle_lbl" xml:lang="en-US" id="dei_Security12bTitle_lbl">Title of 12(b) Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:title="label: Security12bTitle to dei_Security12bTitle_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="NoTradingSymbolFlag" xlink:title="NoTradingSymbolFlag" />
    <link:label xlink:type="resource" xlink:label="dei_NoTradingSymbolFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US" id="dei_NoTradingSymbolFlag_lbl">No Trading Symbol Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:title="label: NoTradingSymbolFlag to dei_NoTradingSymbolFlag_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:label xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_TradingSymbol_lbl" xml:lang="en-US" id="dei_TradingSymbol_lbl">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:title="label: TradingSymbol to dei_TradingSymbol_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:label xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_SecurityExchangeName_lbl" xml:lang="en-US" id="dei_SecurityExchangeName_lbl">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:title="label: SecurityExchangeName to dei_SecurityExchangeName_lbl" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>insm-20221019_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 22.10.1.5080 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://insmed.com/role/DocumentAndEntityInformation" xlink:type="simple" xlink:href="insm-20221019.xsd#DocumentAndEntityInformation" />
  <link:presentationLink xlink:type="extended" xlink:role="http://insmed.com/role/DocumentAndEntityInformation">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentType" xlink:title="presentation: CoverAbstract to DocumentType" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="AmendmentFlag" xlink:title="presentation: CoverAbstract to AmendmentFlag" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentPeriodEndDate" xlink:title="presentation: CoverAbstract to DocumentPeriodEndDate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentFiscalYearFocus" xlink:title="presentation: CoverAbstract to DocumentFiscalYearFocus" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentFiscalPeriodFocus" xlink:title="presentation: CoverAbstract to DocumentFiscalPeriodFocus" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityFileNumber" xlink:title="presentation: CoverAbstract to EntityFileNumber" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityRegistrantName" xlink:title="presentation: CoverAbstract to EntityRegistrantName" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityCentralIndexKey" xlink:title="presentation: CoverAbstract to EntityCentralIndexKey" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityIncorporationStateCountryCode" xlink:title="presentation: CoverAbstract to EntityIncorporationStateCountryCode" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityTaxIdentificationNumber" xlink:title="presentation: CoverAbstract to EntityTaxIdentificationNumber" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine1" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine1" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="EntityAddressAddressLine2" xlink:title="EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine2" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine2" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="EntityAddressAddressLine3" xlink:title="EntityAddressAddressLine3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine3" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine3" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressCityOrTown" xlink:title="presentation: CoverAbstract to EntityAddressCityOrTown" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressStateOrProvince" xlink:title="presentation: CoverAbstract to EntityAddressStateOrProvince" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="EntityAddressCountry" xlink:title="EntityAddressCountry" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressCountry" xlink:title="presentation: CoverAbstract to EntityAddressCountry" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressPostalZipCode" xlink:title="presentation: CoverAbstract to EntityAddressPostalZipCode" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="CityAreaCode" xlink:title="presentation: CoverAbstract to CityAreaCode" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="LocalPhoneNumber" xlink:title="presentation: CoverAbstract to LocalPhoneNumber" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="Security12bTitle" xlink:title="presentation: CoverAbstract to Security12bTitle" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="TradingSymbol" xlink:title="presentation: CoverAbstract to TradingSymbol" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="NoTradingSymbolFlag" xlink:title="NoTradingSymbolFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="NoTradingSymbolFlag" xlink:title="presentation: CoverAbstract to NoTradingSymbolFlag" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="SecurityExchangeName" xlink:title="presentation: CoverAbstract to SecurityExchangeName" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityEmergingGrowthCompany" xlink:title="presentation: CoverAbstract to EntityEmergingGrowthCompany" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="WrittenCommunications" xlink:title="WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="WrittenCommunications" xlink:title="presentation: CoverAbstract to WrittenCommunications" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="SolicitingMaterial" xlink:title="SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="SolicitingMaterial" xlink:title="presentation: CoverAbstract to SolicitingMaterial" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="PreCommencementTenderOffer" xlink:title="PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="PreCommencementTenderOffer" xlink:title="presentation: CoverAbstract to PreCommencementTenderOffer" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="PreCommencementIssuerTenderOffer" xlink:title="PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="PreCommencementIssuerTenderOffer" xlink:title="presentation: CoverAbstract to PreCommencementIssuerTenderOffer" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>ny20005570x4_ex5-1img01.jpg
<TEXT>
begin 644 ny20005570x4_ex5-1img01.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !G 7$# 2(  A$! Q$!_\0
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M_P JL'H:YWN>K3^!>AY;X?N[E_&,4;W$S(9G&TN2.]>IUY-X=_Y'6'_KN_\
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MSLM#RJ^7PIXRG04G:7GKU\BE_P (SXL])O\ P*7_ .*H_P"$9\6>DW_@4O\
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MW</%(,J:\9TO3I=5O/LL!'FE&90>Y SBMOPIX@?0[YK.\RMK(V'#?\LV]?\
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MC3K?[+IEK;GCRXE7\A5B3_5/_NFG4V3_ %3_ .Z:YKW=SV5%1CRKH>5>!_\
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DM6TEO#O46X4G<!SN;U-%% '(_P#"/ZI_S[?^1%_QHHHI@?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>ny20005570x4_ex99-1img01.jpg
<TEXT>
begin 644 ny20005570x4_ex99-1img01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 0K!W4# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HJO<W26\;,2.!FN'U'XD6=C<-$S#(]ZI0;V [UI%7J:!*I
M[UY=+\3K1^0P_.HX_B7:Y^\/SK7V+L.QZP.:*\UC^*%EP-P_.NST;6XM5MA*
MA&#6;@T(UZ*0$&EJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MIT?'6DW 4,=XPM<+5CC:9$[L9L#I3SE>E2!0J<CFF;@:EW-(@6VCBF@G=F@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MIJPH,J*T0@]*D Q6L:42XTT-5%4<#%/I*6MT:V"BBBF 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M,****8!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M3:HKGG*>7C^*NA\.QYVFN[#WN=-"]SNX>8U/M4E1P_ZM?I4E>S'8]-!1115
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MQA1112$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M,1J%J84TIDTX<"N1L]&,;"T444B@HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MBB@ HHHH **** "BBB@!"*.U+10*PQAD4B+BGXI:=Q6"BBBD4%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 (WW3]*^=/BB!_;Q^M?1
M;?=/TKYU^*/&O?C6U#XBH[G&("%%+T-"G*BCKQ7OTOA+$Y)H.: <'%!;%5U
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 44E+20!1113 **** "BBBD C?=/TKYU^*/_(>/UKZ*;[I^E?.
MGQ1_Y#WXUO0^(:.-4Y44O4XH&-HQ0?:O>H[&@F<'%#,0:48HX[U;W "?EK5\
M'_\ (P1GWK*.,5J^#_\ D88_K7/6^$1],Z6<VJ?[HJ_5'3,?94Q_=%7J\*?Q
M&84445(!1110 4444 %%%% !37.*=2$9H 13D4ZD Q2T %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 A /6O./BC"ITW@8XKT8UYY\4#_Q+/PK:B[30]CP?;A\4
MDG!Q2N?WE!&3S7NTYZ%B*N.:7'.:=CBH\G=6B8"LN3FFNN2*<2<\4UR<C%2Q
MV/1?AOQJ2?6O>E^Z/I7@GPW_ .0DGUKWM?NCZ5XF+^,S8M%%%<H@H-%,8G/%
M "@8-&><4'.* .],8ZBBBD(**** "BBB@ HHHH **** "BBB@ HHHI6 **2E
MI@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1136)I7 =12#I1FF M%%% !1110 4444 %%%% !1110 444U
MR<<4 *1D4U5Q2IG'-.H **** "BBB@ HHHH **** "BBB@ HHHH **** "D/
M2BBE<!JMDT^FA0*=1< HHHI@%%%% !1110 44W)S2YXH 6BF@G-.H **** "
MBBB@ HHHH ****0#6&:51@4M%._0 HHHS0 4QER:?10 @Z4M%% !1110 44P
M$[J?0 4444 %%%% !1110 4444 %%%% !1110 4444 -89I5&!2T47 ****
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ME'RR*3]:L;@1D5BT(6BD'-.J;:C"BBBJ$%%%% !1110 4444 %%%% !1110
M4444 %%%-9@HY.* #=S3JIM>V\9^:51^-8VJ^(H;5&*2J<>]6HN3T Z3</6D
M+KZBO&=7^)<UI*0A)YK*;XKW6.IK18>;'8]XDF6--Q(JB^KQ("2PX]Z\3D^*
M-S+%@DU0;Q]<2*>3S6BPTNI21[:WB:W5L;A^=20>(H)GVAA^=?/K^+9F?.3S
M5B+Q?-;KY@)S5K"A97/H<:G&6 W#FK2W",,Y%?.L?Q%N2P)SQ6@GQ/N54#)K
M.6':!)'O98%3R.E?/'Q17.ND@]ZOCXJW73FN.U[6WUN\\Y_6M:&'FI78TK:F
M<GW:<>>E '%'2O6IJPP!QQ1D4@&>:4C-4]P GBM7P?\ \C#&?>LL#(K6\(#_
M (J&,>]<];X1'TOIA!M4Q_=%7ZH:8,6R?[HJ_7A3^(S"BBBI **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M\CI2QGCFFMQA][@TX(%Z5'@LW%2 %>M:\V@F(P!ZTF-O(I&!)XIP'%9\RN(
MW%-))IAR&J0,".E4IJP7'1C=P:1D&>*:&YXIPY-1S@)T.*>RKCBD*X%,&0>:
MM:A<5N%XIT>UEYI",BH]K9XJ9+0">W5?M\/^\*^G?"7_ " 8/]VOE^V1OM\/
M^\*^G_"/_(!@_P!VO(Q9$C>HHHKA)&2_ZIOI7SC\00O]O2>N:^CI?]4WTKYK
M^(2M_P )"Y[9KKPOQC6YRVW/-*HR<&E09%!]J]F%K&E]23 QBF\=!2'.W%,
M.:TT&W<&7'2G$X2EH(R*7,(:HW#)IV,=*4(=F:8K<\TWL Y&);#=*<V-W%#$
M,OR]:8 0.:BV@$MFF=5@_P!X5]/^&_\ D!VX_P!D5\RZ4N_4X?\ >%?37A_Y
M-%A)[+7EXU;$,T+JY2U@+NV *\9\>^-94E:"VDRK<'!K?\>^+HH;:2TC?$GL
M:\1>:6ZF9Y6+<]ZSH4KO4:0R0F>5I7ZL<TJ(2V#]VGNO Q4N]?)P/O5ZD86&
MA,JHVBHF^4Y%"QL>:?VP:VO9 (K9%##O3=I7GM3@0U*XQJY;K3MHI<8IK'/
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MHJ_5'3,?98\?W15ZO#G\1F%%%%0 4444 %%%% !1110 4444 %%%% !1110
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MO;/"O@N""-)F3##VKBKUU$ENQRVB?#>6,I(P/K7INDZ!#:1*K1CCVK<A@6)
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M\Z!!C^[7S#;^9+?PC:>&%?3_ (1&W0( ?[M>7B7J#-T4M%%<A 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !7G7Q2S_9GX5Z+7G?Q0_P"0;^%:T?C0UN>"MGS*
M4^]$G$AII.37N4]C5:CAFF\[O:I,\4W=SBMN@GN(V<\4C9R*=GFFL>14RV$>
MA_#C_D)I]:][7[H^E>!_#<?\31#[U[XOW1]*\/%?&0Q:***YA!1110 4444
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MP'[&V:Z<-N5$\;@P%J4@&H(P<U,<U[M/8L:!S3B!B@CBDSQBG+4-P Q4>/\
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MX &*#TQWI,X&*&.Q'$-M_#C^\*^HO!O_ "+]O_NU\NP@_;X<_P!X5]1>#O\
MD7X/]VO*QZ6A$D=!1117FDC7.$8^U>(?$+6Y!=26V>*]ND_U3?2OG#XA3YU]
MT]ZWPZ]\<=SD4'S,?4U)3<;10 :]V*T-+ 5&<TX&F]Z,9/%:= L.P#UJ&1<X
M J5LXJ6P@-U<B,<G-85G:(=#VSX76:_V4K$<XKTL# Q7&?#^T:UTP*1CBNTK
MPJCO(S84F*6BLQ!1110 4444 %%%% !1110 C?=/TKYT^*/_ "'OQKZ+;[I^
ME?.?Q2(_M['O6]#XAHX\#"BCIS2*#M%+WYKW:.QH &>:"H-)WH(-6]P%[5J^
M#_\ D88Q[UE'I6KX/_Y&"/ZUSUOA$?3.F "U3']T5?JAI8(M4S_=%7Z\.?Q&
M84445 !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MUS5W: F?0>BVHMK55 [5JU'"@6-0/2I*\&3N[F04444@"BBB@ HHHH ****
M"BBB@!&^Z?I7SG\4E_XG^?>OHQONGZ5\X_%//]O_ (UOA_C*CN<BI^44=>*:
MGW13C[5[M+8L3.#B@M@THQWH(%6]P#/RUJ^#_P#D88S[UE'I6KX/_P"1AC^M
M<];X1'TSI;9M4_W15^J.F8^RIC^Z*O5X4_B,PHHHJ0"BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KSKXI#.F?A7HM>=_%#_D
M&_A6M'XT-;G@K#]Y2DX.*)#B0TS.3S7N4UH:K4EQQ4>T[LU)VJ/)W8K43'%>
M]-S\PJ3/&*CQ\U2Q]#T3X<_\A-?K7O2_='TKP7X<_P#(37ZU[TOW1]*\7%_&
M9,6BBBN404444 %%%% !4-U_QZR?[IJ:H;K_ (]9/]TT ?+WC-3_ ,)-,?<U
MD]JUO&C'_A)IA[FLGM7N4/@1HMA/O4@ZXIZC%,_BKK6Q0C'YL4H! IQ7G-(W
M2HDQ7+^CVIN+H#&>:^BO!D'D:2JX[5X)X/7S=2 /K7T3H$8CL5'M7EXS8AFO
M1117GDA1110 4444 %%%% !1110 R3_5M7DOQ,4BS:O6Y/N&O)OB:?\ 0FKI
MP^Y2/&(U.<U*1FH8V.<5,3BO<I[(M 1Q2=L4I/%)VS5,$*!BF XNHO\ >%/!
MXJ,<W46?[PK*I:S ^FO O_(O0_2NGKF/ O\ R+T/T%=/7S\_B9FPHHHJ1!11
M10 4444 %5+NW2ZB9'4'([U:- %-,:/!_'7@R2":2]1<+UX%>9B0B38>,&OK
M+6=*CU2T:%P,$5X!XW\)/I5\?L\9*Y["N^AB+Z,+G*-\JY--,@*TQQ(ORN",
M4JJ#7HPFF:)DB'BG*P:H^G%+]VMKH:N)Y@=]@I6@8<T@0*=PZU*9,I2U#49&
MVS@TZ1,C(J, L<FG%R!BA"L)D!<&F8R<BC!8TI&WI2<$Q"M)<$ 1R,,>AJ[8
M:G=6T@WRMQ[U50XYIK#)S7/.DF%M#U'0/B''I\&R5LG'<UWGA[QI!K3[5(KY
MQ\K<N<UH:1K]QH;[HR:XJF'6XFCZL216'!%/KQ'P?\0I[W4EBN'PF>YKV&#4
M[:<#9(IS[UQ3IN+L07:*0'(S2U !1110 4444 %%%% !1110!Y)\7?\ 4"O&
MT'%>R?%W_4"O&D)QBO2PFQ<=A64GF@ TI/.*.G2O66Q:!@2* #MQ2D\4_'[O
M-0(KX.[;ZUZ;\++(QZEYGJ:\TB^:49]:]=^&PQ<K7!BF^5DR/8 .E/H'2BO)
M("BBB@ HHHH **** "BBB@ KR3XG_P"LKUNO)/B?_K*UH_&-'CSC$IINTYS3
MG.9329.<5[E.]C5 5[T'YN*"QII.WI6O0=QH&'IT@WKCUIY7Y-W>F1DM(!42
M?NDL]2^$%L8IV)]:]MKR+X6QE6R17K0/->%7^-D/<?1116)(4444 %%%% !1
M110 4AZ4M(>E 'C'Q)_X^VKRG_EHU>K_ !)_X^FKR?GS&^M>M@UH:+8<%YH(
MYS0#S323NQ7I(8'YJ<!Q2?=H8D"I8$MMS.!7NGPU7%K^%>$6A/G@U[O\-23:
M_A7F8O8F6QZ+1117F$!1110 4444 >-_&,_(M>01?<%>O?&3[BUY%"/D%>GA
M-BXDX7Y<TSJ:>"=N*9TZ5Z<2D+UX%($(:D!(-.W<9[TY(>P/($.*:S[AQ3A&
M).6II 6IND.X@@8_-FG;3FF&XV\"@2YZTN="N2$4N,KBHFE Z&E$HQG-',@3
M'[<#%'W:;YHQG-,$@8\FCF0;$F.<T8YI-X'>C>/6ESH!S#-':F[QZTAD&.M'
M,GH&Y(?NXI@B+#-)Y@V]:$GXP31S) /C&P\T-R^::9 >]*K*3R:ES0A=F>:3
M[W%.:0#@&F[@O(-"J(8N,<4>U,:4>M*'7&<U,IB"(8OX?]X5]/\ @[_D7X/]
MVOEV&4&_AY_B%?47@[_D7[?_ ':\W%RN9LZ"BBBN(1PGQ(D,>F'GM7S_ '1\
MR<GWKW7XJ2%-)S[5X*K[FS7HX1:%Q8X#:,&E I'.:53ZUZ]M"V&.<T%23FC/
M-!)!I A=N174?#CCQ&OUKEMW'%=9\.5_XJ%3[UQXEM09+V/H]/\ 5K]*=34_
MU:_2G5XAF%%%% !1110 4444 %%%% !1110 C?=/TKYS^*1_XG^/>OHQONGZ
M5\Z?%%?^)]GWK?#_ !CCN<:JX44O0YH4Y44=:]ZEL:"8R<TI&:3.#BAB0:I[
M@*1Q6KX/_P"1@C'O65GY:U?!_P#R,$9]ZYZWPB/IG2QBU3_=%7ZH:62;5/\
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M;6:^<O"?C-]*G2,DG)Q7O6BZ@NH6,<VX985Y-:GR2(-2BBBL1!1110 4444
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MJ^$%_P"*AC'O7/6^$1],Z81]E3']T5>JAI8Q:I_NBK]>%/XC,****D HHHH
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MH\9NHO\ >%95-F!]->!O^1>A^@KIZYCP+_R+T/TKIZ^?G\3,F%%%%2 4444
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MY&!?K7(KQG-=7\.3GQ$OUKBQ*]Q@SZ03[B_2G4U/]6OTIU>(9!1110 4444
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MS$WLQ2/?QTHIJL&7(IU>69!1110 4444 %%%% !1110 4444 %%%% !1110
M44FX9Q2T %-"X.:=10 4444 >;?%A ^D\^E>#HN%Q7OWQ1B:32L+Z5X$04DV
M'K7IX.5HEQ'*-HI0.:",4@XZUZ,+LL7 SFEV@\TG.:#G-6 -TKI_ANW_ !4:
MCWKEI 2O%=+\.W$7B!6;UKFQ"O!DGTPG^K7Z4ZH;:998E(]*FKP7H9A1110
M4444 %%%% !1110 44A.*0L I/I0!QWQ$G,&B,V>U?.DTYN)BW7FO</B?JL3
MZ0\*M\V*\)LQE6W>M>EA(NQ2)QTH/'-!XI #FO4AHBQ0,\T$"DYS2,#FGU >
M!D5K>$%_XJ&/ZUD<@5L>$#_Q/X_7-<]?X1'TMI@ M4_W15^L_2P?LJ9_NBM"
MO#G\1F%%%%0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^E]+;-JG^Z*OUGZ5_P >J?[HK0KPY_$0PHHHJ!!1110 4444 %%%% !1110
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M.&3VIH/.*]E2NB[W#'-!%&>:4FK0Q#\W2F." *?TH(W"E45T(]D^&NL)#8+
MQY->IPME0WK7S/X4U=[7588LD+FOI#3;B.XLHBK G:*\3$049:$/<O4M)CBB
MN38D6BBBF 4444 %(3BEIAY.*!HBGE$41<]!7C?Q,ULW"[(GQCC@UZ9XCU&.
MSTZ4%P&QZU\XZ[JSWM]*I)(W5UX>G=W*2,UF++ECDTJ<K48)(J9  M>Q3BTB
MK !BFX.:<#29YJFKC%I&4DT9YI22*(Z"L':M?P@<^((Q[UD'I6IX//\ Q4,9
M]ZQK+W1,^FM+7%JG^Z*OU0TLYM8_]T5?KPY_$9A1114 %%%% !1110 4444
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MUR5I61-SV[X>6QMM%52,<5V=9NC6'V&U6/VK2KQIN[,PHHHJ0"BBB@ HHHH
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M)/K7O2_='TKP7X<<ZFGUKWI?NCZ5XF+_ (AFQ:***Y1!1110 4444 %0W?\
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M]KB/\0J=6##(KQJ+Q]%YJ*7ZGUKU/1;T7FFQS ]16$H6$:=%(#FEK,04444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7GGQ0_Y!OX5Z'7G7Q2
MS_9G'I6M'XT-;G@\G,AII7!I6SYE*?>O<IO0U6@[&!3=HSFG=JCYW5J)CB.:
M:ZY(H;.ZFOG(Q2 ]&^''&II]:]Z7[H^E>"_#?_D))GUKWI?NCZ5XF+_B&;%H
MHHKE$%%%% !1110 5#=?\>LG^Z:FJ&[_ ./63_=- 'R_XT4?\)+,?>LC;QFM
M;QGG_A)IOJ:RATKWL-\*-(C>IYI2,C%-;KQ3AG%=+T&PVX&*;M %./W:8,X.
M:B6PD=-X'7&J9]Z^B-&_X\U^E?._@?/]J?C7T1HW_'H/I7E8O84C2HHHK@("
MBBB@ HHHH **** "BBB@!LG^K->2?$U<63&O6I/]6:\E^)@/V-LUTX;<I'C4
M2]ZE(S4<=/.:]N#T*0G7BG8XI"..*7G%44&,"DVXI1G%(,YI-7$,*'=G-/"9
M'6G8IA#9XK"5.X#7@)_B-$6]&^\:D&:4E<<=:ATA6+=OJLEHX8,>*]G^&NM/
MJ47S'.!7@ERK&,XKUWX,!PC;JXL1"R)9[12,<"@G%'45PDE:[)-I)]*\%\?<
MR/\ 6O>[P 6DGTKP;Q\0SN!ZUUX;XAHX).8\4\# J-<A*<IXYKW8,L <&EV
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M!KW'Q_X1CGM6EM8OWAZD"O$+FRN+&Y,<P((->I0K71:V$20@8IP7G/K292G
MY%=L970PP%.Z@G><FH\,7]JD,9QD5I;08-R,4HMU(R33%.#S2NY(PM0T&H%
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M@SZ5\Q@ WD7^\*^G?!0_XIV#Z"O+KJQ#.D48I:1:6N0D**** "BBB@ HHHH
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MH*/^$!@SG K3ZT@3/"/[*F'&#0=*F'4&O>#X!@)S@4-X!@(Z"I^LH?,CP?\
MLJ;K@T?V5,><&O>/^$"@VXP*!X!A Q@4?6D',CP?^RIFZ TATN;I@U[RO@*
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M7$;%3PP/2O</#5B]AH\4#]5%:_E)_=%.  &!6$IN6Y W'%"@BGT5#8!1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444F 4444P"BBB@ HHHH 3%
M+110 4444 %%%% !1110 4444 %)FEIH% #J*** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^ 5IT4^9@9@T6U'\ J9=,@7HHJ[12YF!72TC0Y J< "EHH;; ****0!1110
MSG-/HHH **** "BBB@ HHHH #TJ%NO%2GI3%3!I,!R].:=12&C4 !S2TU1@T
MZF#"HI(5?J*EHIIV H-I5N_)45'_ &+:YSL%:=%/F8&=_8UM_<%2)IL"=%%7
M:*7,PN-1 @P*#G-.HI (*6BB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH8!129HI7 6BBBF 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444@"BBBF 4444 %%%% !1110 4444 %%%
M% !0>E%% # 3NI])BEIL HHHI %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 AZ4U22>:?28H 6DQ2T4 %%%% !1110 4444 %%%% !1110
M4444 %%%% "4M%%*P!1113 3O2T44 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1112 ****8!1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %)2T4F 4444 %%%%, HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** &MTH4G%.HI@%%%%( HHHH *
M*** "BBB@ I*6BA@%%%%*P!1113 **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH ***2E<!:*2BBX"T444P"BBB@ HHHH **** "BBB@
M HHHI7 ****8!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !24M% "44M%*P!1113 **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
4@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140153775208000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Oct. 19, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Oct. 19,  2022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-30739<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">INSMED INCORPORATED<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001104506<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">VA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">54-1972729<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">700 US Highway 202/206<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Bridgewater<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">08807<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">908<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">977-9900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.01 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">INSM<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>ny20005570x4_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="insm-20221019.xsd" xlink:type="simple"/>
    <context id="c20221019to20221019">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
        </entity>
        <period>
            <startDate>2022-10-19</startDate>
            <endDate>2022-10-19</endDate>
        </period>
    </context>
    <dei:AmendmentFlag
      contextRef="c20221019to20221019"
      id="Fact_12080f683548407398317973ac4115f0">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="c20221019to20221019"
      id="Fact_0fca47dfceb24a75ba7073caea886f2d">0001104506</dei:EntityCentralIndexKey>
    <dei:SecurityExchangeName
      contextRef="c20221019to20221019"
      id="Fact_f1ba935348d944beb4334223f9085efe">NASDAQ</dei:SecurityExchangeName>
    <dei:DocumentType
      contextRef="c20221019to20221019"
      id="Fact_6bd2a85cffd742b1b45c8f826e21de0e">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="c20221019to20221019"
      id="Fact_ca9cc4d419d34461ac12076991c8d9cd">2022-10-19</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="c20221019to20221019"
      id="Fact_6af2df81733943f1bf092d264f0efc4e">INSMED INCORPORATED</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="c20221019to20221019"
      id="Fact_c8a6a2101a494c618152a5472695866f">VA</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="c20221019to20221019"
      id="Fact_b365274b7891480ba1592eba534cd734">000-30739</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="c20221019to20221019"
      id="Fact_ea56c1b7ac884e7085359da78bad65c8">54-1972729</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="c20221019to20221019"
      id="Fact_5c5bd1f8d99642df8f742745859f658e">700 US Highway 202/206</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="c20221019to20221019"
      id="Fact_9b0559d9e91d4b1397d021799293b805">Bridgewater</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="c20221019to20221019"
      id="Fact_a1c4cd46ec6c43038798d7a1debc1303">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="c20221019to20221019"
      id="Fact_48d5900a88e849c483d178c9438d889b">08807</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="c20221019to20221019"
      id="Fact_7ab65bd35a634a6d9b676a749bf361f7">908</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="c20221019to20221019"
      id="Fact_f0e07600430940d7baf0971ca8888a92">977-9900</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="c20221019to20221019"
      id="Fact_7dc987ae7e6b47d2b9aa2463e2f2a73d">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="c20221019to20221019"
      id="Fact_4cd87d49741942c2b55b244a447b4122">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="c20221019to20221019"
      id="Fact_7e55e6bf99e44949a4dc9281c6ea8825">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="c20221019to20221019"
      id="Fact_ea4abd78b49544e29dfb4fb0c1b4155a">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="c20221019to20221019"
      id="Fact_e518c26a59b2400a805d86ee7512b752">Common Stock, par value $0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="c20221019to20221019"
      id="Fact_a7882ed0fe0f433593bb0ef05e2cf621">INSM</dei:TradingSymbol>
    <dei:EntityEmergingGrowthCompany
      contextRef="c20221019to20221019"
      id="Fact_9ec556f9799d4b259b776721f08a6b71">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>12
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( #R 5%4'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    "  \@%15,GE2P.X    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+/
M:L,P#(=?9?B>R''9#B;-I:.G#@8K;.QF;+4UB_]@:R1]^R5>FS*V!]C1TL^?
M/H%:':4."9]3B)C(8KX;7>^SU''-3D11 F1]0J=R/27\U#R$Y!1-SW2$J/2'
M.B((SA_ (2FC2,$,K.)"9%UKM-0)%85TP1N]X.-GZ@O,:, >'7K*T-0-L&Z>
M&,]CW\(-,,,(D\O?!30+L53_Q)8.L$MRS'9)#<-0#ZN2FW9HX.UI]U+6K:S/
MI+S&Z5>VDLX1U^PZ^76U>=QO62>X$%7#*\'W@DO>R'OQ/KO^\+L)NV#LP?YC
MXZM@U\*ON^B^ %!+ P04    "  \@%15F5R<(Q &  "<)P  $P   'AL+W1H
M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03<VEVV[29A.U.
M'X416(UL>621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X
M8-DOV]:[MR_>X%<R)!%!,!FGK_# "J5,7K5::0##.'W)$Q+#W(*+"$MX%,O6
M7.!;&B\CUNJTV]U6A&ELH1A'9&!]7BQH0-!445IO7R"TY1\S^!7+5(UEHP$3
M5T$FN8BT\OELQ?S:WCYES^DZ'3*!;C ;6"!_SF^GY$Y:B.%4PL3 :F<_5FO'
MT=)(@(+)?90%NDGVH],5"#(-.SJ=6,YV?/;$[9^,RMIT-&T:X./Q>#BVR]*+
M<!P$X%&[GL*=]&R_I$$)M*-IT&38]MJND::JC5-/T_=]W^N;:)P*C5M/TVMW
MW=..B<:MT'@-OO%/A\.NB<:KT'3K:28G_:YKI.D6:$)&X^MZ$A6UY4#3( !8
M<';6S-(#EEXI^G64&MD=N]U!7/!8[CF)$?[&Q036:=(9EC1&<IV0!0X -\31
M3%!\KT&VBN#"DM)<D-;/*;50&@B:R('U1X(AQ=RO_?67N\FD,WJ=?3K.:Y1_
M::L!I^V[F\^3_'/HY)^GD]=-0LYPO"P)\?LC6V&')VX[$W(Z'&="?,_V]I&E
M)3+/[_D*ZTX\9Q]6EK!=S\_DGHQR([O=]EA]]D]';B/7J<"S(M>41B1%G\@M
MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7
MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V<
M/!T3$LV4"P9!AI<D)A*I.7Y-2!/^*Z7:_IS30/"4+R3Z2I&/:;,CIW0FS>@S
M&L%&KQMUAVC2/'K^!?F<-0H<D1L= F<;LT8AA&F[\!ZO)(Z:K<(1*T(^8ADV
M&G*U%H&V<:F$8%H2QM%X3M*T$?Q9K#63/F#([,V1=<[6D0X1DEXW0CYBSHN0
M$;\>ACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0'
MHYI9";V$5FJ?JH<T/J@>,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y
M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RS<C'5*^3*=@Y
MG\#L_6@^GO'M^MDDA*^:62TC%I!+@;-!)+C\B\KP*L0)Z&1;)0G+5--E-XH2
MGD(;;NE3]4J5U^6ON2BX/%ODZ:^A=#XLS_D\7^>TS0LS0[=R2^JVE+ZU)CA*
M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D*
MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-#
MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B
M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P
MOFH]M!5.S_Y9K<B?#!%.%@L22&.4%Z9*HO,94[[G*TG$53B_13.V$I<8O./F
MQW%.4[@2=K8/ C*YNSFI>F4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W
MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2
MD 83 <V4R43P H)DIAR F/H+O?(,N2D5SJT^.7]%+(.&3E[2)1(4BK ,!2$7
M<N/O[Y-J=XS7^BR!;814,F35%\I#B<$],W)#V%0E\Z[:)@N%V^)4S;L:OB9@
M2\-Z;ITM)__;7M0]M!<]1O.CF> >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F
M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+
M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5
M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0    (
M #R 5%7IO&C16@0  )H0   8    >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
MG9AA<^(V$(;_BL;M=-J9))8<$B %9@A)>O0NA ;N;J:=?A"V $ULRY7D$/Y]
M5X;8],ZLF7X)ENU]_7BU?E=*;Z/TBUD+8<E;$J>F[ZVMS6Y\WX1KD7!SH3*1
MPI6ET@FW,-0KWV1:\*@(2F(_H/3:3[A,O4&O.#?5@Y[*;2Q3,=7$Y$G"]?96
MQ&K3]YCW?N)9KM;6G? 'O8ROQ$S8S]E4P\@O52*9B-1(E1(MEGUOR&YN@Y8+
M*.[X(L7&'!P3]RH+I5[<8!SU/>J(1"Q"ZR0X_+R*D8ACIP0<_^Q%O?*9+O#P
M^%W]H7AY>)D%-V*DXJ\RLNN^U_%())8\C^VSVGP0^Q>Z<GJABDWQEVQV][9:
M'@ES8U6R#P:"1*:[7_ZV3\1A #T2$.P#@H)[]Z""\HY;/NAIM2':W0UJ[J!X
MU2(:X&3J9F5F-5R5$&<'=RK,(<F6\#0B]ZF5=DO&Z6ZV(6L]W\)#W*U^N!>\
MW0D&1P2?0GM!6/>,!#0(_AON UL)&)2 0:%W>41OI%Z%)G\-%\9JF,*_ZXAV
M"JUZ!5?7-R;CH>A[4+A&Z%?A#7[Z@5W37Q&^RY+O$E.O$CC?9J(.#@_OG']$
M(%HE1 M5&0)!5% \Q'Q51X''+WEL!,)Q57)<G9:,J=!2N8**")1E;5YPI;*,
MFNKHND2[1@7WM?T@8T$F>;(0N@X*UZ"4GE_2]F47X6F7/.U3>)[%2KK*AIQ-
M>%*;*%QG/)D]WM^1\63T]#Q]>A[.[^\0NDY)USF%;@1SJ7D,CA")-_)1;.OX
M<"7(&6.T=46O$:QNB=4]!6N<ADIG2A<6=49F%DJ,*$U&*@=>P%91;29Q\2]#
MA)#1RE#I*8QS_D;&$>1/+F58@")EUR!YU3IGW7;0#K#"8P>6STXA'$81V*$Y
M>S\@G^ ^\I36IJY!LDTI^3PC'Z ';OC6?;.P+L!FG%7^SU#[_HYVY$8PV7.U
MJ6]/N-RMEM%*;*!B-(97V3_##?Q;O+(8IUJ]RC2LSR:N.?D=0ZN: L-=_5NT
MJ3(6/N8_97;T"VE0I)T.;6-L5:-@N+\7LSB$=>1Q%%R@2SL82-46&.[IGU0(
M.9FN58KUA0:1;KM]WNU2BA%5C8'ACCZ7%GJ46A(6_+SXA<Q$F&O(5BT6KC12
M20*^,[,J?#DC&=?DE<>Y(#_2"\I(!NLJL^8::_RL:A@,]_FYYI%,5V2V318J
MKH7%!5PCPTBJ'L%P'W]/&+E_"]<\78FCG;5!:#*<W0W_P-:P55,(3FH*]XG0
M*Y>EWT#!KJ'VDXRGM5/;(-BT8@NJ;A#@UOT5<F5%ZEB2/-WW*E.+A LU(ATL
M^7&/GJE8AM*Z1#TZHY:\MJ :5!IY*H\/<#^>:G$>0GH$V/ENK0_+;?AZGI;+
M>KMHT&LDJRP^P WY.[*Q,3F0-0+^S_V ?[#3=+OV1^[JV9!8+$&(7K3!M/5N
M([P;6)45F\^%LK"5+0[7@@.;NP&N+Y6R[P.WGRW_'3'X%U!+ P04    "  \
M@%15GZ ;\+$"  #B#   #0   'AL+W-T>6QE<RYX;6S=5VUKVS 0_BM"/V!N
M8FKBD1BV0&&PC4+S85^56'8$>O%DN7/ZZZ>S;"=I=67=A['-H<G=/;J[1W<G
MF:Y;=Y+\X<BY([V2NMW0HW/-^R1I#T>N6/O.-%Q[I#)6,>=56R=M8SDK6W!2
M,EG>W&2)8D+38JT[=:=<2PZFTVY#;VA2K"NCSY:4!H-?RA0GCTQNZ)9)L;=B
M6,N4D*=@7H+A8*2QQ'DJ?$,78&F? KP(&K <XRBAC05C$C*$[_VX_!DP::U7
MA90SP24-AF+=,.>XU7=>&18/QA<0&>7=J?$,:\M.B^4M/3L,/S[)WMB2VSG-
M@DZF8BUY!72LJ(_PZTR3 .B<45XH!:N-9@.'R6,4?-@#E_(!6OBMNHK=5R3T
MXE,);2"PU4GTA$8QA D*Q+^,%F)?A+W]K;"D$8_&?>S\;O2@?^^,X_>65Z(?
M]+Z:\V/1%WATUC3R]$&*6BL>]O[+"8LUF_S(T5CQY+/!I!R\@5M*'KEUXG!I
M^6%9L^.]FZ:IKW#.RW^0\Y^M<\TUMTQ>DO:C_S=7^2V,D_'T7!S1JP,Z6PE<
MA!OZ%>Y7>>9 ]IV03NA1.XJRY/K%.?7A'=O["_PJOE]?\HIUTNUF<$//\A=>
MBD[E\ZI[J,NXZBQ_AOMHD<VWL,\E=,E[7FY'U=;[021>\%G'!QR>(W?#$T<P
MGX#%$<"P/!@#S"=X87G^I_VLT/T$#..VBB(KU&>%^@2O&+(=/EB>N$_NG_A.
M\SQ-LPRKZ'8;9;#%ZI9E\!>/AG$##RP/9'I;K?%NXQ/R^AQ@/7UM0K"=XI.(
M[12O-2#QNH%'GL>[C>4!#ZP+V.Q _G@>F*FX3YI"5S%NV G&D3S'$)C%^(QF
M&5*=##[Q_F"G)$WS/(X %F>0IA@"IQ%', ;  4/2='@//GL?)=-[*CG_5U/\
M!%!+ P04    "  \@%15EXJ[',     3 @  "P   %]R96QS+RYR96QSG9*Y
M;L,P#$!_Q=">, ?0(8@S9?$6!/D!5J(/V!(%BD6=OZ_:I7&0"QEY/3P2W!YI
M0.TXI+:+J1C]$%)I6M6X 4BV)8]ISI%"KM0L'C6'TD!$VV-#L%HL/D N&6:W
MO606IW.D5XA<UYVE/=LO3T%O@*\Z3'%":4A+,P[PS=)_,O?S##5%Y4HCE5L:
M>-/E_G;@2=&A(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%B
MM/XU@LD/['X 4$L#!!0    ( #R 5%4<.&7J/P$  #P"   /    >&PO=V]R
M:V)O;VLN>&ULC5'+;L) #/R5U7Y $U"+5$2XE#Z0JA:5BON2=8C%/B*O RU?
M7R=15*1>>O)Z;(UG9A?G2,=]C$?UY5U(A:Z9FWF6I;(&;])-;"#(I(KD#4M+
MARPU!,:F&H"]RZ9Y/LN\P:"7BY%K0]EU$QE*QA@$[( =PCG]SKM6G3#A'AWR
M=Z'[MP.M/ ;T> %;Z%RK5,?S2R2\Q,#&;4N*SA5Z,@QV0(SE'WC;B?PT^]0C
M;/8?1H04>I8+8864N-_H^8UH/($L#UW+\0D= ZT,PS/%ML%PZ&C$179EH\]A
MK$.(<_I/C+&JL(15+%L/@8<<"5PG,*0:FZ15,!X*/:XH$ZQZ#"PAJ748J&2W
M<RJGUW9PS2+W*D.:HPQH;0?AHUH+%0:P;W(@"2[)E1M27>EYIK=WDWM)J'7N
M0;#W\!J-'<V/'[?\ 5!+ P04    "  \@%15)!Z;HJT   #X 0  &@   'AL
M+U]R96QS+W=O<FMB;V]K+GAM;"YR96QSM9$]#H,P#(6O$N4 -5"I0P5,75@K
M+A %\R,2$L6N"K<OA0&0.G1ALIXM?^_)3I]H%'=NH+;S)$9K!LIDR^SO *1;
MM(HNSN,P3VH7K.)9A@:\TKUJ$)(HND'8,V2>[IFBG#S^0W1UW6E\./VR./ /
M,+Q=Z*E%9"E*%1KD3,)HMC;!4N++3):BJ#(9BBJ6<%H@XLD@;6E6?;!/3K3G
M>1<W]T6NS>,)KM\,<'AT_@%02P,$%     @ /(!45660>9(9 0  SP,  !,
M  !;0V]N=&5N=%]4>7!E<UTN>&ULK9--3L,P$(6O$F5;)2XL6*"F&V +77 !
M8T\:J_Z39UK2VS-.VDJ@$A6%3:QXWKS/GI>LWH\1L.B=]=B4'5%\% )5!TYB
M'2)XKK0A.4G\FK8B2K636Q#WR^6#4,$3>*HH>Y3KU3.T<F^I>.EY&TWP39G
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M+GAM;%!+ 0(4 Q0    ( #R 5%4R>5+ [@   "L"   1              "
M :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( #R 5%697)PC$ 8
M )PG   3              "  <P!  !X;"]T:&5M92]T:&5M93$N>&UL4$L!
M A0#%     @ /(!45>F\:-%:!   FA   !@              ("!#0@  'AL
M+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( #R 5%6?H!OPL0(
M .(,   -              "  9T,  !X;"]S='EL97,N>&UL4$L! A0#%
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K  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     )  D /@(  /T3      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="ny20005570x4_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000100 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://insmed.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: dei:SecurityExchangeName -  ny20005570x4_8k.htm 11</Log>
  </Logs>
  <InputFiles>
    <File doctype="8-K" original="ny20005570x4_8k.htm">ny20005570x4_8k.htm</File>
    <File>insm-20221019.xsd</File>
    <File>insm-20221019_lab.xml</File>
    <File>insm-20221019_pre.xml</File>
    <File>ny20005570x4_ex1-1.htm</File>
    <File>ny20005570x4_ex5-1.htm</File>
    <File>ny20005570x4_ex99-1.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>18
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "ny20005570x4_8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "ny20005570x4_8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "insm-20221019_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "insm-20221019_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "insm-20221019.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2004/ref-2004-08-10.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/currency/2022/currency-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/exch/2022/exch-2022.xsd",
      "https://xbrl.sec.gov/naics/2022/naics-2022.xsd",
      "https://xbrl.sec.gov/sic/2022/sic-2022.xsd",
      "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"
     ]
    }
   },
   "elementCount": 29,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 3,
    "total": 3
   },
   "keyCustom": 0,
   "keyStandard": 22,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "insm",
   "nsuri": "http://insmed.com/20221019",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ny20005570x4_8k.htm",
      "contextRef": "c20221019to20221019",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "000100 - Document - Document and Entity Information",
     "role": "http://insmed.com/role/DocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ny20005570x4_8k.htm",
      "contextRef": "c20221019to20221019",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://insmed.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://insmed.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://insmed.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://insmed.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://insmed.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://insmed.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://insmed.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://insmed.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://insmed.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://insmed.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://insmed.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://insmed.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://insmed.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://insmed.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://insmed.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://insmed.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://insmed.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://insmed.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://insmed.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://insmed.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://insmed.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://insmed.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://insmed.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://insmed.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://insmed.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://insmed.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://insmed.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://insmed.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>19
<FILENAME>0001140361-22-037955-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001140361-22-037955-xbrl.zip
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MR7-[:>=^;0FG_(#XR?DA(OZ(GVA__!]02P,$%     @ /(!456Y>.G<B%@
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M:U]%GL^JZ3@K#=J]MMO""56(SIIW=!>]7_,9"(_OW;)]WB\[-Y[ 5%==?$[
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M7./E6G</SD<_]KM>PJ8'>-'/!A%<_#]02P,$%     @ /(!45<.>7:R0<@
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M^%&ONR_'*\A,"AH[RN2S1S_NB^?+!\(?-_!U%Q;;9-3U]["[K*I93>&8JO+
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M84[ XM1M^KRS7K=G5 =VSZPC244R]'WAU^,FS3C]X2+)3.X\=J\WF>=K-BE
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MJ^/P [)J#<%SNZSIV[EZS\EFQC5?1:5%>-X8/+V\]CH[.0%I+3' ZL+(#G+
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M@_KK?H>F<9BY 3>2];ZTYL"272?T9QIT^W^YN0:X_$_XT!MT!C,CM@V%7,Z
M#!2$MTA++?Q)FO=>O)F%TGO"'B5$%Z<'TDN6NWGNW*1MF!0+K%5:-*AY.+-8
MNII[!J/6$WQ!.-!2W0UF[HREP66XP;/)*[.][ ;M[ [[7,#&#0<IVAT#.QQ#
MF64#K"/LK?K!,'A%*N6\R4V*1(>2]8X' Y!<#,IVIFDW9<^H>4%HSD TAN=U
MD^<D NV][ZHWQ(!Q9+9R<6W% +!%7F@;*](+[H/Y__;;%_3%NQ[!AZR9_K F
M;#(E_0 @QDF-G,Q&;8XRXK8--P.3\"3R!&H()*6 E$D7>]$%L#_%!TY*(U7D
MZ")*BA)\3B:-I,JT1T:[\(-E*S-IN8OQ4"PJ1J[M*["FP*[](NZ,08W75>FQ
M]KRQVBM#K"T>NKB,;>1G$!I3>I"PN<<\[PQMO@G>9A)KH$G0+./R2!.FD#OV
MY[>M77*.OE1MSO]T>OJ^MZ:F4)>+A=UF8U+A:!H01S2SB%)"N/P[K00FE,Z6
MD]9U*Y>DV@RSUF:NQA\+1W5K=BMLQ":QBKJ:8 L_I!R-M49#0N)+PSZT.]W5
MV+)7JR\!$_B*C%6_D20R(RYIOWG<8K$NTH9Q&!0\&&K#P1\4$:R0?6-MLTD;
ML:$QS/;4<>FK)/I$GN&VOMN5RT+10L8!RBHO^&C:Q6R!0D'\GSVC 0KGF";/
MVD13ZK_IE17>_'5V;$FGWD9Z%Z:5]FQFZ2=LU5<7W>?[Q?OF6[H/&?#IT_W(
M */;X"!ZY9&7D%/A3\XB]<)6@K[@2E"NCHP;JZ]4Z6?LI5-?2"==TC^X&0L)
M=R0PGEKO]0>F[A7(!W6WT0\XM6WO\/ T$+48=O3!-:-\B7^?![@2+NUW3_74
M%-FVG$N_HEM1;/K-43&Q##R;IK:8E(M3^5L=-5!ER.3"-W6*]L%V&U57!UNJ
MZM70"@+1UGL*8\.!$M=PL%R6M]2N:%1EC"JQQ_1$O,#8\X,G?H4G_N3!$W_G
MG##+U@VS"R?W>DO4R>0BAR/.ED9C(*T7[*N%S;?%E"W,59*:G1";%%P56(KC
MK@+81\S)W%4QK26M.X%WLZM4986S80M<+AI39>--*W0^!N>\GX[JAM9\#$>0
M[IW\0@D\F,0!A$#;_:'J-:QG3LU-&C#&E)MYZJ>'KM71KC>+=&@R1'],Q=J
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MYHKP*LV<"!']-("HU3V&^EF52'G.D8FZM'9H77!_1+1ZG#,\JB0"8UO9W._
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MP8.#1AT8^'SW<E\'ZS=;_9!,BEF>^N48@?77[YSO!.?H"P40?4BJ(N-P QK
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M!6EC]^,:0;+K]A;6U;>BW&":O<D^K"2SZ"\[[W>"7XIR%N6MD8@A*-L'P2^
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M]+YW\JOV*25QO+<'=Y96F!E?Z";<07N Z6W< S&[%@:X3'<:[3R?PS: -B?
MAOZTN[.[AU-LL62N <#PW-<R"0W2FN&;FU[)G I#X"6M[=S6;%PAX +0.6XF
M29? B'[GT9)F]*:3=(&L4,I7S!7B%4Q@=RE.8(4OTA*GVQ9E7>&3\$W.DX3=
M7&WSRQ#_<BBFF0AV$1][\ZM#.W";D*], 0UQFW5"+Z')I0+N%C6'G4;XWB'#
M()4!UWD!;XD;/M0%761:Q'3;24[5&$7>'C\"?X."...#'=^)<(@!_J02NW?+
M,8#S19E'HU*#%&!4NI;+\2YK0[;( [OA0MX3+#IDL;4W8@X /#)+XEF"J=Y9
M%A)&E-&$ILGR)_A?&M)=+#B]M]0/J5-(BY30_FOX5[+TK(SR6CT5L@*(#U]%
M)7V)X]GMPEF2 ]^$;VG$^E6*G!V>JJ98TE(&H( 0M\<!WS&UE<5A"LCTS5]A
M(+-TA2%H6@54RT$FX4@K_-D5HC,**IH,#K<X#](J:"JN _N 7&SO(-X^< "0
MRU4R\=5GV'@^2X)3'IZ^]^3@D(1D!(B)%64;W:I>K76A<*/"@34QPM'IN&Y#
M52$'HYG?@.98$4 RL2C=09+/23E)*RH7@#42>2_]C5+$@QK\O;4_\L4KO/,J
M6MB+"N@N9\S:B3696Z/ZHRBGIT*:M7U1\$OAW\B[^,($L@GLNIB#["*^\:\&
MAY33->*9RNHB72C&;7<(#.@BX6W@QN@V\?41<[<XJ29E.M::"+*_+(*K9C+A
M T;CXC)!%."**3#ZZHPKIF0B\[*#4#B8&5_'0'#70">=1-6%A\HW%PY_ &_$
MZ8,OXM:5?R#E9%;PZ!D<2 V*A!OH'2T6P 4!UW'@O"-73YUJ([MB-LLNA_&>
M1AX(!\\C=P/3-$Z"63HE]@]DA:(]%-JI0: ASZPC(+.XF#3$2HA-T%<@6H'2
M@!M4)$5PA'J,-;KIN$$BO[U]P]\9I[X1>\I)#YDGB-58+87/  >+Z2^48O!'
MMMQFGENIRBUA5+U*%.Q_<A<P!SE:-2)3B:N6,<M-YF4$TLBJX(@$:7Y99#C"
MG9X7PZ'"VO>5>VKS.S(7 :' %&&.B:M-BJ:L/>$)^MHBP<'HP6^JG B@$=\%
M- 0(==E4M;6-6$_0.H-H!59';<E7_"@%-1.N%7"0Z^EZ'H5#)+V'\ #PY:=1
M=F1H$13D8FBQ-DNC<9KQ@FS<( + EQG803B4OJ;]7UVD(+B0&<AAG'*DI"U2
M'QP"+ ;LFWN19/& &K("3+TD\$SLUB1F?4%,ETE$VIU<G*?X65KWT)S%.#H<
M1MMP W -*:@J$1PM+O(D"=TO$](ZS**)886X'4)?$?)&+V_[WZ(@@VO8!B,B
M2[#%#Q%[#;M@;5+VCR7A?&S0(_A!9:IOI;"YO#!T%N4Y2(U)8EC=%*X-*%'(
M!R]7#%,/S^!<11EVCD>?N;.&]J1%Z9][Q,O1=K7"&6KU"/LAD!UH3#O"+D$[
MW-VYF(Y[QR@^>.>A@!24IQ*4M[1DU  .TR!?!XQPKYB#_.NS0IWVUG?S>$\
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M$RP"1!>4R;H.E%MF<)F@WF 6M3 2X@1ZZ*VTH?6 9!EB'#$X-P0\XR4_F!6
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M     &EN<VTM,C R,C$P,3DN>'-D4$L! A0#%     @ /(!45<<K+3* "
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M,# U-3<P>#1?97@Q+3$N:'1M4$L! A0#%     @ /(!452/#H6EC#0  7CL
M !8              ( !29L  &YY,C P,#4U-S!X-%]E>#4M,2YH=&U02P$"
M% ,4    "  \@%154!"MEA<>  !"=   %P              @ '@J   ;GDR
J,# P-34W,'@T7V5X.3DM,2YH=&U02P4&      < !P#3 0  +,<

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
